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Abstract
Primary cutaneous T-cell lymphoma (CTCL) is a clinically heterogeneous
malignancy of mature skin-homing T-cells. Mycosis fungoides (MF) is an indo-
lent subtype of CTCL whilst Sézary syndrome (SS) is an aggressive leukaemic
variant characterised by the presence of malignant Sézary cells in the periph-
eral blood. A role for epigenetic mechanisms in the pathogenesis of CTCL has
been proposed but not extensively investigated. In this thesis, the contribution of
DNA methylation to the regulation of SHP-1, Fas and PLS3, which have been
implicated in the pathogenesis of CTCL, was examined. Gene expression was
assessed on the mRNA and protein levels using qPCR and flow cytometry re-
spectively whilst DNA methylation was evaluated using bisulphite conversion
and Pyrosequencing. Contrary to results in CTCL cell lines, primary malignant
cells from CTCL patients did not display aberrant DNA methylation or dysregu-
lated expression of SHP-1, a negative regulator of STAT3 signalling. Dysregula-
tion of Fas, a key regulator of apoptosis, was observed in 34/47 SS patients with
13/47 showing over-expression compared to healthy controls and 21/47 showing
under-expression, attributed to the positional hypermethylation of five CpG din-
ucleotides in the Fas CpG island. PLS3, an actin-binding protein not normally
expressed in any haematopoietic cell, was aberrantly expressed in malignant cells
from 21/35 SS patients and 3/8 MF patients with demonstrated clonal blood in-
volvement. CpG dinucleotides 95-99 in the PLS3 CpG island were differentially
methylated between healthy lymphocytes and keratinocytes, and hypomethyla-
tion of these CpG dinucleotides was observed in SS patients expressing PLS3.
To investigate expression of PLS3 on the protein level a novel anti-PLS3 anti-
body was raised and optimised for use in Western blotting, flow cytometry and
immunofluorescence. In conclusion, these data demonstrate that SHP-1 is not
regulated by methylation in primary CTCL cells whilst Fas is dysregulated by
hypermethylation of five key CpG dinucleotides and PLS3 is dysregulated by hy-
pomethylation of CpG dinucleotides 95-99.
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Introduction
1.1 Primary cutaneous T-cell lymphoma
Mycosis fungoides (MF), named by Alibert after the characteristic skin lesions which
‘perfectly resembled morel mushrooms’ was the first recognised lymphoid neoplasm
presenting in the skin (Alibert, 1832). Subsequently Sézary syndrome (SS), distin-
guished by generalised erythroderma, lymphadenopathy and ‘monstrous histiomono-
cytes’ in the circulating blood was described by Sézary & Bouvrain (1938) as a sep-
arate disease. However, electron microscopy of the abnormal cells in both conditions
revealed striking ultrastructural similarities suggesting that the two conditions may
be related (Brownlee & Murad, 1970, Lutzner et al., 1971). Currently, SS and MF
are recognised as subtypes of primary cutaneous lymphoma, a diverse group of lym-
phoid neoplasms with an incidence rate of 10.7 per 1,000,000 person-years with SS
and MF accounting for approximately 40% of cases. A series of consensus meetings
led to the 2005 publication of the WHO-EORTC classification for cutaneous lym-
phomas (Willemze et al., 2005) defining subtypes by the originating lineage, the most
common being cutaneous T-cell lymphoma (CTCL) followed by cutaneous B-cell lym-
phoma and precursor haematological neoplasm. Within each lineage, subtypes are fur-
ther defined based upon their clinical, histological and molecular features. The degree
of relatedness between MF and SS remains a subject of frequent debate, particularly
with respect to the possibility of ‘disease progression’ from MF to SS. The recognised
subtypes of CTCL are listed in Table 1.1 along with incidence and survival data from
a Dutch and Austrian cohort of 1905 cutaneous lymphoma patients (Willemze et al.,
2005) and a US cohort of 3885 cutaneous lymphoma patients (Bradford et al., 2009).
This thesis will focus on SS and MF, both of which usually involve malignant
12













































































































































































































































































































































































































































































































































































































1.1 PRIMARY CUTANEOUS T-CELL LYMPHOMA
transformation of CD3+CD4+ T-lymphocytes. MF presentation is typically restricted
to the skin and is characterised by lesions which begin as flat patches and then progress
to raised infiltrated plaques and further to tumours (Figure 1.1a). MF is generally con-
sidered an indolent disease with progression taking place over years or even decades,
however, in a small proportion of MF patients the malignancy disseminates to the
peripheral blood. By contrast SS is clinically more aggressive, presenting with malig-
nant involvement in the peripheral blood alongside widespread erythroderma demon-
strating total skin involvement (Figure 1.1b). Diagnostic parameters include the pres-
ence of Pautrier’s microabcesses, clusters of atypical lymphocytes within the epider-
mis (Schmidt-Skrabs, 2000) and presence of Sézary cells with distinct cerebriform
nuclei in the blood (Taswell & Winkelmann, 1961) (Figure 1.1c). Molecular genetic
analysis can be used to detect the presence of a clonal expansion of T-cells, strongly
supporting diagnosis, particularly in SS where an identical clone can often be observed
in skin and blood (Bench et al., 2007, Ralfkiaer et al., 1987, Weiss et al., 1985). An
estimate of tumour burden in SS can be obtained through visual inspection of a blood
smear to enumerate the Sézary cells whilst disease severity in both SS and MF is staged
according to an international standardised scoring system assessing the extent of dis-
ease presence within skin, lymph nodes, blood, and visceral organs (Olsen et al., 2011).
Prognostic factors in SS and MF include clinical entity and stage, age, sex, serum lac-
tate dehydrogenase concentration and the presence of a clonal T-cell receptor (TCR)
gene rearrangement in the peripheral blood (Agar et al., 2010). No initiating molecular
defect has been identified as the cause of malignant transformation in CTCL however,
as discussed in detail below, a wide range of phenotypic changes have been identified
along with a multitude of genetic alterations and an increasing number of epigenetic
alterations that may lead to the observed phenotypic changes.
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Figure 1.1: Clinical features of SS and MF
(a) Patch, plaque and tumour stage lesions of MF (b) Erythroderma in SS (c) A




Extensive studies have been made to define the phenotypic features of malignant cells
in CTCL. Ideally a unique and consistent marker would be identified with potential
for use in diagnosis, enumeration of the malignant cells and isolation of the malig-
nant cells. However, thus far no marker has been identified that is consistently ex-
pressed in all patients and on the entire malignant subset of each patient. CTCL is
clinically heterogeneous and this is reflected in the molecular characteristics of ma-
lignant cells from CTCL patients. The origin of the malignant cells is widely agreed
to be CD3+CD4+CD45RO+ mature skin-homing T-lymphocytes in typical cases, and
expansion of the CD4+ subset is used as an indicator of SS (Vonderheid et al., 2002).
There are reports however of diminished CD3 expression (CD3dim) in some CTCL
samples (Edelman & Meyerson, 2000, Hristov et al., 2011, Klemke et al., 2008),
which can be used to identify a subset of malignant cells. The malignant cells are
a clonal expansion so molecular analysis can demonstrate clonal rearrangement of
the TCRβ and TCRγ genes, which is used to support a diagnosis of CTCL (Fraser-
Andrews et al., 2001). Additionally, if the clonal TCRVβ gene segment has been
identified for a given patient, antibodies against that TCRVβ can be used to detect
the malignant cells (Gorochov et al., 1995). Since this requires prior knowledge of
the TCRβ gene rearrangement and a different antibody for each patient it is not of
much value for diagnosis but can be used to identify the malignant cells in research
studies. However, there are several limitations to this technique. Firstly, not all rear-
rangements are suitable for detection in this manner as the clonal rearrangement can
be non-productive, leading to a TCRVβ chain that is not expressed at the cell surface.
Secondly, not all Vβ segments have a corresponding antibody, limiting the repertoire
that can be studied. Additionally, some of the available antibodies do not react consis-
tently with their corresponding clone, leading to an increased false positive rate (Bigler
16
1.1.1 PHENOTYPIC FEATURES
et al., 1996). CD158k, an immunoglobulin-like receptor found on NK cells and some
subsets of T-cells has been proposed as a novel phenotypic marker, expressed on 27%
of SS peripheral blood mononuclear cells (PBMCs) compared to 6% of healthy control
PBMCs (Poszepczynska-Guigné et al., 2004). However, 12% of patients did not show
any significant over-expression of CD158k suggesting that it is not universal to all SS
patients. A recent report (Clark et al., 2011) suggests that a unique population of high
scatter T-cells can be identified by flow cytometry of T-cells isolated from both skin
lesions and peripheral blood. Co-staining with appropriate TCRVβ antibodies demon-
strates that this high scatter population is restricted to the dominant clone however, in
the examples shown clonal cells are also present within the ‘normal’ T-cell population,
suggesting that high scatter is not a feature of the entire clonal population.
The skin-homing characteristics of the malignant cells have led to extensive inves-
tigation of skin-homing antigens on their cell surface, cutaneous lymphocyte antigen
(CLA), which interacts with E-selectin on endothelial cells to initiate extravasation of
T-cells at cutaneous sites, has been demonstrated on PBMCs from CTCL patients (Boro-
witz et al., 1993). The proportion of PBMCs expressing CLA is greater in those with
leukaemic disease than those with skin-restricted disease (Heald et al., 1993). In-
creased expression of the skin-homing chemokine receptors CCR4 and CCR10 has
also been observed on CTCL PBMCs (Capriotti et al., 2007, Ferenczi et al., 2002,
Sokolowska-Wojdylo et al., 2005a). Circulating CLA+CD4+ T-cells in SS have been
found to co-express the lymph node homing receptor CCR7 whilst those from MF
patients with no peripheral involvement and healthy controls did not (Sokolowska-
Wojdylo et al., 2005a). T-cells isolated from the skin lesions of leukaemic CTCL
patients also demonstrated expression of CCR7 whilst those from MF patients with
skin-restricted disease did not (Campbell et al., 2010). Therefore, it appears that the
malignant cells of skin-restricted CTCL express skin-homing antigens consistent with
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originating from a skin resident memory T-cell subset whilst in leukaemic disease the
gain of lymph node homing chemokine receptors allows the malignant cells to circu-
late through peripheral blood and skin compartments. Campbell et al. (2010) also
identified co-expression of L-selectin and CD27 alongside the CCR7 expression in
leukaemic CTCL, indicating that leukaemic CTCL originates from central memory
T-cells whilst skin-restricted disease originates from effector memory T-cells.
Phenotypic features of healthy CD4+ T-cells that are frequently reported to be
lost in malignant CTCL PBMCs include: CD7, which plays a role in T-cell interac-
tions during lymphoid development (Stillwell & Bierer, 2001), and CD26, a peptidase
that is involved in providing the co-stimulatoy signal during TCR signalling (Mori-
moto & Schlossman, 1998). Many groups have demonstrated an increased proportion
of CD4+CD7- cells in CTCL patients when compared to healthy controls (Borowitz
et al., 1993, Haynes et al., 1981, Washington et al., 2002) and some have reported
that the proportion of CD4+CD7- cells is significantly higher in advanced stage MF
and SS than in early stage MF (Harmon et al., 1996, Laetsch et al., 2000, Scala et al.,
1999). However, the prognostic value of CD7 loss is unclear, with Bogen et al. (1996)
finding a strong correlation between the percentage CD4+CD7- cells and the propor-
tion of Sézary cells by nuclear contour analysis in those patients with a significant
CD4+CD7- population, whilst Vonderheid et al. (2005) observed no correlation. Sim-
ilarly, whilst some studies report a correlation between CD7- and appropriate Vβ+ by
co-staining (Bogen et al., 1996, Rappl et al., 2001), another reports that this is not the
case (Dummer et al., 1999) and additionally that both CD4+CD7- and CD4+CD7+
populations contained clonal cells by TCRγ gene rearrangement. Interestingly, an ex-
panded CD4+CD7- subset can be induced in vitro by repeated restimulation of naïve
T-cells (Reinhold et al., 1996) suggesting that this subset could be induced by the cel-
lular microenvironment as an indirect consequence of the malignancy. Loss of CD26
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has been similarly widely reported and is also more significant in SS than early stage
MF (Scala et al., 1999, Sokolowska-Wojdylo et al., 2005b, Washington et al., 2002).
When comparing the diagnostic potential of significant CD7- or CD26- subsets, most
studies have concluded that loss of CD26 is more prevalent, affecting 86%-100% of
SS patients (Jones et al., 2001, Sokolowska-Wojdylo et al., 2005b, Washington et al.,
2002), however, other studies have observed a prevalence as low as 60% (Kelemen
et al., 2008). Since no marker is consistently observed in all patients, Klemke et al.
(2008), who assessed the diagnostic potential of CD3dim, CD7, CD158k+ and TCRVβ,
concluded that assessment of multiple phenotypic anomalies was necessary to ensure
accurate diagnosis of blood involvement in CTCL patients.
A multitude of microarray studies have been performed to delineate changes in
mRNA levels associated with CTCL, some with the intention of establishing ‘gene
signatures’ for the diagnosis of CTCL and some with the intention of highlighting po-
tentially pathogenic gene expression changes. Key findings of these studies are sum-
marised in Table 1.2, frequently noted changes include increases in EPHA4, PLS3,
KIR3DL2, MMP9 and TRAIL and decreases in STAT4, CD26, CD40 and IL2-RB.
One notable gene highlighted by these studies is PLS3 (T-plastin), initially charac-
terised by a representational difference analysis study searching for potential biomark-
ers (Su et al., 2003) and subsequently highlighted by several microarray studies (Booken
et al., 2008, Kari et al., 2003, van Doorn et al., 2004). PLS3 is of particular interest
because it is not normally expressed in haematopoietic cells and could therefore act as
a unique marker of malignant cells if its expression is consistent within and between
patients. General themes emerging from gene expression studies include the down-
regulation of genes involved in the polarisation towards a Th1 effector response such
as the TBX21 transcription factor and up-regulation of genes involved in the polarisa-




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































account for the observed development of a Th2 cytokine profile with disease progres-
sion, which is believed to help malignant T-cells suppress the immune system response
against them (Vowels et al., 1992). Significant changes have also been noted in genes
related to the NF-κB signalling pathway (Martínez-Delgado et al., 2005) and genes
of the TNF receptor superfamily (Tracey et al., 2003), both of which are involved in
T-cell activation.
1.1.2 Genomic abnormalities
Genomic instability is a common feature of malignancy although the molecular basis
for this instability is only recently becoming understood (reviewed by Negrini et al.
(2010)). Early attempts to examine the cytogenetics of Sézary patient PBMCs were
complicated by technical difficulties, namely the inability to induce proliferation, as
discussed in Section 1.1.4, which limited the generation of metaphase spreads. Those
who did succeed observed highly heterogeneous karyotypes including heteroploidy,
structural anomalies, ring chromosomes and minute chromosomes (Johnson et al.,
1985, Whang-Peng et al., 1976). Improved staining methods enabled more detailed
examination of the chromosome segments involved in rearrangements and a 1995 re-
view of 56 published cases of SS concluded that the most frequently involved chromo-
somes were 1 and 2, affected in 43% of cases each, followed by 6, 9, 11, 13, 14 and
17 (Limon et al., 1995). Unlike nodal lymphomas, where disease-specific balanced
chromosomal translocations are common and can be used in diagnosis or monitoring
of disease (Bench et al., 2007), no unique translocation has been found to be associated
with CTCL. Subsequent studies reported translocations in almost all chromosomes but
consistently found around 50% of CTCL patients to be affected, with alterations of 1p,




A summary of results obtained by genome-wide chromosomal rearrangement stud-
ies is presented in Table 1.3, any chromosome that was found to be altered in 2 or more
studies has been included. Advances in assay resolution are apparent with more recent
studies showing multiple small minimal regions of loss/gain in locations such as 10q
and 17p where the older studies detected much wider regions of loss/gain. The most
frequently affected chromosomes are: 1, harbouring both losses and gains, 9 which
appears to be principally affected by losses, and 17 showing gains in 17q and mixed
loss and gain within 17p. Whilst most studies drew their conclusions from a range of
CTCL samples including both MF and SS, van Doorn et al. (2009) compared the two
entities and concluded that the pattern of genomic alterations differed between them,
suggesting potentially different molecular origins. Particularly, they found frequent
gain of 7p13-7p14, 7p21-7p22, 1q31-1q32, and 1p36.2 and losses of 5q13, 9p21, and
13q14-13q31 in MF whilst SS was characterised by gain of 17q23-25 and 8q24 and
loss of 17p13. Alterations in 7p21.1, 1p36 and 13q14 have also been detected in SS,
suggesting that either these may not be unique to MF or the exact region and genes
affected may differ between disease subtypes. Loss of 9p21 appears to be the strongest
candidate for an alteration unique to MF as it is supported by another study examin-
ing only MF samples (Prochazkova et al., 2007). However, loss of heterozygosity at
9p21 has been observed in SS patients in studies examining the CDKN2A-CDKN2B
region (Laharanne et al., 2010a, Scarisbrick et al., 2002), suggesting the limited size
of this deletion leads to it going undetected in genome-wide studies of SS. Of the al-
terations unique to SS, loss of 17p13 is supported by an independent study (Caprini
et al., 2009) although Prochazkova et al. (2007) did observe loss of the whole 17p arm
in some MF patients. Notably, examination of Table 1.3 suggests losses within 10q
to be unique to SS as these are not detected in either of the studies using only MF
samples. However, several more detailed studies of the 10q locus using micro-satellite
22
1.1.2 GENOMIC ABNORMALITIES
markers revealed loss of heterozygosity in 12/50 MF cases (Scarisbrick et al., 2001)
and 15/45 MF cases (Wain et al., 2005) demonstrating that this alteration does also
occur in MF.
The development of array-based analysis of chromosomal rearrangement allowed
integration of this data with gene expression levels, indicating those imbalances that are
more likely to be responsible for disease pathogenesis. Chromosomal arms 1q, 4q and
16q contain genes that are significantly up-regulated in CTCL and this correlates with
gains of these regions detected by comparative genomic hybridisation (CGH) (Hahtola
et al., 2006). Conversely, chromosomal arms 4q and 12q show a significant down-
ward bias in gene expression in CTCL and losses in these regions are detected by
CGH. In another study, minimal regions of loss or gain common to at least 35% of
SS patients were mapped and examined for potential oncogenes or tumour suppres-
sor genes (Vermeer et al., 2008). Gain of 8q24.1-8q24.2, which harbours the MYC
gene, was consistent with over-expression of MYC, whilst negative regulators of the
MYC signalling pathway MXI1 and MNT were located in regions subject to frequent
loss. Additional genes integrating with this pathway, including TWIST and BIM, were
similarly affected at both genetic and gene expression levels suggesting that multiple
genetic aberrations can lead to dysregulation of the MYC signalling pathway. A re-
gion of gain in 17q21 was narrowed down to the candidate genes STAT5A, STAT5B
and STAT3, all of which are strongly dysregulated in SS (Mitchell et al., 2003, Som-
mer et al., 2004). Mao & McElwaine (2008) analysed gene expression array data in
the context of previously defined regions of chromosomal loss and gain and identified
4 regions; gain of 20q11.21-13.33 (66 genes), loss of 1p36.33-22.1 (86 genes), loss of
6q24.1-24.2 (11 genes) and loss of 15q11.2 (12 genes), where the altered gene expres-
sion pattern could separate SS from healthy controls. Caprini et al. (2009) on the other
























































































































































































































































































































































































































































































































































































































































































































































































































































































identify 113 genes whose altered expression was likely due to chromosomal rearrange-
ment within 8p22-21, 8p12-11, 8q13, 8q21-24, 9p13, 9q13, 9q21-22, 9q21-34, 10p13,
10p15, 10q11, 10q21, 10q23, 10q24-26, 17p13-11 and 17q11-25.
In some cases the minimal region of deletion has been mapped to a much higher
resolution. Locus-specific fluorescence in situ hybridisation (FISH) has been used to
identify the gene disrupted by a translocation in 12q as NAV3, resulting in allelic loss
in 50% of early MF patients and 85% of late MF and SS patients (Karenko et al.,
2005). This was disputed by a subsequent study (Marty et al., 2008) however Vermeer
et al. (2008) also detected a deletion affecting NAV3 in 30% of their patients suggest-
ing methodological differences may account for the difference. The minimal region
of deletion affecting chromosome 10q has been mapped using allelotyping of micro-
satellite markers revealing two regions of deletion, 10q23.33-24.1 and 10q24.33-25.1,
and highlighting genes including Fas, PTEN, HHEX and HELLS in these loci, which
could be potentially relevant to the pathogenesis of CTCL (Wain et al., 2005). Other
genes inactivated by allelic loss include p15 and p16, located at 9p21 (Navas et al.,
2000, Scarisbrick et al., 2002), which are involved in cell cycle regulation. Use of
genomic microarrays has identified JunB as having increased copy number that corre-
lated with nuclear expression in 21/23 SS patients (Mao et al., 2003b). Other estab-
lished changes in copy number include a decrease in Bcl-2 (Mao et al., 2004) and an
increase in Her2/neu (Utikal et al., 2006), both of which were shown to be detectable
at the protein level.
Though a wide range of genes that are commonly mutated in cancer have been
investigated in CTCL, very few sequence mutations have been reported. Infrequent
mutations of the Fas gene have been reported in MF (Dereure et al., 2002, Nagasawa
et al., 2004) and a novel splice variant has also been described resulting in a truncated
dysfunctional protein (van Doorn et al., 2002). The SS cell line HuT78 harbours a
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point mutation in p53, a tumour suppressor gene implicated in many different malig-
nancies, however results from primary malignant cells are rather more mixed. Mar-
rogi et al. (1999) reported point mutations and deletions affecting the majority of their
cohort of large cell transformed CTCL patients whilst a study of MF found p53 mu-
tations in 6/17 patients with tumour stage disease but none of 12 with plaque stage
disease suggesting a possible association with disease progression (McGregor et al.,
1999). However, Dereure et al. (2002) found no p53 mutations in a cohort of 44 MF
patients representing all stages. Mutations of p53 also appear to be infrequent in SS
patients (Brito-Babapulle et al., 2000, Marks et al., 1996). One study examined the
nature of 14 different p53 gene mutations identified within a cohort of 55 primary cu-
taneous B-cell and T-cell lymphomas and found that 12 occurred at dipyrimidine sites,
a feature characteristic of UVB induced DNA damage (McGregor et al., 1999). NF-κB
is observed to be constitutively expressed in MF skin lesions (Izban et al., 2000) and a
rearrangement of the NF-κB2 gene is seen in the HuT78 cell line, leading to expression
of a truncated protein and constitutively activated NF-κB transcription (Zhang et al.,
1994) however the presence of this rearrangement in patient samples has not been in-
vestigated. Recently, Curiel-Lewandrowski et al. (2011) have identified mutations in
the IL-16 gene in 11/11 CTCL patients, generating consistent amino acid alterations
from GSA to WNG or WNS in the PDZ1 domain, required for association of pro-
IL-16 with the nuclear chaperone HSC70. Since loss of nuclear pro-IL-16 has been
demonstrated to induce cell cycle progression these mutations may drive proliferation
in CTCL.
1.1.3 Epigenetic abnormalities
Epigenetic modifications, causing heritable changes in gene expression without alter-
ing the nucleotide sequence of DNA, have been recognised as vital to both normal
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cellular function and malignant transformation. Two major categories of modifications
can occur: in malignancy the more intensely characterised is DNA methylation, the
addition of methyl groups to selected cytosine bases, which can lead to transcriptional
silencing (Baylin & Ohm, 2006). As DNA methylation is the focus of this thesis a
more thorough discussion of the discovery, mechanism and role of DNA methylation
in lymphoma can be found in Section 1.2. The other class of epigenetic modification
covers post-translational modifications to the histone proteins that control the pack-
aging of DNA and hence the ‘availability’ of gene promoters to the transcriptional
machinery. A complex code of histone modifications including mono-, di- and tri-
methylation, acetylation and phosphorylation has been discovered to tightly regulate
the conversion between transcriptionally active euchromatin and the highly condensed,
transcriptionally inactive heterochromatin (Cosgrove et al., 2004).
Histone proteins were first identified as inhibitory to gene expression since nuclei
depleted of histones showed enhanced levels of RNA synthesis (Allfrey et al., 1963).
Subsequently, acetylation of the histone proteins was observed to reverse this inhibi-
tion (Allfrey et al., 1964). Since then, a multitude of histone modifications have been
identified, the combinatorial role of which is to regulate the dynamics of nucleosome
positioning and hence DNA accessibility (Cosgrove et al., 2004). Simply establish-
ing the baseline pattern and role of each modification presents a major challenge, the
most commonly used method involves chromatin immunoprecipitation (ChIP) with
antibodies specific to a particular modification followed by array profiling of the en-
riched DNA. However, since each nucleosome contains approximately 150bp of DNA,
analysis on a mono-nucleosomal level requires an incredibly high resolution which has
been overcome by the use of next-generation sequencing methods. Using this method a
picture is being built of the positioning of nucleosomes in resting human CD4+ T-cells
and the rearrangements that take place upon activation by TCR signalling (Schones
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et al., 2008). High-resolution maps have also been generated in resting CD4+ T-cells
for 19 different histone methylations and 18 histone acetylations, identifying a ‘mod-
ule’ of 17 modifications whose presence in a gene promoter is associated with higher
expression levels (Barski et al., 2007, Wang et al., 2008).
Such is the complexity of the histone code that identification of aberrant modifica-
tions which may play a role in malignancy has not been performed to the same extent
as identification of aberrant DNA methylation. A recent review summarised those
modifications that have been associated with a range of malignancies (Füllgrabe et al.,
2011) including loss of H4K16ac, H4K20me3, H3K4me2/me3, H4K12ac and increase
of H3K56ac. Other marks, including H3K18ac and H3K27me3 show more complex
results with some malignancies showing poor prognosis in correlation with increased
levels and others showing the opposite. Given the cell type specificity of nucleosome
positioning and modification patterns, and the coordination shown between ‘modules’
of modifications in CD4+ T-cells, it is perhaps unsurprising that changes in individual
modifications have differing effects in malignancies of different origins. Additionally,
the reviewed studies all examine histone marks on a global level, it seems likely that
much remains to be elucidated through investigation of the alteration in patterns of
histone modification associated with specific genes.
Although changes to the histone code have not been directly investigated in CTCL
the therapeutic success of a range of compounds that act by inhibiting the histone
deacetylase (HDAC) enzymes suggest that aberrant histone acetylation patterns may
play a pathogenic role in CTCL. Two histone deacetylase inhibitors (HDIs), Vorinos-
tat and Romidepsin, have demonstrated efficacy in clinical trials (Duvic et al., 2007,
Whittaker et al., 2010) and have subsequently been approved for treatment of CTCL. In
CTCL models, Romidepsin has been found to induce apoptosis of HuT78 cells (Piekarz
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et al., 2004) whilst ex vivo incubation with Vorinostat induced a greater level of apopto-
sis in CTCL patient PBMCs than in healthy PBMCs (Zhang et al., 2005a), suggesting
that HDIs can selectively target the malignant cells. Further laboratory studies have
demonstrated wide ranging changes in gene expression are induced in primary lym-
phocytes from CTCL and CTCL cell lines upon HDI treatment (Tiffon et al., 2011).
Emerging studies also suggest that the gene expression changes induced by HDI treat-
ment may lead to modulation of the STAT3 pathway (R. McKenzie et. al., manuscript
submitted), which as discussed below, is constitutively activated in CTCL.
1.1.4 Dysregulation of T-cell signalling pathways
Running through the diverse array of abnormalities discussed above is a common
theme of defects in genes associated with various T-cell signalling pathways. Specif-
ically, as discussed below, PBMCs from CTCL display an absent or attenuated pro-
liferative response to mitogen or interleukin stimulation, suggesting dysregulation of
the TCR signalling pathways. Abnormal lymphocytes in CTCL have been shown to
demonstrate limited in vivo proliferation in the peripheral blood compartment, some-
what faster proliferation in the skin and much more extensive proliferation in lymph
nodes (Bunn et al., 1981, Shackney & Schuette, 1983). PBMCs from SS patients
are not tumourigenic when injected into nude mice through various routes, further
suggesting that the peripheral malignant cells are not inclined towards spontaneous
proliferation (Gazdar et al., 1980). Whilst PBMCs from healthy individuals show
spontaneous proliferation when placed in culture, those from CTCL patients showed
no proliferation (Carney et al., 1980, Gazdar et al., 1980). When cultured with mito-
gens or interleukins the response of CTCL patient PBMCs is highly variable as sum-
marised in Table 1.4 and despite extensive studies, no method of stimulation has been
consistently demonstrated to activate the proliferative response of malignant cells in
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CTCL. Some methods have shown more promise as a means of stimulating prolif-
eration, Berger et al. (2002) for example, demonstrated proliferation for up to three
months by stimulating with immature dendritic cells suggesting that malignant cells
in SS require cellular contact to initiate proliferation. However, no follow up studies
were performed to investigate the pathway leading to activation in this protocol and
to the best of our knowledge no other group has successfully reproduced this method
of stimulation. Although lack of proliferation may seem disadvantageous to a malig-
nancy, T-cell signalling induced proliferation normally activates a signalling cascade
that eventually leads to the elimination of the expanded cells through activation in-
duced cell death (AICD) (reviewed by Krammer et al. (2007)). Thus, the lack of
response to TCR and interleukin signalling could lead to resistance to apoptosis, al-
lowing the malignant cells to persist. Evidence of the persistence of malignant cells
is demonstrated by observations that they respond poorly to most chemothereapeutic
agents, which are intended to trigger widespread apoptosis (Meech et al., 2001). Inter-
estingly malignant cells in CTCL often respond to phototherapy, the use of UV light
to induce DNA damage, which in turn triggers the intrinsic apoptotic pathway, sug-
gesting that resistance to apoptosis is more likely to stem from defects in the extrinsic
apoptotic pathway (Meech et al., 2001).
Since the lack of a proliferative response appears to be general to all mitogens and
interleukins, it is unlikely to be due to deficiencies or defects in specific interleukin re-
ceptors. TCR signalling is however a dynamic process requiring rearrangement of the
actin cytoskeleton to form an immunological synapse (Burkhardt et al., 2008), a com-
plex process that could be subject to dysregulation. One protein that is critical to this
rearrangement is L-plastin, an actin-binding protein, which becomes phosphorylated
upon co-stimulation (Wabnitz et al., 2007). In the absence of L-plastin, T-cells form
smaller, less stable immunological synapses (Wang et al., 2010), leading to reduced
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PHA, ConA, PWM, ATS 3/3 MF PBMCs showed similar proliferation to healthy PMBCs but 5/5




PHA, ConA, PWM, SPA Variable maximal proliferative responses in 10 SS PBMCs, 4 were
nearly normal, 4 were poorly responsive, in all SS samples induction of
maximal proliferation required much greater mitogen concentrations
than required in healthy PBMCs.
Gazdar
et al. (1980)
PHA, ConA, PWM, TCGF, SPA 2/5 SS PBMCs unresponsive to all mitogens, 2/5 SS PBMCs showed
similar proliferation to healthy PBMCs, remaining showed some
response to SPA, ConA and PHA only.
Poiesz et al.
(1980)
TCGF Crude TCGF ineffective however a partially purified extract enabled
continuous culture of two SS PBMC samples, three MF PBMC samples






TCGF PBMCs from 23 MF patients generated 5 EBV-transformed
B-lymphoblastoid cell lines but no T-cell lines. 2 MF skin biopsies and
1 lymph node biopsy showed outgrowth of lymphocyte subsets.
Elimination of CD8+ T-cells allowed CD4+ T-cells to proliferate for
over three months. However, the T-cell lines generated ‘have a finite
lifespan and represent T-cells with normal phenotype and function’.
Bang et al.
(2005)
IL-2 + IL-4 T-cell lines that could proliferate for up to 3 months generated from
15/19 MF skin biopsies. Cell lines generated were oligoclonal as




IL-7 Proliferation observed in 12/12 SS PBMCs, 3/8 could be maintained for
> 10 weeks, cultured cells retained the same TCRβ gene rearrangement
as freshly isolated lymphocytes.
Foss et al.
(1994)
IL-2 + IL-7 5/7 SS PBMCs showed synergistic effect on proliferation of both IL-2
and IL-7 as opposed to individually, 2/7 showed additive effect, only
examined over 10 days.
Berger
et al. (2002)
IL-2 + IL-7 PBMCs from 4 erythrodermic MF patients remained viable for at least a
week but not longer than 10 days.
Döbbeling
et al. (1998)
IL-7 + IL-15 2 SS PBMCs had prolonged survival but no significant proliferation.
Berger
et al. (2002)
immature DCs 10/10 SS PBMCs proliferated for up to 3 months, cell contact required
as transwell co-culture prevented proliferation.
Bensussan
et al. (2011)
anti-CD3 Proliferation observed in 2/2 SS PBMCs but of much lower magnitude
than in healthy CD4+ T-cells.
Yoon et al.
(2008)
IL-21 No proliferation observed in 3/3 SS PBMCs.
McCusker
et al. (1997)




SEB Induced proliferation in lymphocytes from a patient with clonal
TCRVβ17 (SEB is a superantigen for Vβ17), no proliferation observed
with SEA, a Vβ3 superantigen or TSST-1, a Vβ2 superantigen.
Table 1.4: Proliferative response of CTCL cells
Summary of studies where CTCL PBMCs have been stimulated with various mitogens, interleukins
and other agents and the observed proliferative response.
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proliferation. Interestingly, L-plastin is closely related to PLS3, the two proteins show
80% identity and in healthy tissues there is no overlap in expression. In solid tissue ma-
lignancy, where PLS3 is normally expressed and L-plastin is aberrantly expressed (Lin
et al., 1993a), this dual expression leads to enhanced tumour cell invasiveness (Foran
et al., 2006, Klemke et al., 2007) suggesting the aberrantly expressed plastin isoform
can interfere with cytoskeletal dynamics. It is therefore interesting to speculate that
the aberrantly expressed PLS3 in SS may influence cytoskeletal dynamics and hence
impact upon TCR signalling.
Multiple signalling pathways act to integrate the myriad of signals being received
by the cell at any one time and coordinate a response. The gene expression studies
discussed in Section 1.1.1 highlight dysregulation of multiple genes within the NF-κB
signalling pathway whilst the genomic studies identified a mutation causing constitu-
tive activation of NF-κB in the HuT78 cell line. NF-κB is a transcription factor that
has been implicated in control of the apoptotic response in malignancy (Rayet & Géli-
nas, 1999). Strong nuclear and cytoplasmic expression of activated p65, a subunit of
the NF-κB dimer, has been identified in 21/23 MF lesions suggesting that the NF-κB
pathway is aberrantly activated in MF (Izban et al., 2000) and constitutive activation
of NF-κB was observed in 30/30 SS patients (Sors et al., 2006). Additionally, CTCL
cell lines showed increased apoptosis after incubation with various inhibitors of NF-
κB (Izban et al., 2000), or transfection with the super-repressor IκBα (Sors et al., 2006),
providing evidence that inappropriate activation of NF-κB may contribute to resistance
to apoptosis in CTCL.
The other central regulators of T-cell signalling that are disrupted in CTCL are the
signal transducer and activator of transcription (STAT) proteins (reviewed by Mitchell
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& John (2005)). Of the seven mammalian STAT family members, four show dysregu-
lation in CTCL. Specifically, STAT4 shows significant down-regulation in gene expres-
sion studies whilst genetic studies demonstrate frequent gain of 17q21, which harbours
STAT3, STAT5A and STAT5B. STAT4 is a key regulator driving Th1 differentiation
therefore the reduction in STAT4 expression is probably the underlying mechanism
for the observed shift towards a Th2 polarizing cytokine profile in CTCL (Papadavid
et al., 2003, Vowels et al., 1992). Whilst STAT5 does not appear to be constitutively
activated in SS (Zhang et al., 1996), the expression of an inactive terminally truncated
isoform has been observed (Mitchell et al., 2003) leading to reduced STAT5 signalling.
STAT3 is the most intensely investigated of the STATs in CTCL, showing constitutive
activation in patient PBMCs (McKenzie et al., 2011, Sommer et al., 2004). Incuba-
tion of CTCL cell lines with JAK inhibitor AG490 prevents the binding of STAT3 to
its consensus sequence, promoting increased expression of the pro-apoptotic Bax gene
and decreased expression of the anti-apoptotic Bcl-2 gene (Nielsen et al., 1999). Fur-
ther to this, transfection of a dominant negative form of STAT3 into CTCL cell lines
led to a significant increase in apoptosis (Sommer et al., 2004), demonstrating that
constitutive activation of STAT3 plays a key role in resistance to apoptosis. Recently,
it has been demonstrated that one of the targets of STAT3 is miR-21 and that silencing
of this microRNA leads to increased apoptosis (van der Fits et al., 2011), suggesting
that STAT3 mediated increased expression of miR-21 may coordinate resistance to
apoptosis. Despite extensive investigation, no clear mechanism responsible for consti-
tutive activation of STAT3 has been defined although various possibilities have been
reviewed by Mitchell & John (2005). The most promising candidate is loss of SHP-
1, a protein tyrosine phosphatase that has been demonstrated to be silenced by DNA
methylation in some CTCL cell lines (Nakase et al., 2009, Zhang et al., 2000) but this
has yet to be validated in primary cells from CTCL patients.
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Another signalling pathway likely to be central to the observed resistance to apop-
tosis in CTCL PBMCs is the Fas system, which is highly regulated during the phases
of a T-cell immune response. The Fas receptor, when expressed at the cell surface,
interacts with its natural ligand FasL, initiating the extrinsic apoptotic pathway. Rest-
ing T-cells express marginal amounts of Fas and are resistant to apoptosis (Klas et al.,
1993). During the activation phase Fas is up-regulated (Ju et al., 1995), although short
term activated effector T-cells remain resistant to AICD (Klas et al., 1993), which is
thought to be due to incomplete death inducing signalling complex (DISC) formation
and the presence of high levels of the apoptosis inhibitor c-FLIP (Kirchhoff et al.,
2000, Schmitz et al., 2004). Long term activated T-cells express comparable levels of
Fas to short term activated T-cells but have complete DISC formation, with concomi-
tant down-regulation of c-FLIP expression and are therefore sensitive to Fas-mediated
AICD (Dhein et al., 1995). The Fas gene is located at 10q24, a region frequently
found to be lost in CTCL as shown in Table 1.3, suggesting that chromosomal rear-
rangement could lead to the elimination of this gene. It has been demonstrated that
9/16 SS patient PBMCs are resistant to FasL induced apoptosis and that decreased Fas
cell surface expression was seen in four of these cases (Contassot et al., 2008). In
the remaining five cases, who showed normal or enhanced Fas expression, the resis-
tance was due to over-expression of the pathway inhibitor c-FLIP demonstrating two
instances of dysregulation within the Fas signalling pathway.
1.1.5 Cell line models of CTCL
Long term cell line models are vital tools in the study of disease mechanisms and
the observed absence of spontaneous or induced proliferation in CTCL PBMCs has
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severely limited the range of SS/MF cell lines available for study. Of the many at-
tempts to expand the malignant cells of CTCL in vivo only a few have led to the es-
tablishment of long term, stable cell lines with a validated malignant origin. Of the
seven samples cultured by Gazdar et al. (1980) two long term cultures were estab-
lished and named HuT78 and HuT102. HuT78 was derived from a patient suffering
from SS and the cell surface antigens, karyotype and morphology were similar to those
of the originating patient cells (Bunn & Foss, 1996) making HuT78 the first SS cell
line to be successfully established. Another SS cell line, SeAx, was produced in 1987
by culturing Sézary patient lymphocytes with TCGF, producing a cell line that was
dependent upon IL-2 (Kaltoft et al., 1987). The SeAx phenotype is CD2+CD3+CD4-
CD8-CD25+ and it has similar chromosomal abnormalities to the fresh patient pe-
ripheral clone. Sez-4, established in 1991 from a patient with stage IVa (T4 N3 B1
M0) MF/SS, was initially dependent upon IL-2 and restimulation every three months
with conditioned medium from another Sézary patient’s lymphocytes that had been
stimulated with ConA (Abrams et al., 1991). After one year the line became indepen-
dent of these stimuli although IL-2 did still induce an increased rate of proliferation.
This line was shown to demonstrate an identical TCR rearrangement to the predom-
inant clone in freshly isolated patient lymphocytes. The phenotype of the cell line,
CD3+CD4+CD8-CD7-CD25+, closely matched that observed on lymphocytes in the
skin, blood and lymph nodes of the originating SS patient. Interestingly, in another
study only one of eight patient samples proliferated upon induction with IL-2 and in
this case the sample contained a high proportion of CD25+ cells (Dalloul et al., 1992).
Only one MF cell line, MyLa, has ever been successfully produced, after culture
of a skin biopsy from an MF patient with IL-2 and IL-4 (Kaltoft et al., 1992). The
MyLa cells had a CD3+CD4+CD8-CD25+ phenotype and a very complex karyotype
that was genetically unstable, leading to alterations of the karyotype over multiple
35
1.2 DNA METHYLATION
passages (Kaltoft et al., 1994). Some other lines that are occasionally used to model
SS/MF cell lines posses features that makes them inappropriate for this use. HuT102,
the other line generated by Gazdar et al. (1980) was produced from the lymph node tis-
sue of a patient with multiple unusual disease characteristics who was later determined
to be suffering from adult T-cell lymphoma/leukaemia (ATLL), which is associated
with HTLV-1 viral infection. In fact, the HuT102 cell line proved vital to the ini-
tial characterisation of HTLV-1, the first human retrovirus to be identified (Rho et al.,
1981). MJ is a cell line derived from the peripheral blood of an MF patient, which
also carries the HTLV-1 virus (Popovic et al., 1983) whilst the IL-2 independent and
CD25 negative HH cell line was also derived from a patient with ATLL (Starkebaum
et al., 1991). PB-1, 2A and 2B are a series of cell lines often cited as originating from
a ‘progressive cutaneous T-cell lymphoproliferative disorder’ and occasionally used to
model CTCL or anaplastic large cell lymphoma (ALCL). They reflect an incredibly
complex case where the patient was originally diagnosed with MF, then additionally
developed Hodgkin’s disease, then lymphomatoid papulosis followed by a shift to ery-
throderma with circulating Sézary like cells, at which point PB-1 was established from
the peripheral blood. Subsequently CD30+ ulcerating skin lesions appeared, from
which PB-2A and PB-2B were established (Davis et al., 1992).
1.2 DNA methylation
5-methylcytosine (5mC), the cytosine base with a methyl group added to C5 of the
pyrimidine ring, was identified as a chemical constituent of the cell well before our
current understanding of DNA was elucidated (Johnson & Coghill, 1925). Advances
in analysis techniques enabled the proportion of 5mC to be determined in multiple
sources, at which point the modification was observed to be both species- and tissue-
specific (Kappler, 1971, Vanyushin et al., 1973). Subsequently it was proposed that the
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methylation of cytosine bases in the CpG context could contribute to X-chromosome
inactivation (Riggs, 1975), stable gene regulation during differentiation (Holliday &
Pugh, 1975) and imprinting (Erickson, 1985) however, experimental evidence to sup-
port these theories was limited. The key to dissecting the role of DNA methylation
in vertebrates came in 1986 with the identification of ‘islands’ containing a high fre-
quency of unmethylated CpG dinucleotides that tended to be located near transcrip-
tional start sites (Bird, 1986).
It had already been recognised that the frequency with which the CpG dinucleotide
appears in vertebrate DNA was much lower than might be expected given random in-
corporation of nucleotides (Josse et al., 1961, Russell et al., 1976, Swartz et al., 1962).
This was proposed to be due to the propensity of 5mC to spontaneously deaminate,
becoming tyrosine (Coulondre et al., 1978) (Figure 1.2a). Since tyrosine is a standard
nucleotide base this change is less to be detected by DNA repair mechanisms, leading
to the propagation of a C→T mutation in subsequent generations and a gradual de-
crease in the proportion of CpG dinucleotides. By contrast, if unmethylated cytosine
deaminates, it becomes uracil (Figure 1.2b), which is recognised by the DNA-uracil
glycosylase enzyme and replaced. Consequently vertebrate genomic DNA is found to
exhibit an increased frequency of TpG, which is proportional to the deficiency in CpG
and the extent of DNA methylation (Bird, 1980).
Upon digestion of vertebrate DNA with the methylation sensitive restriction en-
zyme HpaII, which cleaves within the sequence CCGG, the majority of fragments are
large (Cooper et al., 1983, Gautier et al., 1977, Singer et al., 1979) whereas digestion
with the non-methylation sensitive isoschizomer MspI leads to extensive cleavage, sug-
gesting that the majority of vertebrate CpG dinucleotides are methylated. A small pro-
portion, comprising 0.5-2% of the HpaII digest is observed to be unmethylated, gener-







Figure 1.2: Spontaneous deamination of 5-methylcytosine and cytosine




1983) . Remarkably, this fragment length is inconsistent with the predicted frequency
of CCGG sites within the genome given the reduced frequency of CpG dinucleotides
discussed above. In fact, within the low molecular weight fraction it was calculated that
the HpaII recognition site is present at a frequency 13 times greater than expected, sug-
gesting that unmethylated HpaII sites are clustered within the genome (Cooper et al.,
1983). These clusters of unmethylated HpaII sites, now known as CpG islands (CGIs)
were described by Bird (1986) as ‘HpaII tiny fragment islands’ and were principally
defined by a G+C content greater than 50% and CpG count roughly equal to GpC count
at the expected frequency given the base composition of the sequence. Bird observed
that most of the genes with identified CGIs were housekeeping genes and predicted
that a high proportion of all islands would be gene-associated. Controversially, Bird
also argued that CGIs were not involved in tissue-specific gene regulation despite ev-
idence showing an inverse correlation between tissue-specific DNA methylation level
and gene expression in globin genes (Shen & Maniatis, 1980, van der Ploeg & Flavell,
1980). He further proposed that in these cases methylation may be a secondary event
following some other means of inactivation and may act to imprint the silencing.
The definition of a CGI was greatly refined by Gardiner-Garden & Frommer (1987)
following an in-depth analysis of all the vertebrate genomic sequences from GenBank.
The expected frequency of CpG dinucleotides within a given region was calculated by
multiplying the number of Cs by the number of Gs, giving the number of CpGs that
would be present if nucleotides were incorporated at random. The observed number
of CpGs was then divided by the expected number of CpGs and multiplied by the to-
tal number of nucleotides in the region to give an observed/expected CpG frequency.
Gardiner-Garden & Frommer (1987) calculated this observed/expected CpG frequency
for a 100bp window around each nucleotide and also calculated the percentage G+C
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for each window. A CGI was defined as any stretch of 200bp or more where ob-
served/expected CpG frequency was greater than 0.6 and G+C was greater than 50%.
Of the sequences examined, 68 did not contain a CGI whilst 51 contained a 5’-CGI,
starting upstream of the transcriptional start site, and 11 contained a 3’-CGI, starting
downstream of the translational start site. In addition, five sequences contained both
5’- and 3’-CGIs whilst two sequences contained a CGI starting between transcriptional
and translational start sites. Interestingly, they found that the 5’-CGIs extended much
further into the gene than was expected, in most cases covering part of the coding
sequence.
All manner of interesting avenues for bioinformatic analysis became possible with
the completion of the draft human genome sequence, including the chance to assess
the number of of CGIs present within the genome. Using the definition proposed by
Gardiner-Garden and Frommer, 28,890 CGIs were found within the repeat masked se-
quence (Lander et al., 2001). Interestingly their density per chromosome was quite
variable averaging 10.5 islands per Mb but ranging between 2.9 islands per Mb on
chromosome Y to 43 islands per Mb on chromosome 19. Subsequently, analysis of
SAGE tags and published cDNA sequences allowed the definition of 10,255 gene pro-
moters within the human genome, of which 79% contained a CGI (Bajic et al., 2006).
This was a substantially greater proportion than the previous estimates of 55-57% (An-
tequera & Bird, 1993, Larsen et al., 1992) highlighting the pivotal role played by CGIs
in gene expression, particularly for ubiquitously expressed genes. ChIP-on-chip anal-
ysis of active promoters within fibroblasts, identified using an antibody against RNA
polymerase II pre-initiation complex, defined 9328 active promoters, of which 88%




Bioinformatic detection of CGIs did however highlight some issues with the se-
quence based definition of a CGI as many of the CGIs detected were not associated
with a transcriptional unit. One particular problem is the presence of extensive tracts of
repetitive DNA sequences within the genome including Alu elements, some of which
are notably CpG rich (Britten et al., 1988, Jurka & Smith, 1988). Takai & Jones (2002)
endeavoured to adapt the CGI definition in order to exclude non-gene-related elements
and found that by increasing the stringency of the thresholds to greater than 500bp in
length, greater than 55% G+C and observed/expected CpG frequency of greater than
0.65 they could exclude the majority of Alu repeats and unidentified sequences from
detection as a CGI. However, the length distribution of 5’-CGIs was found to be bipha-
sic with an average length of 1300bp but a small but significant proportion of 5’-CGIs
falling between 200 and 400bp in length therefore their method did exclude a small
proportion of known 5’-CGIs. Subsequently, a study focussing on chromosome 21q
identified 149 CGIs using thresholds of minimal length 400bp, G+C greater than 50%,
and observed/expected CpG frequency of greater than 0.6, on sequence masked for Alu
and LINE-1 elements, thus minimising the incidence of non-gene-associated CGIs to
26 (Yamada et al., 2004). Of these, 10 contained sequences identified as tandem re-
peats that in 8 cases were completely methylated, suggesting that they represented
repeat regions that had not been detected by the sequence masking. Of the remaining
non-gene-associated CGIs, 15 were found to be unmethylated and not contain tandem
repeats suggesting a potential regulatory role, either of a spatially distant gene or of a
currently unidentified gene.
Yamada et al. (2004) also identified 123 gene-associated CGIs, 94 (76%) of which
covered the 5’-untranslated region (5’-UTR) and 26 (21%) of which covered the cod-
ing sequence, introns, or 3’-UTR. Of the 5’-CGIs, 84% were found to be completely
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unmethylated whilst only 19% of the 3’-CGIs were unmethylated, highlighting the po-
tential functional difference between CGIs spanning the 5’ end of the gene and those
within the body and 3’ end of the gene. Further to this, Bock et al. (2007) argued that
in addition to being gene-associated, ‘bone fide’ CGIs ought to be largely unmethy-
lated with strong basal promoter activity in order to have the potential for regulation
by methylation. To evaluate this they compared sequence characteristics of predicted
CGIs with epigenomic datasets for chromosomes 21 and 22 quantifying DNA methy-
lation, RNA polymerase II pre-initiation complex binding, DNaseI hypersensitivity,
SP1 binding and histone modification states to identify features that imply a regula-
tory role. The data were used to generate a combined epigenetic score between 0
and 1, reflecting the ‘strength’ of a CGI. Using a threshold of 0.5 they found 21,631
‘bone fide’ CGIs within the human genome, available as a track in the UCSC genome
browser. However, even with this refinement more than 40% do not overlap with anno-
tated transcriptional start sites suggesting either a substantial number of undiscovered
transcripts, which seems unlikely given the large number of transcriptional datasets
available at the time, or a functional role for CGIs that are spatially separated from
transcriptional start sites.
1.2.1 Functions of DNA methylation
The central functional role of DNA methylation is to prevent expression of nearby
genes. It does this through two key mechanisms: direct blocking of transcription fac-
tor binding when present in the recognition sequence (Campanero et al., 2000), and
recruitment of chromatin modifying enzymes via methyl-CpG binding proteins to ini-
tiate condensation of the local chromatin (reviewed by Klose & Bird (2006)). Gene
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silencing by DNA methylation is essential for normal development during embryoge-
nesis as demonstrated by the generation of mice lacking each of the enzymes respon-
sible for DNA methylation, which are non-viable (Li et al., 1992, Okano et al., 1999).
De novo DNA methylation occurs post-implantation, following a reduction in global
methylation during blastocyst formation (Howlett & Reik, 1991, Monk et al., 1987).
DNA methylation helps to establish the gene expression patterns that characterise each
tissue by silencing those genes that are not required. The pluripotency genes Oct-4
and Nanog, for example, are expressed in embryonic stem cells but silenced by methy-
lation in trophoblast stem cells, enabling further differentiation (Hattori et al., 2004,
2007). The proportion of methylated CGIs in a selection of healthy somatic tissues
varies between 5.7% in brain and 8.3% in muscle with some CGIs methylated only in
one tissue whilst others are methylated in all tissues (Illingworth et al., 2008). Gene
ontology analysis revealed that this subset of genes regulated by DNA methylation
were enriched for developmental specific genes and transcription factors highlighting
their role in lineage definition.
During development, DNA methylation is responsible for X-chromosome inactiva-
tion in females, where one of the X-chromosomes is completely silenced in each cell to
ensure gene dosage is the same as in males who only have one X-chromosome (Lyon,
1961, Ohno et al., 1959). This process is initiated by a long noncoding RNA called
XIST that coats the X-chromosome to be inactivated prior to the establishment of DNA
methylation and histone modifications, which condenses the chromatin into an inacces-
sible state (reviewed by Goto & Monk (1998)). Interestingly XIST expression is in turn
regulated by DNA methylation, the XIST promoter of the inactivated X-chromosome
remains unmethylated whilst the XIST promoter on the active X-chromosome is si-
lenced by methylation (Norris et al., 1994), raising the possibility that differential
methylation is responsible for both triggering and maintaining the inactivation of one
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X-chromosome.
A related role of DNA methylation is genomic imprinting, whereby particular
genes are expressed only from the maternal or paternal allele because the alternate
allele is ‘imprinted’ by extensive DNA methylation. Imprinting is particularly crit-
ical in mammals, where embryos containing two sets of maternal or paternal chro-
mosomes are non-viable (McGrath & Solter, 1984). The first characterised exam-
ple of an imprinted gene was IGF-II, mutations of which were shown to be propa-
gated only through the paternal germ-line in mice because the maternal allele is si-
lenced (DeChiara et al., 1991). IGF-II was later demonstrated to also be paternally
imprinted in humans (Giannoukakis et al., 1993) although some imprinted genes are
species-specific, for example ASCL2 is imprinted in mice but not humans (Guille-
mot et al., 1995, Miyamoto et al., 2002). Several imprinted genes in humans have
been identified through their involvement in human disease. Double gene dosage of
paternally expressed ZAC following paternal uniparental disomy of chromosome 6
has been shown to be involved in transient neonatal diabetes mellitus (Varrault et al.,
2001) whilst Prader-Willi syndrome is caused by deficiencies of the paternally ex-
pressed genes SNRPN (Glenn et al., 1993) and NDN (MacDonald & Wevrick, 1997)
when their gene loci 15q12 is deleted in the paternal allele (Knoll et al., 1989).
In addition to these regulatory roles, the bulk methylation of non-CGI DNA plays
an important protective role in the genome, ensuring that pathogenic DNA elements
such as Alu elements are inactivated. Since Alu elements, with the assistance of the
L1 transposase enzyme can insert themselves throughout the genome by retrotranspo-
sition (Dewannieux et al., 2003), they have the potential to cause widespread disruption
by integrating within genes. One new insertion is estimated to occur in every 200 new
births, contributing to 0.1% of human genetic disorders (Deininger & Batzer, 1999).
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Alu repeats are extensively methylated within the genome (Schmid, 1991) and conse-
quently undergo a high rate of 5mC →T mutation (Britten et al., 1988, Jurka & Smith,
1988). The methylation of CpG dinucleotides within Alu repeats provides an important
regulatory role, recruiting methyl-CpG binding proteins that promote the formation of
heterochromatin (Huang et al., 2004), preventing further retrotransposition and effec-
tively silencing the Alu elements. The importance of this protective role is highlighted
by ICF syndrome, a disorder where satellite DNA that should be methylated is un-
methylated due to mutations in DNA methyltransferase (DNMT) 3b (Xu et al., 1999).
This results in widespread genomic instability, causing a phenotype characterised by
immunodeficiency and facial anomalies.
The critical role of DNA methylation in somatic tissues is the transcriptional re-
pression of genes that are not required in a given cell type. The importance of this
role is highlighted by the potential for malignancy when these methylation patterns
go awry. Aberrant DNA methylation has long been recognised as a key hallmark of
human cancers, often silencing tumour-suppressor genes such as MGMT, CDKN2B
and RASSF1A (reviewed by Jones & Baylin (2002)). Genome-wide analysis of the
DNA ‘methylome’ in cancer has revealed extensive hypomethylation of bulk DNA in
combination with hypermethylation of promoter CGIs (Weber et al., 2005). In breast
cancer cell lines a clear shift in methylation pattern was observed upon epithelial-
to-mesenchymal transition (Ruike et al., 2010), which accompanies progression to
metastatic disease, whilst another study identified 5 genes whose methylation status
allowed discrimination between tumour subtypes (Bediaga et al., 2010). Additionally,
the extent of demethylation of the LINE-1 element in colon tissue has recently been
demonstrated to be predictive of colon cancer risk (Kamiyama et al., 2012) suggest-
ing that DNA methylation patterns could provide valuable biomarkers for the early
detection, diagnosis and prognosis of malignancy.
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1.2.2 Mechanism of DNA methylation and demethylation
DNMT3a and DNMT3b, identified by sequence similarity search with a bacterial
DNMT, are capable of methylating completely unmethylated DNA (Okano et al.,
1998). Both are highly expressed in embryonic stem cells but down-regulated in dif-
ferentiated embryoid bodies and adult somatic tissues (Okano et al., 1998). In ad-
dition, inactivation of these genes in mice blocks de novo methylation in embryonic
stem cells (Okano et al., 1999) suggesting that DNMT3a and 3b represent the de novo
methyltransferases. Each has a different specificity, conferred by the N-terminal do-
main, with DNMT3a crucial to parent of origin specific gene imprinting (Kaneda et al.,
2004) whilst DNMT3b targets centromeric minor satellite repeat regions (Okano et al.,
1999). A further member of the DNMT3 family, DNMT3L has mutations within the
catalytic domain that prevent it from acting as a methyltransferase (Hata et al., 2002).
However, it is required for correct formation of the maternal imprint (Bourc’his et al.,
2001), acting as a stimulating factor for DNMT3a (Chedin et al., 2002). Once the
methylation pattern has been established it it is stably maintained through cell replica-
tion (Stein et al., 1982, Wigler et al., 1981). DNMT1 has been identified as the mainte-
nance methyltransferase (Bestor et al., 1988), efficiently methylating hemimethylated
CpG dinucleotides but not unmethylated DNA in vitro (Gruenbaum et al., 1982).
Demethylation of CGIs promotes formation of an open chromatin structure thus
permitting gene expression in a tissue or developmental stage-specific fashion. De-
methylation could occur as an active, enzyme catalysed reaction where the methyl
group is cleaved from the cytosine base. Alternatively it could be a passive process
whereby exclusion of DNMT1 from the replication fork prevents the maintenance of
the methylation state, leading to hemimethylated DNA that upon subsequent repli-
cation events excluding DNMT1 would become completely unmethylated. Evidence
for both mechanisms has been identified during embryogenesis where the paternal
46
1.2.2 MECHANISM OF DNA METHYLATION AND DEMETHYLATION
genome is demethylated within eight hours post fertilisation and prior to any cell divi-
sion whilst the maternal genome becomes demethylated over several rounds of DNA
replication (Mayer et al., 2000). Despite compelling evidence for the existence of
active demethylation, both in a global (Hajkova et al., 2002) and locus-specific fash-
ion (Lubin et al., 2008), the mechanism and enzymes that lead to demethylation remain
contentious.
The demethylation pathway has been characterised in plants, where a 5mC-specific
glycosylase removes the entire base, leaving an abasic site into which enzymes of
the base excision repair pathway ligate an unmethylated cytosine base (Zhu, 2009).
However, no mammalian homologue of the plant 5mC-specific glycosylases have been
identified suggesting that this pathway may not be used in mammals. Base excision
repair could be used following a different modification to the 5mC base such as deam-
ination to thymidine, which would activate a mismatch repair pathway. Recent stud-
ies have shown that activation induced cytosine deaminase (AID) is involved in active
DNA demethylation during reprogramming towards pluripotency (Bhutani et al., 2010,
Popp et al., 2010). However, AID knockout mice are viable, showing a phenotype re-
stricted to anomalies of B-cell terminal differentiation (Muramatsu et al., 2000), whilst
homozygous mutations of the AID gene have been identified in patients with hyper-
IgM syndrome (Revy et al., 2000). This suggests that whilst AID may contribute to
active demethylation, loss of AID does not lead to complete disruption of demethyla-
tion pathways, which would result in developmental defects. RNF4, an E3 ubiquitin
ligase, has been demonstrated to be critical to DNA demethylation through interaction
with the base excision repair proteins TDG and APE1 (Hu et al., 2010). Homozygous
knockout of RNF4 is embryonic lethal and causes global hypomethylation in mouse
embryonic fibroblasts suggesting a potential role in developmental methylation how-
ever the exact role of RNF4 is unclear, as is the glycosylase or deaminase initiating
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this pathway, though the evidence suggests it is not AID (Hu et al., 2010).
Other studies have suggested that GADD45a, a DNA damage response protein,
is involved in in active demethylation by recruiting components of the nucleotide ex-
cision repair pathway (Barreto et al., 2007, Schmitz et al., 2009). However, the re-
sults are open to debate as others have failed to replicate them (Jin et al., 2008) and
GADD45a knockout mice do not show global or locus-specific hypermethylation (En-
gel et al., 2009). One group has identified a protein, MBD2, with specific cytosine
demethylase activity in an in vitro system that can directly release the methyl group
from 5mC (Bhattacharya et al., 1999), an impressive catalytic achievement as it in-
volves the breaking of a thermodynamically stable carbon-carbon bond. MBD2 is re-
quired for valproate induced demethylation of a replication deficient reporter construct
in HEK293 cells (Detich et al., 2003) supporting its role as an active demethylase.
However, another report suggests that in vivo MBD2 is a component of a transcrip-
tional repression complex that strongly binds to methylated DNA without demethylat-
ing it (Ng et al., 1999). Additionally, paternal demethylation in oocytes from MBD2
knockout mice proceeded normally, suggesting that MBD2 is not involved in develop-
mental reprogramming (Santos et al., 2002). All these potential DNA demethylation
mechanisms are outlined in Figure 1.3.
1.2.3 Methods for quantification of DNA methylation
There are two main approaches for detecting methylation: direct methods using en-
zymes that recognise or are blocked by the methyl group or indirect methods using
bisulphite conversion to convert all cytosines to tyrosines leaving the 5mC uncon-
verted. The fact that some restriction enzymes are unable to cleave DNA if their
recognition site contains 5mC has been used as a tool since the very early studies
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Figure 1.3: Potential DNA demethylation mechanisms
It remains unclear how DNA demethylation occurs in mammalian systems. Potential
mechanisms are presented here along with a diagrammatic representation of the
changes being described. Firstly methyl-cytosine could be deaminated to thymidine,
which would then be detected and replaced by the mismatch repair pathway.
Alternatively, the methyl-cytosine base could be excised by a glycosylase followed by
replacement of cytosine by the base excision repair pathway. Another possibility,
though highly chemically unlikely, is that the methyl group may be directly cleaved
from the cytosine base. Finally, the entire methyl-cytosine nucleotide could be
excised by the nucleotide excision repair pathway and replaced by the actions of DNA
polymerase and ligase.
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on DNA methylation, often in conjunction with Southern blotting to detect the methy-
lation level in specific genes such as ApoAI (Shemer et al., 1990). This is a very
sensitive and accurate technique but requires large quantities of input DNA and a spe-
cific probe for the region of interest. In addition a restriction site needs to be present
in the region of interest, which can limit the regions to be examined. Methyl-sensitive
restriction digestion can also be used in a genome-wide manner to perform a variant
of restriction landmark genomic scanning (Takamiya et al., 2006) or in combination
with ligation mediated PCR (Khulan et al., 2006). These techniques can be used to
highlight a substantial number of differentially methylated regions within the genome
but are not truly ‘genome-wide’ as they are only interrogating methylation within the
restriction sites used.
The alternative approach to direct identification of methylated DNA involves im-
munoprecipitation of the methylated DNA fraction using anti-5mC antibodies (Weber
et al., 2005) or methyl-CpG binding domain based proteins (Gebhard et al., 2006).
Initially the methylated and unmethylated DNA fractions were compared by hybridi-
sation to arrays, either specifically interrogating known CGIs or on whole genome
tiling arrays (Wilson et al., 2006). More recently, direct sequencing of the methylated
fraction has been employed (Down et al., 2008) allowing a more thorough analysis.
One major advantage of this method is that it can be performed in parallel with ChIP,
allowing analysis of the overlap between DNA methylation and chromatin marks in
identical samples. This approach has been used to determine that CGIs which are sus-
ceptible to methylation in prostate cancer cell lines are characterised by the presence of
a H3K27me3 modification whilst those which are resistant to methylation are charac-
terised by H3Ac, H3K4me3 and the presence of RNA polymerase II (Takeshima et al.,
2009). This pattern was maintained in breast cancer cell lines even though the subset of
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methylation susceptible CGIs was substantially different between the two tissues, sug-
gesting a possible mechanistic role in malignancy associated hypermethylation. The
main limitation of these techniques is the affinity and specificity of the proteins used
to isolate methyl-DNA, which can introduce a bias by isolating fractions only within a
specific range of CpG densities (Robinson et al., 2010).
Bisulphite conversion based techniques rely on the use of sodium bisulphite to add
a sulphate group to cytosine under acidic conditions, encouraging hydrolytic deami-
nation of the cytosine sulphonate to uracil sulphonate. However, the methyl group of
5mC protects the amino group from deamination leaving all 5mC residues unaffected
(Figure 1.4). During re-purification of the DNA it is subjected to alkaline desulphona-
tion leaving uracil residues at each position that was previously an unmethylated cy-
tosine (Frommer et al., 1992). Bisulphite conversion carries the risk of DNA degra-
dation and incomplete conversion if not optimised and controlled properly however
it does offer the opportunity to acquire extensive methylation data by detecting un-
methylated C as a C→T polymorphism in downstream analysis. A popular technique
for assessing methylation is methylation specific PCR (MSP), which uses primers spe-
cific to the bisulphite converted methylated sequence to detect methylated DNA and
primers specific to the bisulphite converted unmethylated sequence to detect unmethy-
lated DNA (Herman et al., 1996). This is a very sensitive technique that can be used
to detect a small proportion of methylated DNA within an unmethylated background
but it is limited by primer design, which can cover only a few CpG dinucleotides each.
One solution to this is to use bisulphite specific primers for PCR then subject the am-
plicon to high resolution melt analysis (Wojdacz & Dobrovic, 2007). The melting
temperature will be affected by the C/T content of the amplicon and thus reflects the
overall methylation of the amplicon but gives no information on the individual CpG
dinucleotides.
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Figure 1.4: Mechanism of bisulphite conversion
Chemical structures showing the stages of bisulphite conversion. The sulphonation
reaction cannot proceed in the presence of a methyl group on the cytosine base.
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The most comprehensive method of downstream analysis is to sequence the bisul-
phite converted DNA, allowing examination of the whole CGI. Direct sequencing of
bisulphite converted DNA is possible if the original sample is expected to have homo-
geneous levels of DNA methylation but if a mixed population of input cells has been
used it is necessary to clone the bisulphite converted DNA and sequence a number
of clones in order to determine the percentage of cells with 5mC at each CpG dinu-
cleotide. Pyrosequencing, a sequencing by synthesis technique, enables quantitation of
the proportions of each base present at a polymorphic site (Tost et al., 2006). Pyrose-
quencing of bisulphite converted DNA therefore enables the proportion of DNA me-
thylated at each CpG site within a CGI to be measured, which is useful when measuring
DNA methylation in a mixed population of cells. With the reduction in cost and in-
crease in availability of next-generation sequencing technologies, whole genome bisul-
phite sequencing represents an approach with the potential to generate huge volumes of
DNA methylation data. However, the bisulphite conversion step reduces the complex-
ity of the DNA sequence making the short read data generated by these technologies
difficult to map to a reference genome (Xi & Li, 2009). Although still in the early
stages of development, third-generation single molecule sequencing has the potential
to circumvent these issues, generating read lengths in excess of 100bp and possibly
much longer (Schadt et al., 2010). In addition to this, nano-pore based sequencing can
innately detect the difference between methylated and unmethylated cytosine (Wallace
et al., 2010), thus promising to remove the requirement for any manipulation of DNA
prior to detection of methylation at some point in the future.
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1.2.4 DNA methylation in T-cells
The importance of DNA methylation to the development of T-cell lineages was first
shown in 1986 when it was observed that treatment of CD8+ T-cells with the methy-
lation inhibitor 5-aza-2’-deoxycytidine (5aza) led to the expression of CD4 on their
surface (Richardson et al., 1986), suggesting that DNA methylation is responsible for
silencing the CD4 antigen in CD8+ T-cells. By contrast, treatment of CD4+ T-cells
with 5aza did not lead to any alteration in the cell surface marker phenotype how-
ever the previously antigen-specific cells did become self-reactive, a change that could
be blocked using anti-CD3 (Richardson, 1986). Interestingly, both CD4+ and CD8+
T-cells developed thymocyte-like features upon treatment with 5aza suggesting that
DNA methylation is crucial to the progression of T-cell maturation. Further support-
ing this theory, mature T-cells were found to contain a significantly greater proportion
of 5mC than thymocytes (Golbus et al., 1990). Selective inactivation of DNMT1 at
different stages of thymocyte development in a transgenic mouse model led to sub-
stantial changes in their T-cell differentiation (Lee et al., 2001). DNMT1 knockout in
double-negative thymocytes led to a decreased proportion of TCRαβ cells and an in-
creased proportion of TCRγδ cells that aberrantly expressed CD8. DNMT1 knockout
in double positive thymocytes did not affect the number or proportion of CD4+TCRαβ,
CD8+TCRαβ or TCRγδ cells but it did generate a reduced proportion of memory T-
cells. This was due to reduced activation induced proliferation and increased cytokine
mRNA expression in the naïve T-cells of these mice.
T-cells taken from patients with the autoimmune disease systemic lupus erythe-
matosus have been found to display global hypomethylation when compared to healthy
T-cells (Richardson et al., 1990). In addition, the drugs hydralazine and procainamide,
which have been observed to initiate a lupus-like autoimmune disease in some patients,
have been shown to act by inhibition of DNA methylation (Cornacchia et al., 1988) and
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treatment of activated murine CD4+ T-cells with DNMT inhibitors prior to adoptive
transfer into syngeneric recipients induces a lupus like disease (Quddus et al., 1993).
These observations suggest that hypomethylation of T-cells induces changes in gene
expression that are sufficient to substantially alter the functional role of the T-cells.
Fascinatingly, a more recent study (Zhao et al., 2011) suggests that over-expression
of miR-126 in CD4+ T-cells from lupus patients is responsible for down-regulation
of DNMT1 expression, contributing to the observed hypomethylation. Thus, targeted
down-regulation of miR-126 may have potential as a mechanism to reverse the hy-
pomethylation and restore the T-cells to their original state.
Several genes critical to T-cell lineage commitment have been investigated with
respect to DNA methylation and two examples have been chosen here to highlight the
variety of regulatory mechanisms that DNA methylation can induce. Rapid induction
of IL-2 expression is observed upon the activation of naïve T-cells: the secretion of
IL-2 initiates a signalling pathway leading to rapid proliferation of the activated T-
cells (Smith, 1984). Concomitant with this induction, CpG dinucleotides 2-6 in the IL-
2 promoter become rapidly demethylated, an alteration which is sufficient to enhance
IL-2 expression in an IL-2 promoter driven reporter construct (Bruniquel & Schwartz,
2003). Of note, demethylation was observed within seven hours of T-cell activation
whilst 48 hours was required to observe any cell division. In addition, blocking of the
cell cycle with rapamycin did not prevent demethylation, strongly suggesting that an
active demethylation process is being observed.
Th1 or Th2 polarisation is induced by the cytokine milieu present during antigen
presentation by dendritic cells (Kapsenberg, 2003). Polarisation induces the expres-
sion of a ‘master regulator’ transcription factor, Tbet for Th1 (Szabo et al., 2000) and
GATA3 for Th2 (Zheng & Flavell, 1997), driving expression of the relevant cytokines.
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The Th2 cytokines IL-4, IL-13 and IL-5 are coordinately regulated by the CNS-1 el-
ement (Loots et al., 2000). In naïve T-cells the IL-4 promoter and intron 1 are 70%
methylated whilst the CNS-1 is 90% methylated allowing only basal levels of IL-4
transcription (Makar et al., 2003). Upon Th2 polarisation the IL-4 promoter and intron
1 become hypomethylated within four days whilst the CNS-1 becomes hypomethylated
over a week later (Lee et al., 2002). Since IL-4 expression is induced within hours and
the rate of demethylation is relatively slow, in this case passive demethylation through
non-recruitment of DNMT1 to the replication fork is likely to be responsible and hy-
pomethylation is being used to maintain rather than initiate the change in expression.
More recent studies have begun to use high throughput methods to define charac-
teristic patterns of DNA methylation in T-cells. Examination of 27,458 CGIs revealed
that only 5% were methylated in primary human CD4+ T-cells (Hughes et al., 2010).
In addition 388 genes were identified that had a methylation peak within -5kb and
+1kb of the transcriptional start site. Of these, 72.8% were not expressed and func-
tional network analysis revealed these genes to be involved in antigen presentation
and immune response. The genes that were expressed despite the presence of a DNA
methylation peak were observed to be involved in cellular signalling and proliferation.
The majority of these genes were also found to have a DNaseI hypersensitivity site
spanning the transcriptional start site, suggesting that the chromatin remained accessi-
ble despite the presence of DNA methylation. Comparison of CD4+CD25high Treg cells
to CD4+CD25- conventional T-cells using an array targeting genes that were differen-
tially expressed between the two cell types revealed 132 regions of lineage-specific
methylation associated with 53 genes (Schmidl et al., 2009). Interestingly only seven
of these overlapped with the transcriptional start site of a gene, including FOXP3 the
major transcriptional regulator of Treg cells (Fontenot et al., 2003), whilst the remain-
der were located within gene bodies or intergenic regions. It was further determined
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that a proportion of these regions showed enhancer activity that could be prevented by
methylation suggesting a key functional role for gene distal methylation.
1.2.5 DNA methylation in lymphoma
DNA methylation anomalies are frequently described in malignancy and associated
with all stages of tumour formation and progression (Baylin & Ohm, 2006). Aberrant
DNA methylation often affects genes associated with the DNA repair and cell cycle
checkpoints (Toyota et al., 2009), thus releasing cells from normal growth control and
increasing the rate of genetic mutations. Since correct formation and maintenance of
DNA methylation is vital to the development of different T-cell lineages it is expected
that disruption of DNA methylation in T-cells could lead to errors in the stability of
T-cell subsets and hence the delicate balance of the immune system.
Hypermethylation of the cell cycle regulators p15 and p16 is a feature common
to haematological malignancies (Herman et al., 1997) and has also been repeatedly
characterised in CTCL (Gallardo et al., 2004, Navas et al., 2000, Scarisbrick et al.,
2002). Other genes in which silencing by promoter methylation has been characterised
in CTCL include MLH1 (Scarisbrick et al., 2003) and SHP-1 (Zhang et al., 2000).
MLH1, a DNA mismatch repair gene, was investigated in patients showing micro-
satellite instability and found to show promoter hypermethylation in 9/14 cases. In
five of these, promoter hypermethylation correlated with abnormal MLH1 expression
suggesting that this might contribute to micro-satellite instability. SHP-1, a tyrosine
phosphatase was found to have evidence of promoter hypermethylation in the HuT78
cell line associated with a lack of mRNA or protein. Since an inhibitor of methylation
restored expression, loss of SHP-1 can be attributed to promoter hypermethylation in
this cell line however studies of SHP-1 methylation in primary malignant cells taken
from lymphoma patients showed mixed results as discussed further in Section 3.1.
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Global DNA methylation analysis of 367 haematological malignancy samples re-
vealed that lymphoid malignancies are associated with higher levels of DNA methy-
lation than myeloid malignancies and that DNA hypermethylation was particularly
prevalent in malignancies of lymphoid precursor cells (Martin-Subero et al., 2009).
DNA hypomethylation was also observed with 108 genes hypermethylated and 47
genes hypomethylated across the T-cell lymphomas examined. Only one study has
used an array to examine methylation of CGIs within CTCL samples. This identified
35 genes whose promoters were hypermethylated in at least 4 of 28 MF samples (van
Doorn et al., 2005) when compared to healthy T-cells. Bisulphite sequencing was used
to confirm the presence of hypermethylation in BCL7a, TPTRG, THBS4, p15, p16,
p73, MGMT, TMS1 and CHFR. Further to this, demethylation of the MyLa cell line
with 5aza was demonstrated to reactivate expression of BCL7a and PTPRG. However,
the array used in this study only interrogated 8640 CGIs thus missing a proportion of
potentially informative CGIs and no SS samples were included.
1.3 Aims of the thesis
It is clear that a myriad of molecular defects contribute to the malignant transformation
of skin-homing T-lymphocytes in SS and MF. The integration point of these defects
is the T-cell signalling pathways which, through constitutive activation or signalling
blockade, combine to generate a population of T-cells that proliferate only slowly but
are resistant to apoptosis. Whilst extensive gene expression and genomic studies have
been performed to delineate the mechanisms leading to dysregulation of T-cell sig-
nalling pathways, limited investigation of the role of DNA methylation has been per-
formed. Therefore, the aim of this thesis was to investigate the contribution of DNA
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methylation to the regulation of three genes with potentially central roles in dysregula-
tion of T-cell signalling. A target gene approach was chosen in order to enable the in-
vestigation of CGI methylation in greater detail than is possible using high throughput
methods. The genes chosen for investigation were: SHP-1, silencing of which could
contribute to constitutive STAT3 activation; Fas, silencing of which could contribute
to reduced AICD; and PLS3, re-expression of which could contribute to disruption of
cytoskeletal rearrangements at the immunological synapse. Each gene contains a CGI
upstream of or spanning the transcriptional start site and was not included in the DNA
methylation arrays used by van Doorn et al. (2005) (Heisler et al., 2005). Further
background to the individual genes is provided in Sections 3.1, 4.1 and 5.1.
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Materials and methods
2.1 Collection and processing of samples
All patient samples were obtained from a national approved research tissue bank (07/
H10712/106) of cutaneous lymphoma samples. For all samples, informed consent
was obtained in accordance with the declaration of Helsinki 1975 as revised in 2005.
Blood and tissue samples were obtained from consenting patients during the course of
standard clinical procedures. Healthy blood samples were obtained from volunteers
with project-specific approval from the Guy’s and St. Thomas’ hospital research ethics
committee (EC01/301) or through the national blood service.
All patients fulfilled the WHO-EORTC diagnostic criteria for CTCL (Willemze
et al., 2005). T-cell clonality was assessed in blood and tissue samples using TCRVβ
and γ gene rearrangement studies with BIOMED-2 primer sets (van Krieken et al.,
2007). For each sample, total lymphocyte and lymphocyte subset counts were recorded
at the time of sampling as an indicator of circulating tumour burden. For SS patients
the percentage of Sézary cells in the lymphocyte population was counted in blood
smears by one expert investigator at regular intervals but not alongside each sample.
Tissue samples were bisected and half was formalin fixed and paraffin embedded
(FFPE) prior to immunohistochemical analysis for diagnostic purposes. FFPE blocks
were then stored in the tissue bank for future research use. DNA was extracted from
the remaining half of each tissue section prior to TCR gene rearrangement studies.
Any remaining DNA was then deposited in the tissue bank.
Blood was collected into EDTA vacutainers prior to Lymphoprep (Axis-shield,
Kimbolton, UK) gradient centrifugation to isolate PBMCs. To isolate CD4+ T-cells,
blood was incubated with RosetteSep CD4+ T-cell enrichment cocktail (Stem Cell
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Technologies, London, UK) prior to Lymphoprep gradient centrifugation. Negative
selection was chosen as an isolation method in order to avoid activating the cells dur-
ing processing, which could potentially cause changes in gene expression. Isolated
PBMCs or CD4+ T-cells were suspended at 1×106 cells/ml in freezing medium of
90% FCS (Invitrogen Ltd., Paisley, UK) and 10% DMSO (Sigma Aldrich, Dorset,
UK) then stored under liquid nitrogen until required.
2.2 Cell culture
Cell stocks were resuscitated from liquid nitrogen storage a few weeks prior to use.
The SS cell lines HuT78 and SeAx, MF cell line MyLa and leukaemic cell line Ju-
rkat were maintained in RPMI (Invitrogen) supplemented with 10% FCS (Invitro-
gen) and 1×penicillin/streptomycin (Invitrogen). SeAx cells were additionally sup-
plemented with 25U/ml IL-2 (Invitrogen). HEK293 (human embryonic kidney) cells
were maintained in D-MEM (Invitrogen) supplemented with 10% FCS (Invitrogen)
and 1×penicillin/streptomycin (Invitrogen). Cells were passaged every 3-4 days up to
a maximum of 25 passages. Kit225, HeLa and primary keratinocytes and fibroblasts
were generously provided by colleagues as a cell pellet prior to lysis.
2.3 Extraction of RNA
Pelleted cells were lysed in buffer RLT from the RNeasy mini kit (Qiagen Ltd., Craw-
ley, UK) then homogenised using a QIAshredder column (Qiagen). RNA extraction
was completed using the RNeasy mini kit (Qiagen) according to the manufacturers
instructions. RNA concentration was measured using the Nanodrop-1000 (Thermo
Scientific, Epsom, UK). FACS sorted cells that had previously been subject to fixation
were digested with proteinase K in Buffer PKD from the RNeasy FFPE kit (Qiagen)
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for 15 min at 55°C followed by 15 min at 80°C in order to release the RNA from the
cross linked protein matrix. RNA extraction was completed using the RNeasy FFPE
kit (Qiagen).
2.4 Generation of cDNA
The high capacity cDNA archive kit (Applied Biosystems, Warrington, UK) was used
to generate randomly primed cDNA from up to 1µg of RNA in a 20µl reaction ac-
cording to the manufacturers instructions then reverse transcription PCR (RT-PCR)
using primers against the housekeeping gene Cyclophilin was performed as described
in Section 2.5 to check for successful generation of cDNA prior to further use of the
cDNA.
2.5 Reverse transcription PCR
RT-PCR was performed in 25µl reactions containing GeneAmp PCR Buffer II, 0.4mM
each primer, 1.5mM MgCl2, 0.2mM each dNTP and 0.625U of AmpliTaq Gold DNA
Polymerase (Applied Biosystems). All primers were ordered from MWG (Ebersberg,
Germany) and annealing temperature (Ta) was optimised for each primer pair from a
starting point of 5°C below the calculated melting temperature (Tm). PCR cycles were
performed in a GeneAmp 9700 thermal cycler (Applied Biosystems) and comprised
10 min initial denaturation at 95°C followed by 25-35 cycles of 30 sec denaturation at
95°C, 30 sec annealing at the relavent Ta and 60 sec extension at 72°C, reactions were
completed with a 5 min final extension at 72°C followed by holding at 4°C. Primer
details and Ta for each primer set used are provided in Table 2.1. PCR products were
electrophoresed through a 1.5% agarose gel and visualised using ethidium bromide.
Each set of reactions included a negative control containing water instead of cDNA
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Assay Primer sequences Size/bp Ta/°C
SHP-1 total GACTGTGACATTGACATCCAG 350 52
CTTCCTCTTGAGGGAACCCTT
SHP-1 isoform I TGGCTTCCCCCTCCCTACAGAGA 179 60
GTCACCTGATCCCCCACCCTGACG
SHP-1 isoform II CCCCCAGGATGGTGAGGTGGTT 157 60
GTCACCTGATCCCCCACCCTGACG
PLS3 TAAGGACAAGACGATCAGCTCC 495 55
TATGAGCACATTTCAGGCGTGC
Fas ACTGCGTGCCCTGCCAAGAAG 186/295 56
AAGACAAAGCCACCCCAAGTTAGA
Cyclophilin AAAGCATACGGGTCCTGGCATC 223 55
CGAGTTGTCCACAGTCAGCAATG
Table 2.1: RT-PCR primer details
and if available a known positive control.
2.6 Quantitative PCR
Real-time quantitative PCR (qPCR) was performed on the ABI Prism 7000 (Applied
Biosystems) using the manufacturers recommended cycling profile of 10 min initial
denaturation at 95°C followed by 15 cycles of 15 sec denaturation at 95°C and 60 sec
annealing and extension at 60°C. The following optimised TaqMan probe/primer sets
were used: Hs00192406_m1 - PLS3; Hs00236330_m1 - Fas and Hs99999904_m1 -
Cyclophilin in combination with TaqMan gene expression master mix (Applied Biosys-
tems) and cDNA generated from 50ng RNA in each 25µl reaction. Each sample was
analysed in triplicate for both the target gene and an endogenous control (Cyclophilin).
Target and control genes were measured on the same plate to reduce run-to-run vari-
ability and a non-template control substituting water for cDNA was included on each
plate for each TaqMan probe/primer set. ∆Ct calculations were used to normalise ex-
pression level in each sample relative to expression of the endogenous control whilst
∆∆Ct calculations were used to present patient expression as a fold change relative to
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the average of the healthy control group. No TaqMan probe/primer sets were avail-
able that could discriminate between the isoforms of SHP-1 so isoform-specific primer
sets, listed in Table 2.1, were used at 0.3mM each primer in combination with SYBR
Green PCR master mix (Applied Biosystems) to enable quantitation. PCR cycles were
the same as used for TaqMan probe/primer sets with the addition of a melting curve
analysis upon completion of the cycles to confirm the absence of non-specific ampli-
fication. Serial dilution of one sample was first used to ensure that the efficiency of
amplification from each primer set was close to 100%.
2.7 Extraction of DNA
Pelleted cells were lysed in nuclei lysis buffer (Promega, Southampton, UK) and di-
gested with proteinase K (Promega) for 24 hours. Proteins were removed using protein
precipitation solution (Promega) prior to isopropanol precipitation of the DNA. The
DNA pellet was then washed in 70% ethanol and finally resuspended in MilliQ water.
DNA concentration was measured using the Nanodrop-1000 (Thermo Scientific). For
extraction from FACS sorted cells where a low yield of DNA was expected, GenElute-
LPA (Sigma Aldrich) was added prior to isopropanol precipitation to act as a carrier
and help visualise the DNA pellet.
2.8 Generation of DNA with known methylation
For each CGI investigated, methylation level was first determined in a selection of cell
lines in order to find a completely unmethylated control. An aliquot of DNA from the
relevant cell line was then in vitro methylated in order to generate a completely methy-
lated DNA control. 1µg DNA was incubated with 4U M.SssI CpG methyltransferase
enzyme (New England Biolabs, Hitchin, UK) in NEBuffer 2 (New England Biolabs)
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supplemented with 160µM S-adenosylmethionine (New England Biolabs) for 4 hours
at 37°C followed by heat inactivation at 65°C for 20 min. The completely methylated
DNA was then isolated from the reaction mixture using a DNA clean and concentra-
tor column (Zymo Research, Orange, CA) and mixed in varying proportions with the
unmethylated DNA to create mixtures of known methylation level.
2.9 Bisulphite conversion of DNA
DNA was bisulphite treated in 10µl aliquots containing 500ng DNA using the EZ
DNA methylation kit (Zymo Research) according to the manufacturers instructions.
Following elution the converted DNA was made up to a total volume of 100µl in TE
buffer (Sigma Aldrich).
2.10 Methylation specific PCR
Bisulphite converted DNA was amplified using the previously published (Oka et al.,
2002) primers. PCR was performed in 25µl reactions containing GeneAmp PCR
Buffer II, 0.5mM each primer, 1.5mM MgCl2, 0.25mM each dNTP, 0.625U of Am-
pliTaq Gold DNA Polymerase (Applied Biosystems) and 200ng bisulphite converted
DNA. Cycles used were as described for RT-PCR in Section 2.5, primer details and Ta
are listed in Table 2.2. Products were electrophoresed through a 2% agarose gel and
visualised using ethidium bromide. Reactions with MSP and unmethylation specific
PCR (USP) primers were performed concurrently for each set of samples and each
PCR included completely methylated, completely unmethylated and negative controls.
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Assay Primer sequences Size/bp Ta/°C
SHP1MSP GAACGTTATTATAGTATAGCGTTC 158 60
TCACGCATACGAACCCAAACG
SHP1USP GTGAATGTTATTATAGTATAGTGTTTGG 161 60
TTCACACATACAAACCCAAACAAT
Table 2.2: Primers used for MSP
2.11 Pyrosequencing to measure DNA methylation
PCR using primers specific for the bisulphite treated DNA (Table 2.3) was performed
on 50ng of the converted DNA. Reactions were performed in a total volume of 50µl
containing GeneAmp PCR Buffer II, 0.2mM F and R primers, 0.2mM each dNTP,
1.5mM MgCl2 and 1.25U of AmpliTaq Gold DNA Polymerase (Applied Biosystems).
PCR cycles were performed in an GeneAmp 9700 thermal cycler (Applied Biosys-
tems) and comprised 10 min initial denaturation at 95°C followed by 35 cycles of 30
sec denaturation at 95°C, 30 sec annealing at the relevant Ta and 2 min extension at
66°C, reactions were completed with a 5 min final extension at 66°C followed by hold-
ing at 4°C. Annealing temperature was optimised for each primer pair from a starting
point of 5°C below the Tm. For the PLS3 primers a touchdown approach was found
to be optimal therefore over 10 cycles the Ta was sequentially reducing from 62°C to
52°C followed by 25 cycles at 52°C. 10µl of each PCR product was electrophoresed
through a 1.5% agarose gel and visualised using ethidium bromide to check for a good
yield of product of the expected size.
In each assay either the forward or reverse PCR primer was biotinylated (denoted
by bF or bR in Table 2.3) allowing the PCR product to be immobilised by incubation
with 3µl streptavidin sepharose HP beads (GE Healthcare UK Ltd., Little Chalfont,
UK) in binding buffer (Biotage AB, Uppsala, Sweden). A vacuum prep workstation
(Biotage) was used to capture the beads with immobilised PCR product from a 96
well plate onto filter probes. After washing in 70% ethanol the complementary strand
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Assay Primer sequences Size/bp Ta/°C
S1-bF, S2-bR TGTTTTATAGGGTTGTGGTGAGA 223 61
CTCCAAACCCAAATAATACTTCA
F5.6-bF, F7-bR GGGATAGGAATGTTTATTTGTGTA 272 60
CCTAAAACTCCAACCAAATCACTC
F8-bR, F9-bF GAGTGATTTGGTTGGAGTTTTAG 181 57
AAATCCAAATACCCAACATAATTA
F10.11.12.13-bR AATTATGTTGGGTATTTGGATTTT 394 57
ACCCTAAAACTTCCCAAACTTC
F14-bF TTGTTTTTTTTGGGTTTTGATG 422 62
ACTCATTCAACCCCCATATAACT
F15.17-bR, F16-bF GGGGATTTTGGTTGGAGAG 263 62
CATTCAACCCCCATATAACTTTT
PLS39599F-bF TGGAGTGGGGGTTAATGGTAT 205 Bisulphite
PLS39599R-bR CCTCCCAATCCCTCTTAACAAA touchdown
Table 2.3: Primers used for PCR prior to Pyrosequencing
was removed by denaturation in 0.2M NaOH and the resultant single stranded PCR
product washed in a neutralising buffer (Biotage). Beads with bound single stranded
PCR product were then deposited into a Pyrosequencing plate (Biotage) pre-filled with
3.6µmol of sequencing primer diluted in annealing buffer (Biotage). The plate was
heated to 80°C and allowed to cool to room temperature in order to anneal the se-
quencing primer. The Pyrosequencing reaction was carried out using a PSQ HS 96
machine (Biotage) following the manufacturers instructions for methylation analysis.
2.12 Sequencing
PCR was carried out in a total volume of 50µl containing GeneAmp PCR Buffer II,
0.4mM each primer, 1.5mM MgCl2, 0.2mM each dNTP and 0.625U of AmpliTaq Gold
DNA Polymerase (Applied Biosystems) using the primer sets and annealing temper-
atures described in Table 2.5. Cycles were as described for RT-PCR in Section 2.5.
Touchdown cycles were used for many of the primer sets, this comprised 10 cycles
where the Ta was sequentially reducing from 62°C to 52°C followed by 25 cycles at
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Table 2.4: Sequencing primers used in Pyrosequencing
52°C. 10µl of each PCR reaction was electrophoresed through a 1-1.5% agarose gel
to check for the presence of a single unique band of the expected size. The remaining
40µl of PCR product was purified through a clean and concentrator 5 column (Zymo
Research) and sent for sequencing (Geneservice, London, UK) using the original PCR
primers. Data were examined using Geneous (Drummond et al., 2011) with a 25%
peak height similarity cut off to detect potential mutations.
2.13 Single strand conformational polymorphism
PCR for single strand conformational polymorphism (SSCP) analysis was performed
with primer pairs described by Beltinger et al. (1998) designed to amplify all nine
exons and the 3’ end of the promoter. PCR products were labeled by substituting
α-33PdCTP for a proportion of the dCTP in the dNTP mixture. PCR products were
denatured for 10 min at 95°C then rapidly cooled prior to electrophoresis through non-
denaturing polyacrylamide gels containing both 5% glycerol and no glycerol. Gels
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Assay Primer sequences Size/bp Ta/°C
PLS3mRNA2 GATTCCGAGGTGCAGAAGTT 400 Touchdown
GAGCACAAATACCTTCTTTCCTG
PLSmRNA5b AAACTCATGCTGGATGGTGA 424 55
CCAAGTTCAAGTTTTCCTGA
PLS3mRNA7 GAAAGAGCAATCAACAAGAAGAAAC 401 Touchdown
CCTTTTGGTGCGATTTGATT
PLS3mRNA9 ATTTGGAAAACTCGGGCTGG 400 Touchdown
TTGACACCAAGAGAGTTCATCC
PLS3mRNA12 GAAACTCGTGAAGAAAGAACCTT 403 Touchdown
TGTTCACCCAGTTCACAATGA
PLS3mRNA15 TCAATGTCCTGGAAGATCTTGG 475 Touchdown
AATGGCCAAGAGTTCCTTAAGC
PLS3mRNA16 ATGATTCGCAGGTCAGCTAT 453 Touchdown
CGGCAAATTTTCAGTACTAC
PLS3mRNA17 ATGAGTATCCTTTGCTTATC 504 Touchdown
CATTTCTTTGTTTCAGGTGT
PLS3CGIT1 TTATTTTTTTTGGGTGTTTAT 263 Failed to
CAAAATCCTAAATCTAACCC optimize
PLS3CGIT2 AGTGGGGGTTAATGGTATTTGAT 204 Bisulphite
TCCTCCCAATCCCTCTTAACA touchdown
PLS3CGIT9 TGGTTTTAGAGTTATAGTTGTAAA 418 Bisulphite
ACCCAAAACTAACAACAAATT touchdown
PLS3CGIT12 TTAGTTTTGGGTTGGAGTTTTAGA 531 Failed to
TTTACCTCTCTCTCTCCAAAAATC optimize
PLS3PROPCR1 TCCCTCAAACTCTGGCTCTC 999 55
GGCGCCTACAAAGCACTTAC
PLS3PROPCR2 TCGGACCAATGTAAGCTTTTT 965 55
GAGAGCCAGAGTTTGAGGGA
Table 2.5: Primer pairs for PLS3 mRNA and promoter sequencing
were dried on to 3-mm Whatman paper and exposed to X-ray film to visualise the
bands. A negative control substituting water for the DNA was performed for each
primer pair. DNA from healthy individuals was used as a positive control.
2.14 Extraction of whole cell lysates
7×complete mini protease inhibitor and 10×complete mini phosphatase inhibitor cock-
tails (Roche) were prepared from tablets once every three months and kept at -20°C.
RIPA lysis buffer (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was supplemented
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with protease and phosphatase inhibitors immediately prior to cell lysis using 1ml
of complete RIPA buffer per 2×107 cells. After one hour of disruption on ice the
lysate was centrifuged to remove solid debris. Protein concentration was colourimet-
rically assessed using the bicinchoninic acid kit (Sigma Aldrich) and measured on the
Nanodrop-1000 (Thermo Scientific).
2.15 Western blotting
Whole cell lysates containing 5µg protein were denatured by boiling with Laemmli
sample buffer (Bio-Rad Laboratories, Hemel Hempstead, UK) for 5 min at 95°C then
loaded onto an 8% PAGE gel. After electrophoresis the proteins were transferred to
PVDF membrane using the XCell II blot system (Invitrogen). Blots were blocked
in 3% BSA/0.1% Tween/PBS or 1% Marvel/0.1% Tween/PBS and then sequentially
incubated with optimised dilutions of primary antibody (see Table 2.6) and HRP-
conjugated anti-mouse or anti-rabbit secondary antibody at 1 in 10,000 (Abcam, Cam-
bridge, UK). Chemiluminescent visualisation was performed using the ECL plus West-
ern blotting detection system (GE Healthcare) followed by exposure to X-ray film. Pre-
cision plus protein WesternC standards (Bio-Rad) were included on each gel to enable
monitoring of the gel running and transfer. Biotin-linked HRP (Bio-Rad) was added at
1 in 10,000 to the secondary antibody dilution to enable visualisation of the molecular
weight marker via the integrated Strep-tag.
2.16 Anti-PLS3 antibody generation
All stages of antibody production were completed by Cambridge Research Biochemi-
cals (Billingham, UK). An antigenic peptide unique to PLS3 (Ac-MATTQISKDELDE-
LKC-amide) was synthesised and used to immunize two rabbits six times at two-week
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Target Dye Isotype Manufacturer Dilution
SHP-1 Unconjugated Rb pIgG Atlas Antibodies 1 in 5000
pSTAT3 Unconjugated Mo mIgG1 NEB 1 in 1000
STAT3 Unconjugated Mo mIgG2a NEB 1 in 1000
CD45RO PacificBlue Mo mIgG2a Biolegend 1 in 50
Fas PE Mo mIgG1 BD Bioscience 1 in 20
CD4 PE-TexasRed Mo mIgG2a Caltag 1 in 50
CD25 PE Mo mIgG1 ebioscience 1 in 30
CD26 APC Mo mIgG2a Miltenyi 1 in 10
CD3 PE-Cy7 Mo mIgG1 ebioscience 1 in 50
CD7 PE-Cy5 Mo mIgG1 ebioscience 1 in 10
PLS3 DyLight488 Rb pIgG CRB 1 in 50 for FACS
1 in 5000 for Western
CD158k APC-Cy7 Mo mIgG2a Dr. Bagot 1 in 100
β-actin Unconjugated Mo mIgG1 Abcam 1 in 5000
Table 2.6: Antibodies used for immunodetection
intervals. One week after each immunisation blood samples were taken and antibody
titre was assessed by ELISA. After three months, antisera was harvested and subject to
affinity purification on thiopropyl sepharose 6B derivatised with the antigen. Purified
antisera was then eluted using both TEA and glycine. Serum from the final bleed was
provided for testing along with the TEA and glycine purified eluates. An aliquot of the
antigenic peptide was also provided and used as a blocking peptide when testing the
antibody specificity.
2.17 Labelling of antibodies
The CD158k and PLS3 antibodies were fluorescently labelled prior to use in flow cy-
tometry. Since the PLS3 antibody contained glycerol which interferes with the conju-
gation reaction, antibody was dialysed against PBS for 3×3 hours using a slide-a-lyzer
mini dialysis device (Thermo Scientific) then returned back to its original concentra-
tion by dialysis against slide-a-lyzer concentrating solution (Thermo Scientific). The
DyLight microscale antibody labelling kit (Thermo Scientific) was then used to label
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100µg of antibody with DyLight 488. An isotype control was labelled alongside the
specific antibody and fluorescence:protein ratio was calculated from A280 and A493 to
confirm successful staining at similar molar ratios for both specific and isotype control.
The quantity of CD158k antibody provided was insufficient for use in the DyLight mi-
croscale kit so the Lightning-Link APC-Cy7 kit (Innova Bioscience, Cambridge, UK)
was used to conjugate APC-Cy7 to CD158k antibody and its isotype control according
to the manufacturers instructions.
2.18 Staining for flow cytometry
Aliquots of frozen lymphocytes were thawed rapidly at 37°C, resuspended in pre-
warmed RPMI (Invitrogen) then washed twice in PBS (Invitrogen) containing 2%
FCS(Invitrogen) and 2mM EDTA (Sigma Aldrich) prior to incubation with the appro-
priate cocktail of antibodies from Table 2.6. SHP-1, pSTAT3 and STAT3 antibodies
were visualised using Alexa Fluor 488 conjugated anti-mouse or anti-rabbit secondary
antibody diluted to 1 in 1000 (Invitrogen). For intracellular staining, fixation in 1%
paraformaldehyde (Sigma Aldrich) followed by permeabilisation in methanol (Sigma
Aldrich) was required to allow the antibody to access its antigen. To ensure any non-
viable cells were excluded from the analysis, cells were incubated with LIVE/DEAD
fixable aqua dye (Invitrogen) prior to fixation. Prior to multi-parameter staining in-
cluding both intracellular and cell surface antigens optimisation experiments were per-
formed to investigate the effect of fixation on cell surface antigens. CD26 and CD158k
antibodies were shown to be specific only when applied prior to fixation whilst CD3,
CD4, CD45RO, CD7, and CD25 could be applied post fixation.
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2.19 Flow cytometry analysis
Flow cytometry analysis was performed on a FACSAria II (BD Bioscience, Oxford,
UK) and data were analysed using FlowJo software (Tree Star Inc., Ashland, OR).
Each tube was first gated on the viable population of lymphocytes using either FSC/SSC,
for live stained cells, or LIVE/DEAD fixable aqua dye for fixed cells. Gates were then
defined using the isotype controls for each dye used then the stained tubes were gated
by the population of interest to determine the percentage positive cells.
2.20 Fluorescence activated cell sorting
Cells were stained as described in Section 2.18 immediately prior to sorting and kept
on ice during the procedure. Accudrop fluorescent beads (BD Bioscience) were used
to set up the FACSAria II stream ready for sorting. Single stained control tubes were
used to calculate the compensation matrix to account for spectral overlap between the
fluorescent dyes. Data acquired from the isotype control and n-1 control tubes were
used to set up sorting gates. Cells were sorted into tubes containing 1ml of PBS/2%
FBS/2mM EDTA then pelleted prior to either RNA or DNA extraction as described in
Sections 2.3 and 2.7.
2.21 Immunofluorescent staining
One PLS3 expressing patient and one healthy PBMC sample were used to test the use
of the PLS3 antibody for immunofluorescent staining. 1×106 cells per well were dis-
pensed into a 96 well plate which was then spun at 800g for 5 min to attach the cells
to the bottom of the plate. Cells were then fixed and permeabilised using a range of
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reagents prior to blocking and staining with anti-PLS3 or rabbit polyclonal isotype con-
trol. A DAPI counterstain was used to visualise the nuclei then the fluorescent staining
was examined using a Zeiss Axio Observer Z1 inverted microscope. The final protocol,
found to yield strong specific staining was fixation with 1% paraformaldehyde for 15
min followed by permeabilisation in ice cold methanol for 30 min. Following a brief
wash in PBS/0.1% Tween, blocking was performed using 5% Marvel in PBS/0.1%
Tween followed by primary antibody at 5µg/ml and secondary antibody at 2µg/ml.
2.22 Patient-specific qPCR assay
The diagnostic DNA sample from the patient who provided sample R164 was retrieved
from the tissue bank and subject to PCR using the BIOMED-2 primer set incorporat-
ing α-33PdCTP. PCR products were subject to SSCP gel electrophoresis as described
in Section 2.13. All clonal bands were excised from the gel and submerged in 60µl
water, the PCR product was allowed to elute for 24 hours at 4°C then 5µl was used for
a second round of PCR with the BIOMED-2 primer set. PCR products were recovered
using the clean and concentrator 5 kit (Zymo Research) and sent for sequencing (Gene-
service) using multiplexed forward or reverse primers from the BIOMED-2 primer set.
Once the rearranged TCRβ gene sequence had been determined, a rearrangement spe-
cific forward primer was designed to cover the end of the V region, part of the D region
and the N region. J region specific reverse primers and probes were ordered accord-
ing to published sequences (Brüggemann et al., 2004). Patient-specific assays were
validated using the diagnostic sample as a positive control and pooled healthy lympho-
cyte DNA as a negative control. Sensitivity was tested and a standard curve generated
by spiking a synthetic positive control into pooled healthy lymphocyte DNA. qPCR
was performed on an ABI 7000 using 150ng DNA, 300nM each primer and 250nM
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Assay Primer and probe sequences Size/bp Ta/°C












Table 2.7: Primer and probe sets used for patient-specific qPCR assay
each probe in TaqMan universal master mix II (Applied Biosystems). In order to de-
termine the proportion of tumour cells present in each cell subset, patient-specific Ct
values were normalised against Ct values from previously validated assays detecting
the diploid genomic control regions SDC4 and BCMA (Preter et al., 2002). Primer
sequences and annealing temperatures for all assays are provided in Table 2.7.
2.23 Cloning by overlap extension PCR
This protocol was based on the method of Bryksin & Matsumura (2010), a schematic of
the cloning procedure is shown in Figure 5.13. The PCR amplification primers shown
in Table 2.7 were ordered with the sequence CTTACGCGTGCTAGCCCGGG added to
the 5’ end of each forward primer and ACCAACAGTACCGGAATGCCAAGC added
to the 5’ end of each reverse primer. These tails were designed to be complementary
to the pGL3 plasmid (Promega). PCR was carried out in a total volume of 25µl using
Phusion HF buffer, 0.6mM each tailed primer, 0.2mM each dNTP, 0.5U Phusion hot
start II DNA polymerase (New England Biolabs) and 50ng template DNA (R164 di-
agnostic sample for R164 specific rearrangement and healthy PBMCs for BCMA and
SDC4). 30 cycles of PCR were performed with an annealing temperature of 65°C. 5µl
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of each PCR reaction was electrophoresed through a 2% agarose gel to check for the
presence of a single unique band of the expected size. The remaining PCR was puri-
fied through a clean and concentrator 5 column (Zymo Research) and the concentration
was determined using a Nanodrop-1000 (Thermo Scientific). The insertion PCR was
then performed in a total volume of 25µl using Phusion HF buffer, 0.2mM each dNTP,
20ng pGL3 plasmid, 150ng tailed insert and 0.5U Phusion hot start II DNA polymerase
(New England Biolabs). 20 PCR cycles were performed with an annealing temperature
of 60°C and an extended extension step of 2 min to allow for copying of the whole plas-
mid. To check for incorporation of the insert, 5µl of the completed insertion reaction
was digested with 10U XbaI and 10U XhoI in NEB buffer 4 whilst 5µl was mock di-
gested. The sizes of the fragments generated was assessed by electrophoresis through
a 0.8% agarose gel. The remaining insertion reaction was digested with 10U XhoI
to linearise any remaining empty vector followed by digestion with 10U exonuclease
I and 2.5U λ exonuclease to remove the linearised empty vector. Insert containing
vector was purified through a clean and concentrator 5 column (Zymo Research) and
then transformed into competent E.coli, plated onto ampicillin LB agar and incubated
at 37°C overnight. Colony PCR was then performed to identify those colonies that
contained vector with insert. For each transformation, 10 colonies were streaked onto
fresh ampicillin LB agar plates then the pick was agitated in 20µl PCR mix containing
2% Tween-20 and the following pGL3 specific primers which should amplify across
the insert, F-TGTCCCCAGTGCAAGTGCAGG R-GCGGATAGAATGGCGCCGGG.
Amplicon size was assessed by electrophoresing an aliquot of PCR product through a
1.5% agarose gel then the remainder was sent for sequencing to confirm the correct




Data summarisation was performed using pivot tables in Microsoft Excel then im-
ported into R (http://www.r-project.org/) for statistical calculations and graphing. A
p value of less than 0.05 was considered significant in all cases. All comparisons be-
tween healthy and patient groups were made using Student’s t-test. Comparisons be-
tween three or more groups were made using ANOVA. In some cases a non-parametric
test was considered more appropriate for multiple group comparisons in which case
Wilcoxon unpaired U-test was used. Comparisons between subsets of cells or multiple
samples from the same patients were made using paired Student’s t-test. Correlation
was assessed using Pearson’s product moment correlation coefficient. Confidence in-
tervals for healthy population limits were calculated using 2 standard deviations (95%)




SHP-1 is a non-receptor type protein tyrosine phosphatase that has a key role control-
ling the intracellular phosphotyrosine level in lymphocytes thus providing a threshold
for activation or initiating an activation terminating signal (Wu et al., 2003). SHP-1
has been shown to act through dephosphorylation of JAKs (Jiao et al., 1996, Pandey
et al., 2009) to regulate STAT3 signalling. Lack of SHP-1, as observed in the ‘moth-
eaten’ mouse model that contains a splice site mutation in the mouse homologue of
SHP-1, results in unregulated TCR signalling and consequent hyper-proliferation of
T-cells (Lorenz et al., 1996).
The structure of the SHP-1 gene was first characterised by Banville et al. (1995)
who found that two alternate promoters regulate the expression of SHP-1, promoter
I located upstream of exon 1 and promoter II located between exon 1 and exon 2
(Figure 3.1). Exons 1 and 2 are mutually exclusive and each contains a translational
initiation codon therefore expression from promoter I generates transcript I includ-
ing exon 1 but not exon 2 whilst expression from promoter II generating transcript
II containing exon 2 but not exon 1. Banville et al. (1995) found that expression of
the two isoforms of SHP-1 is tissue-specific with transcript I expressed only in non-
haematopoietic tissue and transcript II expressed only in haematopoietic cells. How-
ever, it was subsequently shown that activation of haematopoietic cells with PHA can
lead to an up-regulation of SHP-1 transcript I although transcript II remains the pre-
dominant form (Tsui et al., 2002).
The two mRNA transcripts differ in their 5’-UTR and in the first few coding nu-








Figure 3.1: Diagram of SHP-1 CpG island
Diagram showing the exon structure of the SHP-1 gene. The black box represents the
CGI, in the amplified section above each CpG dinucleotide is represented by a circle.
The binding sites of the MSP primers is represented by the red arrows.
79
3.1 INTRODUCTION
et al., 2006), the remainder of the coding sequence is identical. Since the difference
in protein sequence does not affect the catalytic domains of SHP-1 (Walton & Dixon,
1993), these differences are not expected to have any impact on the catalytic activity of
SHP-1 however this has not been biochemically assessed. The minimal differences in
protein coding sequence led Tsui et al. (2002) to conclude that the two different iso-
forms existed principally to enable differential regulation from the different promoters
rather than to generate functionally different protein isoforms.
Located upstream of SHP-1 promoter II is a short CGI that has been shown to
contribute to the tissue-specific expression of SHP-1 isoform II mRNA whilst pro-
moter 1 does not have an associated CGI. The promoter II CGI is methylated in ep-
ithelial tissue, which does not express isoform II and unmethylated in haematopoietic
cells, which do express isoform II (Ruchusatsawat et al., 2006). Aberrant SHP-1 CGI
methylation has been identified in many haematological malignancies using the MSP
primers described in Oka et al. (2001) however the frequency of methylation observed
in different studies of the same malignancy can be quite varied as highlighted in Ta-
ble 3.1. CGI methylation is also observed in HTLV-1 transformed cell lines and has
been shown to correlate with loss of SHP-1 mRNA expression in these lines (Cheng
et al., 2004).
Treatment with the demethylating agent 5aza has been used to restore SHP-1 ex-
pression in cell line models of chronic myeloid leukaemia (K-562), B-cell lymphoma
(BC-3), SS (HuT78), Adult T-cell leukaemia (EDS and MT1), B-cell acute lymphoblas-
tic leukaemia (KW) and Hodgkins disease (HDLM2 and L428) (Koyama et al., 2003,
Oka et al., 2002, Reddy et al., 2005). SHP-1 expression could also be recovered by
5aza treatment of an NK cell (NK-TY2) and a T-cell (IWA3) line immortalised with
HTLV-I (Oka et al., 2002).
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Disease Frequency of methylation (n)
BCR/ABL-negative
meloproliferative disorder 7% (112)1 0% (28)2
Myelodysplastic syndrome 0% (70)3
Monoclonal gammopathy
of undetermined significance 32% (19)4 20% (20)5
Multiple myeloma 84% (32)4 15% (40)5 79% (34)6
Chronic myeloid leukaemia 30% (23)7 100% (11)8
Adult T-cell leukaemia 90% (20)8
NK/T-cell lymphoma 91% (11)8
Acute myeloid leukaemia 5% (20)1 11% (121)3 52% (50)9 90% (10)8
Diffuse large B-cell lymphoma 78% (46)10 70% (108)11 94% (45)12
MALT lymphoma 82% (17)12
Mantle cell lymphoma 75% (4)12
Follicular lymphoma 96% (24)12
Plasmacytoma 100% (5)12
Acute lymphoblastic leukaemia 12% (336)13 24% (25)9 63% (8)8
Anaplastic large cell lymphoma 64% (14)14
Non-Hodgkins
lymphoma/leukaemia 97% (90)15
Table 3.1: SHP-1 methylation in haematological malignancies
Summary of the frequency of methylation observed in all studies of haematological
malignancies using the MSP primers described in Oka et al. (2001). The number of patients
examined (n) is included in brackets. References are as follows 1. Capello et al. (2008) 2. Jost
et al. (2007) 3. Johan et al. (2005) 4. Chim et al. (2007) 5. Reddy et al. (2005) 6. Chim et al.
(2004a) 7. Amin et al. (2007) 8. Oka et al. (2002) 9. Chim et al. (2004b) 10. Amara et al.
(2008) 11. Amara et al. (2007) 12. Koyama et al. (2003) 13. Roman-Gomez et al. (2005)
14. Khoury et al. (2004) 15. Shivapurkar et al. (2004).
Some controversy exists over the demethylation of U266, a multiple myeloma cell
line. Koyama et al. (2003) could not induce SHP-1 expression upon treatment with
5aza however Reddy et al. (2005) and Chim et al. (2004a) succesfully demethylated
the SHP-1 CGI, inducing expression of SHP-1. Chim et al. (2004a) found dephospho-
rylation of STAT3 upon demethylation of the SHP-1 CGI whilst Reddy et al. (2005)
did not observe any phosphorylation of STAT3 in U266 cells. Han et al. (2006) ob-
served SHP-1 expression alongside STAT3 phosphorylation in U266 cells and did not
identify any changes in SHP-1 expression or STAT3 phosphorylation after 5aza treat-
ment. In ALK+ ALCL cell lines (Karpas 299 and SUDHL-1) SHP-1 methylation
has been successfully reversed using 5aza and shown to correlate with restoration of
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SHP-1 expression and concurrent decreases in JAK3 and STAT3 phosphorylation (Han
et al., 2006), A complex containing DNMT, pSTAT3 and HDAC has been identified
to be responsible for methylation of the SHP-1 promoter in SUDHL-1 (Zhang et al.,
2005b).
Lymphocytes from SS patients display constitutive activation of STAT3 (McKen-
zie et al., 2011, van Kester et al., 2008) suggesting an impairment somewhere upstream
in the signalling pathway. Loss of SHP-1 gene expression through CGI methylation is a
potential candidate mechanism that could lead to the constitutive activation of STAT3.
Reduced SHP-1 mRNA expression has been observed in the SS cell line HuT78 and
found to be associated with CGI methylation (Nakase et al., 2009) however the role of
SHP-1 has not yet been investigated in primary Sézary cells.
3.2 Aim
The aim of this study was to establish whether SHP-1 silencing through promoter
methylation contributes to aberrant STAT3 activation in SS. This was approached
by assessing the expression of SHP-1 at the mRNA and protein level in SS patient
PBMCs as compared to healthy control PBMCs to determine if any loss of SHP-1 was
detectable. The methylation level of the SHP-1 CGI was also assessed in SS patient
PBMCs as compared to healthy control PBMCs. Finally SHP-1 expression and methy-
lation were compared to determine whether there is any correlation and both measures




3.3.1 Quantification of SHP-1 mRNA expression
Expression of SHP-1 mRNA in cell lines, healthy control and patient PBMCs was de-
termined by RT-PCR. The primer sequences, reaction conditions and expected product
size are listed in Table 2.1. RNA and cDNA were prepared as described in Section 2.3
and Section 2.4 and RT-PCR was performed as described in Section 2.5. A previously
published primer pair binding in exons 14 and 16 (León et al., 2002) was used to
detect total SHP-1 mRNA. In order to detect the specific isoforms, primer pairs were
designed to anneal to exons 1 and 3 (isoform I) or in exons 2 and 3 (isoform II).
Primers were first tested on cell line cDNA using 30 PCR cycles to verify the
specificity. Each primer set gave a band of the expected size in at least one sample
and no additional bands were observed. Figure 3.2 shows expression of SHP-1 mRNA
by the MF cell line MyLa, the leukaemic cell line Jurkat and healthy CD4+ T-cells,
which can be mainly attributed to isoform II expression although Jurkat and healthy
CD4+ cells do show some isoform I expression. Primary keratinocytes show weaker
expression of SHP-1, which can be attributed to isoform I expression whilst HEK293
and Kit225 cells show no expression of SHP-1. SeAx, HuT78 and HeLa cells show
very weak expression of SHP-1 total mRNA but no bands are visible for the individual
isoforms suggesting that the total expression is only just strong enough to be detectable
on a gel.
Once the primers had been validated, they were used to examine total SHP-1
mRNA expression in 11 SS patient PBMC samples and 11 healthy control PBMC sam-
ples. The Jurkat cell line was used as a positive control and the cell line Kit225 as a
negative control (Figure 3.3). Reactions were performed using a sub-threshold number
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Figure 3.2: SHP-1 isoform expression in cell lines
RT-PCR was performed on 7 cell lines and 2 primary cell populations to assess total
and isoform specific SHP-1 expression. cDNAs were also amplified with primers
specific to the housekeeping gene Cyclophilin to ensure sample integrity. A negative
control using water as a template for the RT-PCR reaction was included in each
experiment.
84
3.3.1 QUANTIFICATION OF SHP-1 MRNA EXPRESSION
of 25 cycles to generate semi-quantitative data. No clear difference in the band inten-
sities of the SHP-1 amplicon was discernible between SS and healthy samples. Patient
samples were derived from PBMCs rather than a purified population of malignant cells
since, as discussed in Section 1.1.1 there is currently no suitable immunophenotypic
marker for the isolation of Sézary cells. SHP-1 mRNA is clearly expressed by non-
malignant cells of the peripheral blood, as demonstrated by the healthy control PBMC
samples in Figure 3.3. It is therefore possible that SHP-1 mRNA from non-malignant
cells is masking any loss of SHP-1 mRNA in malignant T-cells. Also, since RT-PCR
examines the end stage of the PCR reaction, it is not accurately quantitative, although
this experiment was performed using a sub-threshold number of PCR cycles in order
to enhance the sensitivity of quantification.
Since some expression of both isoforms was observed in the healthy CD4+ sample
by RT-PCR, expression of both isoforms was further quantified using qPCR. SYBR
green was used to detect amplification using SHP-1 isoform I, SHP-1 isoform II or
Cyclophilin primers as described in Section 2.6, then the expression of each isoform
was normalised against Cyclophilin. Cyclophilin was chosen as a reference gene as
previous studies in our lab have shown that it is the most stable housekeeping gene in
lymphocytes with no change in expression upon lymphocyte stimulation. qPCR was
performed on CD4+ lymphocyte cDNA samples from 11 healthy controls and 18 SS
patients. Student’s t-test was performed as described in Section 2.24 to compare ex-
pression between SS patient and healthy samples and revealed no difference in expres-
sion of total SHP-1 mRNA (Figure 3.4c) or of SHP-1 isoform I (Figure 3.4a) or SHP-1
isoform II (Figure 3.4b). Since the distribution of expression in SS patients was wider
than that in healthy controls, a 99% confidence interval was generated as described in
Section 2.24 to define the limits of the healthy population and SS patient values were
compared to this limit. Using this method five of the 18 patient samples were observed
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Figure 3.3: SHP-1 expression in SS patient and healthy control PBMCs
RT-PCR was performed on 11 SS patient cDNA samples and 11 healthy control
cDNA samples using primers specific to all isoforms of SHP-1, which should
generate a band of 350bp. cDNAs were also amplified with primers specific to the
housekeeping gene Cyclophilin (223bp) to ensure sample integrity. The cell line
Jurkat was included as a positive control for SHP-1 expression and Kit225 as a
negative control for SHP-1 expression. A negative control using water as a template
for the RT-PCR reaction was included in each experiment.
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to have a significant reduction in SHP-1 total mRNA and SHP-1 isoform II suggesting
that only isoform II is down-regulated in those patients with decreased SHP-1 total
mRNA.
The correlation between isoform I and isoform II expression was also examined
as described in Section 2.24 (Figure 3.4d) and found to be strongly positive with a
correlation coefficient of 0.866 (p<0.001) for the healthy samples suggesting that the
two isoforms are produced in a similar ratio in healthy lymphocytes. Some of the
patient samples clustered with the healthy samples whilst the others clustered along a
line of slightly shallower gradient suggesting a slight increase in the isoform I:isoform
II ratio. Overall the patient samples maintained a weak positive correlation however
this did not achieve significance.
The level of expression of SHP-1 mRNA was compared with total lymphocyte
count, CD4+ count, percentage CD4+, CD4:CD8 ratio and percentage Sézary cells
across the patient cohort using Pearson’s product-moment correlation as described in
Section 2.24. It was observed that total lymphocyte count correlated very strongly with
CD4+ count (correlation co-efficient=0.998 p<0.05) therefore only total lymphocyte
count is shown in the plots in Figure 3.5. A weak negative correlation (correlation coef-
ficients between -0.5 and -0.54 p<0.05) was observed between SHP-1 mRNA quantity
and each of the measures of tumour burden, with the exception of Sézary cell percent-
age. The patient samples that clustered with the healthy controls in terms of isoform
I:isoform II ratio were also compared to those that didn’t to see if there was any differ-
ence in tumour burden between the two groups however no notable differences were
observed.
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Figure 3.4: qPCR quantification of SHP-1 mRNA
Quantitative PCR analysis of SHP-1 mRNA expression in cDNA samples from 18 SS
patients and 11 healthy controls. Measurements were performed in triplicate and
expressed relative to the expression of Cyclophilin.(a) Comparison of SHP-1 isoform
I mRNA expression (b) Comparison of SHP-1 isoform II mRNA expression (c)
Comparison of total SHP-1 mRNA expression (d) Scatter plot showing the correlation
between isoform I and isoform II expression.
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Figure 3.5: Relationship between SHP-1 mRNA quantity and measures of tumour
burden
Plots to show the relationship between SHP-1 mRNA quantity, expressed relative to
Cyclophilin, and measures of tumour burden: (a) Total lymphocyte count (b)
Percentage CD4+ cells (c) CD4:CD8 ratio (d) Sézary cell percentage.
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3.3.2 Quantification of SHP-1 protein expression
Western blotting was performed as described in Section 2.15 to investigate whether
loss or decrease of SHP-1 was evident on the protein level (Figure 3.6). Whole cell
lysates from six SS patient PBMC samples, two healthy control samples and the MyLa
cell line were examined. In addition to the SHP-1 antibody, blots were probed using
antibodies against pSTAT3, to confirm STAT3 activation status, STAT3 to confirm the
presence of STAT3 and β-actin, as a loading control. Details of all antibodies and dilu-
tions used are summarised in Table 2.6 and the Western blotting was kindly performed
by Robert McKenzie. High levels of pSTAT3 were observed in all the SS patient sam-
ples and in the MyLa cell line whereas no pSTAT3 was observed in the healthy control
samples. Similar amounts of total STAT3 were observed in all samples suggesting that
the lack of pSTAT3 in healthy control samples is not due to a lack of STAT3. No dif-
ference in SHP-1 protein level were observed between SS patient and healthy control
samples.
Since the SHP-1 antibody had proved highly specific it was further optimised for
use in flow cytometry of fixed and permeabilised cells in order to accurately quantitate
the level of SHP-1 protein present. Fixation, permeabilisation and intracellular staining
was performed as described in Section 2.18. Data acquisition was performed on a BD
FACS Aria II and analysed using FlowJo software as described in Section 2.19. Stain-
ing was performed on four healthy control CD4+ T-cell samples and nine SS patient
CD4+ T-cell samples, including those five patients that showed a significant reduction
in SHP-1 mRNA. A much wider distribution of SHP-1 expression was observed in SS
patient than in healthy controls but no significant difference was observed between the
two groups (Figure 3.7) using Student’s t-test as described in Section 2.24. No signif-
icant correlation was observed between SHP-1 mRNA and protein expression in the
patient cohort and the patients with reduced SHP-1 mRNA expression do not appear
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Figure 3.6: pSTAT3 and SHP-1 Western blot
Western blot analysis of pSTAT3, STAT3 and SHP-1 expression in 6 SS patients
(R102-R133), the MF cell line MyLa and 2 healthy control samples (H1 and H2).
β-actin was used as a loading control. Data kindly provided by Robert McKenzie.
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to have any coincident reduction in SHP-1 protein expression.
Intracellular staining and flow cytometry was also used to examine the expres-
sion of SHP-1 in the SS cell lines HuT78 and SeAx, the MF cell line MyLa and the
leukaemic cell line Jurkat (Figure 3.7). Expression of SHP-1 was much lower in all the
cell lines than in healthy and SS patient samples. This corresponds with the RT-PCR
results shown in Figure 3.2 where the healthy CD4+ sample showed a much stronger
band than any cell line and expression was lower in HuT78 and SeAx than in MyLa
and Jurkat.
3.3.3 Methylation specific PCR of the SHP-1 CGI
As mentioned previously, methylation of the SHP-1 CGI has been widely studied in
other haematopoietic malignancies using MSP. In MSP DNA is first bisulphite con-
verted, transforming all unmethylated cytosine residues to uracil but not affecting those
cytosine residues that are methylated. Primers are then designed to be complementary
to either the methylated sequence (MSP primers) or the unmethylated sequence (USP
primers) and used to amplify the bisulphite converted DNA. After separation on an
agarose gel the intensity of MSP and USP bands are compared to determine whether
the samples are methylated, unmethylated or partially methylated. The primers are
generally designed to cover several CpG dinucleotides in order to provide maximum
discrimination. In this study the primers used in the majority of published MSP studies
of SHP-1 CGI methylation were used, encompassing two CpG dinucleotides in the for-
ward primer and three CpG dinucleotides in the reverse primer as shown in Figure 3.1.
Bisulphite conversion of DNA was performed as described in Section 2.9. MSP
and USP was performed on bisulphite converted DNA from 47 SS PBMC samples and
11 healthy PBMC samples as described in Section 2.10 using the primers and reaction
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Figure 3.7: SHP-1 protein quantified by intracellular staining and flow cytometry
The cell lines (CL) MyLa, Jurkat, HuT78 and SeAx and CD4+ T-cells isolated from 9
SS patients (SS) and 4 healthy controls (H) were fixed in 1% PFA, permeabilised in
methanol then fluorescently stained using a SHP-1 antibody. ∆MFI was calculated by
subtracting the mean fluorescent intensity obtained using an isotype control antibody
from the mean fluorescent intensity obtained using the SHP-1 specific antibody.
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conditions detailed in Table 2.2. A methylation specific band was observed in only one
of 47 SS samples and one of 11 healthy samples. An example gel image of MSP and
USP amplicons is shown in Figure 3.8. MSP and USP were also performed on cell line
DNA, detecting methylation in HuT78 and SeAx, partial methylation in MyLa and no
methylation in Jurkat. Each set of PCR reactions included an artificially methylated
positive control for the MSP reaction, a completely unmethylated positive control for
the USP reaction and a negative control using water as the template.
3.3.4 Pyrosequencing analysis of the SHP-1 CGI
Since the MSP/USP assays do not cover all CpG dinucleotides in the SHP-1 CGI it is
possible that some changes in methylation were missed by these assays therefore Py-
rosequencing assays S1 and S2 (Tables 2.3 and 2.4) were developed to cover the 232bp
CGI to give a more detailed and quantitative view of the methylation at each CpG din-
ucleotide as discussed in Section 1.2.3. The PSQ assay design program was used to
design primers against the bisulphite converted sequence of the SHP-1 CGI with all
potentially methylated cytosines, those occurring in the context of a CG dinucleotide,
highlighted as potential C/T polymorphisms. Assays were designed such that the PCR
and sequencing primers did not cover any CpG dinucleotides in order to avoid biasing
the PCR reaction towards selective amplification of only the unmethylated template
and therefore to allow the Pyrosequencing to be quantitative.
The PCR primers were first optimised without including the biotin tag to ensure
they produced only one discrete band as any misprimed or truncated amplicons have
the potential to interfere with accurate quantitation. It was observed that the yield of
fully optimised PCR reactions using bisulphite converted DNA was noticeably lower
than what would be expected from a standard PCR using DNA as a template. Initially
this was attributed to the increase in fragmentation produced by the bisulphite reaction,
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Figure 3.8: SHP-1 methylation specific PCR
Representative gel images showing the results of PCR amplification of bisulphite
converted DNA using MSP and USP primers specific to the SHP-1 CGI.
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which is known to have a degrading effect on DNA (Warnecke et al., 2002). However,
tests with increased input DNA concentration did not yield any noticeable improve-
ment suggesting that fragmentation was not the main factor affecting the efficiency of
the PCR. Several methods are available for improving PCR amplification of CG rich
sequence, which can be particularly hard to amplify due to the increased stability of
secondary structure within the amplicon. However, bisulphite conversion, by convert-
ing cytosine to tyrosine, creates AT rich sequence that should therefore have less sec-
ondary structure. Discussions on the Protocol Online Bioforum (http://www.protocol-
online.org/forums/index.php) proposed that in particularly AT rich sequence the poly-
merase becomes displaced from template more easily, leading to decreased amplifi-
cation efficiency and Nakase et al. (2009) confirmed that decreasing the extension
temperature could counteract this effect. Therefore the extension temperature of bisul-
phite PCR reactions was decreased to 66°C, resulting in a substantial increase in PCR
product yield.
Once the PCR reaction was optimised to generate a strong, specific product, one
primer was exchanged for a biotin tagged version to allow capture in the next stage
of the process. The Pyrosequencing reaction was then performed as described in Sec-
tion 2.11, firstly testing 100% methylated and 0% methylated control DNA samples
generated as described in Section 2.8. Each plate included a series of controls to en-
sure accuracy of the results: biotinylated PCR template with no sequencing primer
was included to ensure that secondary structure within the amplicon could not prime
the Pyrosequencing reaction; water was used as a template for the biotinylated PCR
and then taken on into the Pyrosequencing reaction to identify any contamination; se-
quencing primer only and biotinylated PCR primer only were included to check for
mis-priming caused by homo-dimerisation of these primers; finally one well contained
annealing buffer only to identify contamination during the Pyrosequencing reaction.
96
3.3.4 PYROSEQUENCING ANALYSIS OF THE SHP-1 CGI
The highly quantitative nature of the assays was then assessed by mixing 100%
methylated DNA with 0% methylated DNA in varying proportions and plotting the
measured degree of methylation (Figure 3.9). The relationship between proportion
of methylated DNA added and proportion of methylated DNA measured is not lin-
ear as might be expected. This is due to the fact that bisulphite conversion leads to
the presence of two slightly different templates for PCR with unmethylated template
DNA containing a greater proportion of Ts than methylated template DNA. Whilst the
primers are designed to avoid variable positions, subtle differences in the structure of
the template is likely to lead to a difference in the kinetics of primer binding. This
contributes to a ‘PCR bias’ whereby either the methylated or unmethylated template
is amplified slightly more efficiently than the other. Despite the small departure from
linearity, Figure 3.9 shows clear differentiation between samples with a 10% differ-
ence in methylation, confirming the choice of Pyrosequencing as appropriate for the
measurement of DNA methylation in samples that may contain a mixed population of
malignant and reactive T-cells and therefore show only a small change in methylation.
Controls were also incorporated to check the detection limit of the Pyrosequencer
and the completion of the bisulphite conversion. This was done by altering the known
sequence to be incorporated such that the proportion of C to T was measured at a
known T and a C not in the CpG context. The T should be measured as 0% methylated,
confirming the detection limit on the Pyrosequencer whilst the C not in a CpG context
should also be measured as 0% methylated if the bisulphite conversion reaction has
occurred to completion. These internal controls have been included in all the assays
and have consistently returned values of 0-5%. Where a sample measured greater than
5% in either of these controls a fresh bisulphite conversion reaction was performed
prior to repeating the Pyrosequencing.
The optimised and calibrated SHP-1 Pyrosequencing assays were then performed
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Figure 3.9: Assessment of SHP-1 Pyrosequencing sensitivity
Known input methylation samples were created by mixing 100% methylated DNA
with 0% methylated DNA in various proportions prior to bisulphite conversion.
Measured percentage methylation is plotted as an average across the 11 CpG
dinucleotides of the CGI with error bars representing the SEM. The line of best fit has
been added in blue.
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on seven healthy PBMC samples and nine SS patient PBMC samples, including the five
patients shown to have reduced SHP-1 mRNA and the patient shown to have methy-
lation by MSP. None of the 11 potential CpG sites showed any increase in methy-
lation level between patient and healthy samples (Figure 3.10). The level of SHP-1
methylation was averaged across the 11 CpG dinucleotides of the CGI for each patient
and compared with total lymphocyte count, percentage CD4+, CD4:CD8 ratio and
percentage Sézary cells using Pearson’s product-moment correlation as described in
Section 2.24. No correlation was observed between SHP-1 CGI methylation and total
lymphocyte count, percentage CD4+ or percentage Sézary cells (Figure 3.11). A neg-
ative correlation was observed between SHP-1 CGI methylation and CD4:CD8 ratio
(correlation co-efficient=-0.72 p<0.05). This is the reverse of what would be expected
if tumour burden was affecting SHP-1 methylation since those patients with a higher
CD4:CD8 ratio actually appear to have less SHP-1 methylation.
Assays performed on the cell line DNA confirmed the results of the MSP in that
HuT78 and SeAx were found to be fully methylated (Figure 3.10) whilst Jurkat was
found to have a minimal level of methylation, similar to that observed in healthy
PBMCs. MyLa was determined to have a similar level of methylation to Jurkat in
contrast to the MSP/USP assays which suggested that MyLa was partially methylated.
The SHP-1 CGI methylation of primary keratinocytes was also assessed, confirming
the presence of tissue-specific methylation of the SHP-1 CGI in healthy tissue.
Finally, the relationship between SHP-1 expression and CGI methylation was as-
sessed in the patient samples (Figure 3.12). No correlation was observed between
SHP-1 mRNA expression and SHP-1 CGI methylation however, these data were biased
by the selection of those samples with low SHP-1 mRNA quantities as input for the
methylation assays. A negative correlation did appear between SHP-1 protein expres-
sion and SHP-1 CGI methylation upon examination of Figure 3.12b. This correlation
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Figure 3.10: SHP-1 Pyrosequencing of cell lines, healthy and SS samples
Summary of data obtained by Pyrosequencing of bisulphite converted DNA from 6
cell lines (CL), 7 healthy controls (H) and 9 SS patients (SS). Percentage methylation
in each of the 11 CpG dinucleotides is plotted for each sample, which are grouped by
type. The cell lines have been identified by use of coloured points. Convert is the
conversion control, performed by measuring ‘methylation’ at a cytosine that cannot
be methylated, if the bisulphite conversion reaction has worked to completion this
should measure 0.
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Figure 3.11: Relationship between SHP-1 CGI methylation and measures of tumour
burden
Plots to show the relationship between SHP-1 CGI methylation, averaged across the
11 CpG dinucleotides, and measures of tumour burden: (a) Total lymphocyte count
(b) Percentage CD4+ cells (c) CD4:CD8 ratio (d) Sézary cell percentage.
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had a coefficient of -0.85 but did not reach significance (p=0.06) reflecting the lim-
ited number of data points available. The correlation could have occurred by random
chance and a much larger cohort would need to be assessed to determine its relevance.
In the absence of significant methylation in any sample, this was felt unnecessary.
3.4 Discussion
SHP-1 plays a complex role in the immune system, the motheaten mouse model has
myriad defects in haematopoeisis leading to widespread inflammation and autoimmu-
nity (mouse genome informatics database MGI:1856073 Blake et al. (2011)) Mice
with homozygous conditional knockout of SHP-1 in their single positive T-cells have
naïve CD8+ T-cells with a lower threshold for peptide activation and greater expansion
upon antigen stimulation than those from control mice (Fowler et al., 2010). However,
heterozygous conditional knockout mice have a similar threshold for peptide activa-
tion and capacity for expansion upon antigen stimulation to that found in control mice,
suggesting that a complete absence of SHP-1 is necessary to cause dysregulation of the
activation and expansion of naïve T-cells. The same study also examined central mem-
ory CD8+ T-cells lacking SHP-1 and found that expansion upon antigen challenge
was negatively proportional to SHP-1 quantity, suggesting a more sensitive mode of
regulation in mature T-cells.
In addition to its role in determining the threshold for TCR signalling, SHP-1 plays
a more active role in the inhibition of T-cell responses. Antagonistic peptides have been
described that can prevent the proliferation induced by agonistic peptides (Evavold
et al., 1993). Increased SHP-1 activity is observed following treatment of pre-stimulated
T-cells with antagonistic peptides and the presence of a dominant negative version of
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Figure 3.12: Relationship between SHP-1 CGI methylation and SHP-1 expression
Plots to show the relationship between SHP-1 CGI methylation, averaged across the




et al., 2003). Similarly, IL-10 can prevent CD2 induced proliferation through direct re-
cruitment of SHP-1 to the CD2 signalling complex. Expression of dominant negative
SHP-1 or silencing of SHP-1 expression with siRNA removes the inhibitory effect of
IL-10 on CD2 induced proliferation (Taylor et al., 2009).
Given the potential for uncontrolled expansion in the absence of SHP-1 it is no
surprise that SHP-1 deficiencies have been widely observed in haematological malig-
nancies, as discussed Section 3.1. In the majority of cases, the mechanism leading
to decreased expression of SHP-1 has been identified as DNA methylation of the pro-
moter II CGI, as summarised in Table 3.1. A few reports have identified aberrant
SHP-1 mRNA splicing (Jin et al., 1999, Ma et al., 2003) in cell lines and RNA hyper-
editing has been observed in AML (Beghini et al., 2000) whilst there are no published
reports of SHP-1 loss through gene deletion.
SHP-1 is known to be directly involved in the regulation of STAT3, the drugs 5-
hydroxy-2-methyl-1,4-naphthoquinone and acetyl-11-keto-β-boswellic acid have been
found to inhibit both constitutive and IL-6 induced activation of JAK2 and STAT3 in
multiple myeloma cell lines via the induction of SHP-1 expression (Kunnumakkara
et al., 2009, Sandur et al., 2010). Constitutive STAT3 activation is recognised as a key
pathogenetic mechanism in CTCL with pSTAT3 positive malignant cells observed in
MF tumours (Sommer et al., 2004) and SS lymphocytes (Eriksen et al., 2001, McKen-
zie et al., 2011, van Kester et al., 2008, Zhang et al., 2010) however, upstream events
leading to this constitutive activation are currently unclear. Therefore, loss of SHP-1, if
present, represented a pathogenetic mechanism that could be targeted by agents induc-
ing SHP-1 transcription or demethylation of the SHP-1 CGI, in order to down-regulate
constitutive STAT3 activation.
The results of this study however suggest that loss of SHP-1 does not occur in SS
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patient tumour cells. Interestingly, although loss was observed at the mRNA level in
five SS patients, this did not correspond to loss on the protein level. A weak negative
correlation was observed between various measures of tumour burden and SHP-1 to-
tal mRNA quantity (Figure 3.5), indicating that there may be some down-regulation
of SHP-1 expression in patients with a higher tumour burden. However, no down-
regulation of SHP-1 was observed at the protein level and there was no correlation
between SHP-1 mRNA and SHP-1 protein levels. This suggests that SHP-1 expres-
sion is regulated at the translational level in addition to the transcriptional level. Since
down-regulation of SHP-1 mRNA level is not reflected in down-regulation at the pro-
tein level it is unlikely to play a functional role. Another study performed in our lab
found no correlation between SHP-1 protein and pSTAT3 in a cohort of 18 SS patients
assessed by intracellular staining and flow cytometry (McKenzie et al., 2011), provid-
ing further evidence that SHP-1 is not involved in the aberrant activation of STAT3 in
SS.
Previous investigation of SHP-1 in CTCL had been performed on immortalised cell
lines rather than primary tissue and suggested that SHP-1 methylation may play a role
in contributing to aberrant STAT3 activation (Nakase et al., 2009, Zhang et al., 2000).
In this study, whilst SHP-1 silencing through promoter methylation was not observed
in the SS patient lymphocyte samples it was observed in two SS cell lines, SeAx and
HuT78. It appears therefore that where methylation is observed in SS cell lines this is a
feature of the cell lines rather than their originating primary tissue and may have been a
contributing factor to their transformation. Methylation as a consequence of immortal-
isation has been previously recognised (Jones et al., 1990). A survey of multiple CGIs
revealed that in the majority of loci methylation status in cell lines reflected that in the
original primary tissue however there are infrequent instances of methylation arising
as a consequence of the escape from senescence (Ueki et al., 2002), as has happened
105
3.4 DISCUSSION
in the case of SHP-1 methylation in CTCL cell lines.
The detection of SHP-1 methylation in primary epithelial cells however does con-
firm that methylation of this CGI plays a role in healthy tissues, contributing to the
tissue-specific expression of particular isoforms of the protein. It is unclear what role
these tissue-specific isoforms play since there is only a two amino acid difference be-
tween the two, which is not predicted to have any impact on the catalytic activity. One
possibility is that the use of different promoters in different tissues allows the gene
to be regulated by different signalling pathways and transcription factors in different
tissues. Promoter I for example has been shown to have binding sites for NF-Y and
USF1/USF2 (Tsui et al., 2002, Xu et al., 2001) whilst promoter II has binding sites
for PU.1 Sp1 and Oct1, which mediate recruitment of NF-κB (Cheng et al., 2007,
Nakase et al., 2009, Wlodarski et al., 2007). In a murine CNS glial culture system
promoter I transcription can be induced by IFN-β and IFN-γ acting through STAT-1
and IRF-1 whilst promoter II transcription can be induced by IFN-β and IL-6 acting
through STAT3 (Christophi et al., 2008). Use of different activating pathways may be
necessary to allow SHP-1 to function in alternative roles in different tissues whilst the
presence of the CGI in promoter II permits an additional level of control whereby one
isoform can be completely silenced.
The literature on SHP-1 methylation in various haematological malignancies, as
summarised in Table 3.1 displayed a surprising range of methylation frequencies for
the same conditions despite using the same experimental technique, MSP. This was
particularly notable for AML where the frequencies observed across four studies var-
ied between 5% and 90%. This is probably influenced in part by the exact factors
used to define patient inclusion in individual studies, however, when working with this
technique it became clear that a reasonable proportion of this variation may be due to
technical differences. Although all studies utilised the same primer sequences, very
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few state the PCR reaction conditions used and, during the optimisation of the MSP
reactions shown in Section 3.3.3 it was observed that annealing temperature, MgCl2
concentration and cycle number could all dramatically affect the results therefore a
comprehensive range of controls was necessary to ensure the validity of any conclu-
sion drawn. This is a consequence of the fact that rather than directly measuring the
methylation in a CpG dinucleotide, MSP represents the kinetics of a PCR reaction
where two or three CpG dinucleotides may contribute unequally to the primer binding
and that the efficiency of the MSP and USP reactions are unlikely to be equal. The
technique of MSP also relies on the assumption that all CpG dinucleotides in a CGI
are either 100% methylated or 0% methylated, which is rarely likely to be the case,
particularly when the sample is made up of a mixed population of cells.
Pyrosequencing of bisulphite converted DNA enables the proportion of DNA me-
thylated at each CpG site within the SHP-1 CGI to be measured. This allows iden-
tification of DNA methylation even if present in only a small proportion of cells and
will also establish whether different regions of the island are subjected to differential
methylation. Hence, Pyrosequencing of bisulphite converted DNA was used as a sen-
sitive and comprehensive method for the analysis of DNA methylation in the SHP-1
CGI. Since Pyrosequencing is a much more labour intensive technique than MSP a
small selection of samples were chosen for Pyrosequencing analysis, including those
that had shown methylation by MSP. Even with careful controlling of the MSP reac-
tions some differences were observed between the MSP and Pyrosequencing results.
In particular, MyLa was observed to be partially methylated by MSP whilst Jurkat was
completely unmethylated however, by Pyrosequencing they had very similar levels of
methylation. One possible explanation for this is that the quantity of template was
slightly greater in the MyLa sample than Jurkat so the very low level of methylation
present was amplified sufficiently to produce a band only in the MyLa sample. Using
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Pyrosequencing the proportion methylation is calculated from the relative difference
in height between C and T peaks at a particular CpG dinucleotide thus rendering this
method independent of template quantity.
A further observation was that of the two samples, one SS, one healthy that showed
methylation by MSP, the SS patient sample failed Pyrosequencing quality control with
signals too low for accurate quantification, suggesting a restricted template quality
may have led to the presence of a band in the MSP. The healthy sample that showed
methylation by MSP had similar methylation to the other healthy samples over CpG
dinucleotides 1-5 but noticeably higher methylation over CpG dinucleotides 6-11. The
reverse primer was sited over CpG dinucleotides 8-10, which had a methylation level
of around 12% suggesting that this level of methylation was sufficient to generate an
MSP amplicon. Given that all samples showed higher methylation in the first half of
the island it is possible that the MSP reaction was becoming primed and extended in
the forward direction in all samples but the reverse primer could only bind in a few
samples to generate exponential amplification. Through the use of MSP screening of a
large cohort and Pyrosequencing to examine a small subset of patients at much higher
level of detail, it has been comprehensively demonstrated that there is an absence of
SHP-1 methylation in SS patient lymphocytes.
Having excluded loss of SHP-1 as a mechanism for constitutive STAT3 activation
in SS, further work in this area will remain focussed on determining what mechanism is
responsible. Other known regulators of the STAT3 activation pathway include SOCS
proteins, which bind to activated JAKs to prevent their kinase activity (Endo et al.,
1997, Naka et al., 1997, Starr et al., 1997), and PIAS3, which binds to activated STAT3
blocking its DNA binding activity (Chung et al., 1997). SOCS3 has been found to be
constitutively expressed in MF and SS cell lines however, this constitutive expression
appears to be being driven by the constitutive activation of STAT3 rather than driving
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the constitutive activation of STAT3 since transfection of dominant negative STAT3
into these cell lines leads to down-regulation of STAT3 (Brender et al., 2001). PIAS3
is normally constitutively expressed and located in the nucleus in complex with another
protein MITF, preventing it from binding to activated STAT3. Under certain cytokine
signalling conditions MITF becomes phosphorylated and releases PIAS3, allowing it
to sequester STAT3 thus preventing STAT3 target gene expression (Yagil et al., 2010).
Since this mechanism of action occurs downstream of STAT3 phosphorylation its dys-
regulation is unlikely to be able to induce the constitutive phosphorylation of STAT3
observed in SS.
Studies in our lab (McKenzie et al., 2011) have examined JAK activation in SS
patient samples and found that JAK1 and JAK2 are also constitutively activated in SS.
Inhibition of JAK activation using the pan-JAK inhibitor P6 leads to a decrease in JAK
activation and concurrent decrease in STAT3 activation in ex vivo SS patient CD4+ T-
cells. Furthermore, this inhibition leads to widespread changes in STAT3 driven gene
expression and ultimately to an increased level of apoptosis in primary SS tumour
cells that, without P6 treatment, are known to be resistant to apoptosis. These data
strongly implicate JAK1 and JAK2 activation in the constitutive activation of STAT3 in
SS. Ongoing work has ruled out the most common activating mutations, JAK1V658F
and JAK2V617F as the mechanism for persistent activation of JAK1 and JAK2 in SS
however a complete mutational screen remains to be completed. Investigations will
also be extended to receptors upstream of JAK activation, however a complex and
incompletely delineated network of signalling occurs between over 40 receptors, 4
JAKs and 7 STATs (Murray, 2007) so pinpointing the original defect will become
increasingly challenging as the search is extended to include receptors.
Another mechanism that could potentially be involved in the regulation of STAT3
is methylation of a conserved arginine residue by protein arginine methyltransferase
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(PRMT), which is suggested to be essential for prompt dephosphorylation of STATs (Zhu
et al., 2002). Arginine methylation of STAT1 (Mowen et al., 2001) and STAT6 (Chen
et al., 2004) has been demonstrated to have have a regulatory effect on their ability to
activate transcription and STAT3 has been identified amongst the proteins immunopre-
cipitated by an anti-methyl-arginine antibody (Rho et al., 2001) suggesting that STAT
methylation is a frequently used regulatory mechanism. In contrast to these results,
(Komyod et al., 2005) did not observe arginine methylation of STAT1 and STAT3 in
melanoma cell lines. Recently, STAT3 methylation mediated by PRMT2 has been
characterised in mouse hypothalamus and shown to lead to prolonged STAT3 phos-
phorylation and altered transcriptional activity (Iwasaki et al., 2010). This suggest that
STAT3 methylation is a critical regulatory mechanism in some tissues and investiga-
tion of STAT3 methylation may be of particular interest in SS lymphocytes, where the
timescale of dephosphorylation has been substantially altered.
In summary, no significant difference in expression of SHP-1 was observed in
SS patients at the mRNA level (Section 3.3.1) or at the protein level (Section 3.3.2)
compared to healthy controls. In addition no difference was observed in the methyla-
tion status of the SHP-1 CGI between SS patient PBMCs and healthy controls (Sec-
tion 3.3.4). These results indicate that SHP-1 silencing through promoter methylation
in not a contributory factor to aberrant STAT3 activation in SS cells in vivo. Silencing
of SHP-1 expression through methylation of the SHP-1 promoter II CGI was however
observed in the cell lines SeAx and HuT78 indicating that this feature is an artefact of
the immortalisation process. Further work is ongoing to determine the mechanism that




The death receptor Fas (CD95/APO-1) plays a crucial role in regulating T-cell home-
ostasis, contributing to negative selection of immature T-cells (Dautigny et al., 1999)
and regulating the induction of apoptosis via AICD in mature T-cells (Alderson et al.,
1995). Fas has also been implicated in non-specific and antigen-specific Ca2+- inde-
pendent T-cell mediated cytotoxicity (Rouvier et al., 1993).
As discussed in Section 1.1.4, malignant cells in CTCL display substantial defects
of the normal T-cell signalling and homeostasis mechanisms resulting in their persis-
tence. A report in 2008 demonstrated frequent resistance (9/16 cases) to FasL induced
apoptosis in freshly isolated primary Sézary cells (Contassot et al., 2008) suggesting
that dysregulation of the Fas signalling pathway may contribute to the persistence of
malignant cells in SS. Heterogeneity of Fas expression levels was observed, with five
cases showing normal or increased Fas expression and four cases showing reduced Fas
expression. In those cases with normal or enhanced Fas expression, resistance to apop-
tosis was attributed to increased expression of the apoptosis inhibitor c-FLIP. However,
the mechanism mediating reduced Fas expression was not addressed.
The Fas gene is located on chromosome 10q, a region of frequent genomic loss
in many malignancies (Cappellen et al., 1997, Komiya et al., 1996) including CTCL
(Vermeer et al., 2008, Wain et al., 2005). The gene is made up of nine exons separated
by eight introns and generates a 48kDa protein consisting of three cysteine-rich extra-
cellular subdomains, a transmembrane helix and an intracellular portion that includes
the death domain (Behrmann et al., 1994, Cheng et al., 1995). Fas is activated by
its natural ligand (FasL/CD95L) enabling the formation of a multi-molecular complex
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called the DISC at the cell surface. The DISC comprises a tetrameric arrangement of
Fas receptors and Fas-associated protein with death domain (FADD) proteins (Scott
et al., 2009) and this aggregation of death domains exposes binding sites for caspase
8, which self-activates through auto-proteolysis. This in turn triggers a cascade of
caspase activation that constitutes the activation phase of apoptosis.
Seven alternatively spliced transcript variants are listed in the NCBI genome anno-
tation (Figure 4.1) however, only three have associated protein coding sequence. Bioin-
formatic analysis suggests that transcripts 4-7 are candidates for nonsense-mediated
decay (Hillman et al., 2004), explaining why no protein isoforms corresponding to
these mRNA isoforms have been observed. Isoform 2 lacks exon 6 which encodes the
transmembrane domain, leading to the expression of a soluble protein that may neg-
atively regulate apoptosis (Cascino et al., 1995, Papoff et al., 1996). Soluble Fas ex-
pression is found to be increased in patients with systemic lupus erythematosus where
it may contribute to the development of autoimmunity (Cheng et al., 1994). In rest-
ing PBMCs only isoforms 1 and 6 are expressed in appreciable quantities (Liu et al.,
1995). Activation of PBMCs leads to increased isoform 1 expression and decreased
isoform 6 expression generating an increase in cell surface Fas receptor (Liu et al.,
1995). This suggests that the expression of alternative transcripts represents a regula-
tory mechanism for Fas gene expression.
Heterozygous germ line mutations of the Fas gene have been identified in patients
with autoimmune lymphoproliferative syndrome (ALPS), a condition characterised by
accumulation of double negative T-cells and autoimmune responses (Drappa et al.,
1996). Studies of T-cells from ALPS patients have confirmed that Fas-mediated apop-
tosis is defective as a result of the identified mutations (Fisher et al., 1995). In severe













Figure 4.1: Diagram showing the exon structure of the Fas gene
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marrow transplantation has been used to reconstitute the immune system with lympho-
cytes carrying a functional Fas receptor (Benkerrou et al., 1997, Kahwash et al., 2007,
Sleight et al., 1998). In the lpr mouse, which harbours a germ line spontaneous mu-
tation of the Fas gene, lentiviral gene transfer has been used to introduce normal Fas
cDNA into haematopoietic stem cells, leading to expression of functional Fas receptors
on the surface of lymphocytes. Interestingly, ALPS patients have been found to have
a significantly higher risk of both Hodgkin and non-Hodgkin lymphomas, suggesting
that loss of functional Fas receptor can contribute to the development of lymphoma
(Straus et al., 2001).
Substantial rearrangement, allelic loss or amplification of the Fas gene has been
detected at a low frequency (6/70) in non-Hodgkin lymphoma but not in 31 Hodgkin
lymphoma samples (Xerri et al., 1995). Somatic loss of function Fas mutations have
been described in both lymphoid (Takakuwa et al., 2002, Wohlfart et al., 2004) and
non-lymphoid (Lee et al., 1999, Park et al., 2001, Takayama et al., 2002) malignancies
and in some cases have been found to inhibit FasL induced apoptosis in a dominant
negative mode (Wohlfart et al., 2004). Somatic Fas gene mutations have been de-
scribed rarely in tumour cells isolated from skin lesions of MF (Dereure et al., 2002,
Nagasawa et al., 2004) whilst SSCP analysis performed in our lab by Dr. Mary Wain
covering all 9 exons and the promoter region of Fas identified band shifts in 4/20
SS samples (Jones et al., 2010). Sequencing of these bands revealed that one corre-
sponded to a previously reported silent polymorphism of exon 3 (250A→G) whilst
the other three anomalies were found to be single base substitutions within the pro-
moter region (one -274C→A and two -34A→G). It remains to be determined if these
mutations contribute to Fas dysregulation however, a similar frequency of promoter




The Fas gene contains a 1072bp CGI that spans the transcriptional start site and
exon 1. Murine CD8+ cells have been shown to down-regulate Fas in response to
in vitro antigen-specific restimulation, rendering the clones resistant to FasL induced
apoptosis. This down-regulation of Fas could be reversed by treatment of the clones
with 5aza suggesting that DNA methylation was responsible for the silencing of Fas
expression. Interestingly, the same phenomenon was not observed after in vivo antigen-
specific restimulation, indicating that whilst DNA methylation can lead to silencing of
Fas expression, it may not be doing so under normal physiological conditions. There
are no reports of tissue- or development-specific Fas methylation events in humans
however, hypermethylation of the Fas gene promoter has been described in colon, pro-
static and small cell lung carcinoma (Hopkins-Donaldson et al., 2003, Petak et al.,
2003, Santourlidis et al., 2001) and associated with decreased Fas gene expression in
these malignancies. Petak et. al. also used 5aza to demethylate the Fas promoter
in a colon carcinoma cell line, leading to induction of Fas expression and increased
sensitivity to FasL induced apoptosis.
4.2 Aim
The aim of this study was to examine Fas promoter hypermethylation as a potential
contributor to the dysregulation of Fas expression in tumour cell populations from pa-
tients with SS. The expression of Fas at the mRNA and cell surface protein level was
first determined a cohort of SS patient PBMC samples with expression status deter-
mined by comparison with PBMCs derived from healthy controls. The methylation
level across the Fas CGI was then measured in patient and healthy PBMCs to identify





4.3.1 Quantification of Fas mRNA expression
qPCR was used to determine Fas mRNA expression levels in CD4+ T-cells isolated
from the peripheral blood of SS patients and healthy controls. qPCR was performed
using TaqMan primer/probe sets as described in Section 2.6. The TaqMan assay cho-
sen spans intron 2 and thus should quantify expression of isoform 1 but not isoform 6
and should therefore reflect the expression of functional cell surface Fas receptor. The
expression of Fas mRNA was measured in 47 SS patients and compared to average ex-
pression levels from 24 healthy controls (Figure 4.2a). Student’s t-test was performed
as described in Section 2.24 to compare expression between SS patient and healthy
samples and revealed no difference in average expression between the two groups. It
is however evident from Figure 4.2a that whilst Fas mRNA expression in the healthy
control samples showed little variation, expression in SS patients was highly hetero-
geneous, ranging from a three fold increase to a thirty fold reduction as compared to
healthy controls. A 99% confidence interval was generated to define the limits of Fas
mRNA expression from the healthy control samples as described in Section 2.24. Ex-
pression from a patient sample was considered significantly different to healthy if it
lay outside of this interval. Overall, 21 patients showed significant under-expression
and 13 showed significant over-expression of Fas mRNA. The obtained Fas mRNA ex-
pression data represent a fold change in expression that, if displayed on a linear scale
would give a two fold increase much greater prominence than a two fold decrease. For
this reason, data are plotted on a logarithmic scale to allow equivalence between over-
and under-expression in terms of visual deviation from the healthy average of 1.
Two samples were available from 12 patients of the original cohort, allowing inves-
tigation of changes in Fas mRNA expression over time. Figure 4.2b shows the change
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in expression for each patient between their first and second samples. The general trend
is towards a decrease in Fas expression over time which was shown to be significant us-
ing a pair-wise t-test (p=0.021) as described in Section 2.24 however, a notable subset
of patients maintained a consistent level of Fas expression. Each sample was classi-
fied as either over-expressing, under-expressing or normal relative to the healthy con-
trol samples. Overall four patients remained within normal expression over time, one
had consistent over-expression and two had consistent under-expression. Five patients
showed a change in expression category with one decreasing from over-expression to
normal expression, two decreasing from over-expression to under-expression and two
decreasing from normal expression to under-expression.
To determine whether Fas expression status correlated with any of the features
of blood tumour burden, Fas mRNA expression was compared to total lymphocyte
count, CD4+ count, percentage CD4+, CD4:CD8 ratio and percentage Sézary cells
across the patient cohort using Pearson’s product-moment correlation as described in
Section 2.24. It was observed that total lymphocyte count correlated very strongly
with CD4+ count (correlation co-efficient=0.979 p<0.05) therefore only total lympho-
cyte count is shown in the plots in Figure 4.3. No correlation was observed between
log transformed Fas mRNA quantity data and total lymphocyte count (Figure 4.3a)
or percentage Sézary cells (Figure 4.3d). A weak negative correlation was observed
between Fas mRNA quantity and percentage CD4+ (correlation co-efficient=-0.28
p<0.05)(Figure 4.3b) and between Fas mRNA quantity and CD4:CD8 ratio (corre-
lation co-efficient=-0.30 p<0.05)(Figure 4.3c).
Figure 4.3 demonstrates no clear association between the observed decrease in Fas
expression and changes in tumour burden suggesting this decrease is not simply due to
an increase in tumour burden. Looking at the paired data samples in Figure 4.3, most
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Figure 4.2: Expression of Fas mRNA in SS patient samples
qPCR analysis of Fas mRNA expression in 47 SS samples expressed as a fold change
in amount of mRNA relative to the average healthy control value. Measurements were
performed in triplicate and normalised against Cyclophilin. (a) Comparison of the SS
patient samples to the healthy controls (b) Change in Fas mRNA expression over time
in 12 SS patients where a second sample was available.
118





























































































































































Figure 4.3: Relationship between Fas mRNA quantity and measures of tumour bur-
den
Plots showing the relationship between quantity of Fas mRNA and: (a) Total
lymphocyte count (b) Percentage CD4+ cells (c) CD4:CD8 ratio (d) Percentage
Sézary cells in 59 samples taken from 47 SS patients. In the 12 cases where two
samples from the same patient were measured they are connected by a line.
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patients maintained fairly consistent tumour burden counts despite significant reduc-
tions in Fas expression as identified by the vertical connections. Exceptions include
patient 6 (P6), where the increase in lymphocyte count and Sézary cell percentage
corresponded to only a small reduction in Fas mRNA and patient 5 (P5), where the
increase in Sézary cell percentage is coincident with the reduction in Fas expression
however, this is not mirrored by changes in lymphocyte count, percentage CD4+ or
CD4:CD8 ratio.
4.3.2 Quantification of Fas cell surface protein expression
To validate the Fas mRNA expression data the level of cell surface protein expres-
sion of Fas on the CD3+CD4+CD45RO+ T-cell population was determined by flow
cytometry using PBMCs from 10 SS patients and 6 healthy controls as described in
Sections 2.18 and 2.19. Cell surface Fas expression was also examined on the Sézary
cell lines SeAx and HuT78 and the MF cell line MyLa. Figure 4.4 shows represen-
tative Fas histogram plots for one healthy individual (H6), two SS patients (P3, P17)
and the cell lines. Whilst HuT78 and MyLa expressed Fas, SeAx displayed a complete
absence of cell surface Fas protein.
The proportion of Fas positive cells within the CD3+CD4+CD45RO+ population
was calculated for each sample (Figure 4.5a). Consistent with previously published
work (Miyawaki et al., 1992), nearly all of the memory T-cells in healthy control sam-
ples expressed Fas protein on their cell surface (range: 95.2-99.4% Fas +ve). Patient
samples however showed loss of cell surface Fas expression in a proportion of their
memory T-cells (range: 1.5-96% Fas +ve). Patient samples were considered signif-
icantly different to healthy if the proportion of Fas positive cells within the CD3+-
CD4+CD45RO+ cell population was less than 80.7% (mean healthy proportion - 10
standard deviations). The threshold was defined more stringently than the usual 99%
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Figure 4.4: Fas cell surface protein expression by flow cytometry
Histogram plots showing the expression of Fas in one healthy control (H6), two SS
patients (P3 and P17) and the SeAx, HuT78 and MyLa cell lines. The isotype control
is shown with the curve filled in grey.
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Figure 4.5: Fas cell surface protein expression in SS patient samples
PBMCs from 6 healthy controls and 10 SS patients were stained with antibodies
against CD3, CD4, CD45RO and Fas and 10,000 events per sample were acquired on
a FACSAriaII. (a) Percentage Fas+ cells were assessed in the CD3+CD4+CD45RO+
populations and compared between SS patient samples and healthy controls (b)
Correlation of Fas mRNA quantity with percentage Fas+ in the CD3+CD4+ subset.
122






























































































0 20 40 60 80 100
(d)
Figure 4.6: Relationship between Fas cell surface protein expression and measures
of tumour burden
Plots showing the relationship between percentage Fas+ cells within the
CD4+CD45RO+ subset and: (a) Total lymphocyte count (b) Percentage CD4+ cells
(c) CD4:CD8 ratio (d) Percentage Sézary cells in 10 SS patient samples. Three
patients did not have a Sézary cell count associated with the sample used for flow
cytometry so only 7 SS patients are included in part (d).
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interval using three standard deviations because of the small number of healthy sam-
ples measured and the lack of deviation between them. Whilst this may be indicative
of the population wide results, without further measurements it is difficult to extrapo-
late and use of 10 standard deviations was considered necessary to ensure only those
samples with very definite loss of Fas cell surface protein expression were classified
as having loss. Overall 7/10 SS patients showed a significant loss of Fas cell surface
protein expression on their memory T-cell population.
Since Fas functions at the cell surface it was of interest to establish whether Fas
mRNA quantity accurately reflected the quantity of Fas protein at the cell surface.
SS patient samples show a positive correlation between relative quantification of Fas
mRNA in the CD4+ population and the percentage Fas+ cells within the CD4+ pop-
ulation (correlation co-efficient=0.53) (Figure 4.5b) however the correlation does not
reach significance (p=0.11). This may be due to the use of a proportion of positive cells
as the measurement for Fas protein where each cell may have different expression lev-
els. Absolute mean fluorescent intensity values cannot however be used as these data
were obtained in multiple experiments and therefore the absolute fluorescence level is
not comparable between the sets of samples.
The relationship between cell surface Fas and measures of tumour burden was
also assessed. No correlation was observed between percentage Fas+ cells within
the CD3+CD4+CD45RO+ subset and CD4:CD8 (Figure 4.6c) or percentage Sézary
cells (Figure 4.6d) however, a negative correlation was observed between percentage
Fas+ cells within the CD3+CD4+CD45RO+ subset and lymphocyte count (correlation
coefficient=-0.725, p<0.05) (Figure 4.6a) and between percentage Fas+ cells within
the CD3+CD4+CD45RO+ subset and percentage CD4+ (correlation coefficient=-0.661,
p<0.05) (Figure 4.6b).
124





















































































































Figure 4.7: PLS3 and Fas expression within FACS sorted SS patient cells
Lymphocytes from six SS patients and one healthy control were stained and sorted
into subsets prior to mRNA extraction and qPCR: (a) PLS3 mRNA distribution was
compared between CD26- and CD26+ subsets. The healthy control demonstrated no
PLS3 mRNA in either subset. (b) Fas mRNA distribution was compared between
CD26- and CD26+ subsets (c) Fas mean fluorescent intensity distribution was
compared between CD26- and CD26+ subsets (d) PLS3 mRNA distribution was
compared between Fas- and Fas+ subsets. Only four samples were available for
analysis in this experiment, R67 is a sample from the same patient as R55 taken one
month later.
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Figure 4.8: Correlation between Fas protein and mRNA
Mean fluorescent intensity of Fas cell surface protein expression was compared to Fas
mRNA expression in both CD26- and CD26+ subsets from six SS patients and one
healthy control.
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When this work was submitted for publication it was suggested by the review-
ers that loss of the cell surface marker CD26 could help further identify the tumour
cell population to establish whether Fas loss was restricted to these cells. This was
based upon the assumption that the frequent loss of CD26 in SS patients (Jones et al.,
2001) is restricted to the tumour cell population. To determine whether this was the
case, anti-CD26 antibody was added to the FACS antibody staining cocktail and the
CD3+CD4+CD45RO+CD26+ and CD3+CD4+CD45RO+CD26- subsets were iso-
lated as described in Section 2.20. RNA was extracted and qPCR used to detect the
expression of PLS3 in each subset as described in Sections 2.3, 2.4 and 2.6. Since
PLS3 is not normally expressed in any haematopoietic cells (Lin et al., 1993b) but is
expressed in a proportion of SS patients the expression of PLS3 is likely to be unique
to the malignant cells. An enrichment for PLS3 would therefore be expected in the
CD26- subset if loss of CD26 expression is an immunophenotypic marker of the tu-
mour cells. The approach of sorting cells and extracting mRNA for analysis was cho-
sen because no antibody was available at the time for the detection of PLS3 through
flow cytometry. In five SS patients, both CD26+ and CD26- subsets had detectable
PLS3 expression and a paired t-test revealed no significant difference between the two
subsets (Figure 4.7a). One healthy and one SS patient sample showed no PLS3 ex-
pression in either subset and the absence of PLS3 mRNA was further confirmed in
the corresponding PBMC samples. Fas mRNA expression (Figure 4.7b) and Fas mean
fluorescent intensity (Figure 4.7c) were also assessed in each subset. Results from the
healthy control sample suggest that Fas is more highly expressed in the CD26- subset
than the CD26+ subset however, no pattern is seen within the SS patient samples with
no significant difference between CD26- and CD26+ subsets on either the mRNA or
protein level using a paired t-test.
To investigate whether loss of Fas could be used as a marker to enrich for tumour
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cells, stained cells were also sorted into CD3+CD4+CD45RO+Fas+ and CD3+CD4+-
CD45RO+Fas- subsets and examined for PLS3 expression (Figure 4.7a). Sample R67
was taken from the same patient as R55 but one month later. R48 does show an en-
richment for PLS3 expression in the Fas- subset suggesting that in this case the Fas-
cells may further define the tumour cell subset however, the other three samples show
roughly equivalent expression between Fas- and Fas+ subsets suggesting that Fas is
not a consistent marker of the tumour cell population. Since these experiments gen-
erated absolute quantification of Fas mRNA and protein in identical populations, the
two measurements were compared (Figure 4.8). This demonstrated a strong correla-
tion between Fas mRNA expression and cell surface protein expression (correlation
co-efficient=0.816 p<0.01) suggesting that Fas mRNA quantity accurately reflects cell
surface protein expression and the failure to achieve a significant correlation between
Fas mRNA and cell surface protein expression in Figure 4.5b was in fact due to the
limitation of using percentage positive cells as a proxy for absolute quantity of Fas
protein.
4.3.3 SSCP analysis of Fas promoter and coding sequence
As mentioned previously, SSCP analysis had already been used to establish that the
frequency of Fas promoter and coding sequence polymorphisms within a cohort of 20
SS samples was similar to that observed in 20 healthy controls (Jones et al., 2010).
PBMC DNA samples from patient 3 (P3), patient 14 (P14) and the SeAx cell line
were subject to further SSCP analysis as described in Section 2.13 to determine if pro-
moter or coding sequence polymorphisms were contributing to the down-regulation
of Fas in these samples. P3 and P14 were selected because less than 10% of their
CD3+CD4+CD45RO+ population expressed cell surface Fas protein suggesting a sub-
stantial down-regulation of Fas had occurred in these samples. Similarly, Fas mutations
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Healthy     P3a        P3b        P14
Figure 4.9: SSCP analysis of the Fas gene in SS patients
Sequential samples from Patient 3 and one sample from Patient 14 who showed
minimal cell surface protein expression of Fas by flow cytometry; arrows indicate the
decreased intensity of bands in exon two consistent with allelic loss.
129
4.3.4 PYROSEQUENCING ANALYSIS OF THE FAS CGI
were further investigated in the SeAx cell line because it showed a complete absence
of cell surface Fas expression.
PCR amplification of SeAx DNA revealed no bands for any of the exons of the
Fas gene, suggesting that the Fas gene has been deleted in this cell line. Further in-
vestigation revealed a complete absence of Fas mRNA in SeAx cells in addition to
the absence of Fas protein. In the two patients who showed minimal cell surface Fas
expression, SSCP analysis revealed a loss of some bands using primer pairs 1.1 (P3a,
P3b and P14), 2 (P3a, P3b and P14) and 3 (P14). This suggests that allelic loss of some
exons may have occurred in the malignant cells of these patients (Figure 4.9).
4.3.4 Pyrosequencing analysis of the Fas CGI
To establish if promoter methylation contributes to the down-regulation of Fas gene
expression in CTCL, Pyrosequencing was used as described in Section 2.11 to eluci-
date the methylation status of the 74 CpG dinucleotides within the Fas CGI in healthy
and CTCL patient PBMC samples. Assays F5-F18 (Tables 2.3 and 2.4) were designed
to cover the whole CGI and optimised as described in Section 3.3.4. The sensitivity of
the assays was tested using DNA that had been artificially methylated using the M.SssI
CpG methyltransferase enzyme as described in Section 2.8 and then mixed in varying
proportions with unmethylated DNA prior to bisulphite conversion. Average methyla-
tion across the CGI was plotted for each of these mixtures (Figure 4.10), this shows
a linear relationship across the entire range of measurements suggesting no PCR bias.
However, the graph only achieved a maximum methylation measurement of 80%. This
is likely to be due to the CpG methyltransferase reaction not proceeding to completion
rather than any deficiency in the actual measurement. Controls were also incorporated
to check the detection limit of the Pyrosequencer and the completion of the bisulphite
conversion as described in Section 3.3.4.
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Figure 4.10: Assessment of Fas Pyrosequencing assay sensitivity
Mixtures of artificially methylated and unmethylated DNA were quantified at each
CpG dinucleotide. Data represent the mean methylation across all CpG dinucleotides
± SEM. The line of best fit has been added in blue.
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Figure 4.11: Quantification of methylation in the Fas CGI
Methylation in each sample at five CpG dinucleotides showing significantly increased
methylation in SS patients with down-regulation of Fas mRNA (SS D) but not the
remainder of the SS samples (SS) when compared to the 11 healthy samples (H).
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Figure 4.12: Diagram of the Fas CpG island
Diagram of the region around the Fas promoter numbered relative to the
transcriptional start site (TSS). CpG dinucleotides are marked by a vertical dash, the 5
hypermethylated CpG dinucleotides are highlighted by * and important gene
regulatory elements within the CGI are marked.
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Methylation of each CpG dinucleotide was then measured in bisulphite converted
DNA from 10 healthy control samples and 35 patient samples comprising 16 who
showed down-regulation of Fas mRNA expression, 9 who showed normal Fas mRNA
expression and 10 who showed up-regulation of Fas mRNA expression. The qual-
ity control procedure within the Pyrosequencer software checks for low signal, un-
expected sequence and incorrect total height of C/T variable peaks and scores each
well as passed, some errors or failed. All results with errors were examined by eye to
determine the cause, on several occasions the nucleotide dispensing tips had become
blocked during a run and this had led to no further nucleotide incorporation peaks.
Where this occurred, CpG positions measured before the blockage were manually ad-
justed to pass as the data up until the blockage was considered valid. In addition to
this any plate where the negative controls showed signal were failed in their entirety.
It was observed early on that whilst most samples had run-to-run variability of <1%, a
few samples had run-to-run variance of up to 10%. Further examination revealed that
all samples showing this property were generating much smaller peaks during Pyrose-
quencing. It was determined that the first single nucleotide peak needed to measure
100U in order to generate reproducible data. A method was therefore developed for
post-processing of the data in excel in order to exclude those traces where the first
single nucleotide peak measured less than 100U.
All data passing the quality control procedure were summarised as described in
Section 2.24 and the percentage methylation in each CpG dinucleotide was hence de-
termined for each sample. Wilcoxon unpaired U-test was used to compare the methy-
lation in each group of patients with that in healthy controls at each CpG dinucleotide
as described in Section 2.24. Five CpG dinucleotides (1, 2, 3, 31 and 51 numbered
from the start of the CGI) were found to have significantly more methylation in the
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patient group showing down-regulation of Fas mRNA expression than in healthy con-
trols (Figure 4.11). No significant excess of methylation was observed in patients with
normal Fas mRNA expression or up-regulation of Fas mRNA expression compared
to healthy controls in these CpG dinucleotides. The CpG dinucleotides that showed
hypermethylation in patients with down-regulated Fas mRNA expression have been
highlighted on the schematic diagram of the Fas CGI shown in Figure 4.12. Also high-
lighted are the experimentally validated NF-κB (Chan et al., 1999) and p53 (Schilling
et al., 2009) transcription factor binding sites and the transcriptional start site and first
exon of the gene.
4.4 Discussion
Induction of an immune response following antigen challenge leads to rapid clonal ex-
pansion and differentiation of naïve T-cells resulting in a large pool of effector T-cells.
During the termination phase of the immune response the vast majority of effector
T-cells are eliminated via AICD with only a small proportion surviving AICD and en-
tering the memory T-cell pool (reviewed by Krammer et al. (2007)). Several studies
have revealed that the Fas system is highly regulated during the phases of a T-cell im-
mune response. Resting T-cells express marginal amounts of Fas and are resistant to
apoptosis (Klas et al., 1993). During the activation phase Fas is up-regulated (Ju et al.,
1995), although short term activated effector T-cells remain resistant to AICD (Klas
et al., 1993), which is thought to be due to incomplete DISC formation and the pres-
ence of high levels of the apoptosis inhibitor c-FLIP (Kirchhoff et al., 2000, Schmitz
et al., 2004). Long term activated T-cells express comparable levels of Fas to short term
activated T-cells but have complete DISC formation with concomitant down-regulation
of c-FLIP expression and are therefore sensitive to Fas-mediated AICD (Dhein et al.,
1995). Given the fundamental role of the Fas system in the development of a T-cell
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response and the dysregulation of T-cell signalling observed in CTCL, dysregulation
of Fas represents a strong candidate pathomechanism in the development of CTCL.
This study observed a distinct heterogeneity in Fas mRNA levels, with signifi-
cant under-expression in 21/47 (45%) and over-expression in 13/47 (28%) of patient-
derived CD4+ T-cells compared to healthy controls (Figure 4.2a). These data are con-
sistent with the findings of Contassot et al. (2008) who reported disparity in the levels
of Fas expression in a cohort of 16 SS patients. Furthermore, analysis of samples taken
at least 6 months apart demonstrated a trend for decreased Fas mRNA expression over
time (Figure 4.2b). No clear correlation between Fas expression and tumour burden
was observed (Figure 4.3) however, review of the clinical observations suggested that
those patients with the most significant reduction in Fas mRNA expression had expe-
rienced an increase in disease severity over time. Because of the small numbers of
patients studied these observations remain speculative and it would be of great interest
to perform a longitudinal study of Fas expression to determine how closely it relates
to disease progression. Immunostaining of MF lesions has been used to show that loss
of Fas expression occurs in a greater proportion patients with tumour stage or CD30
negative large cell transformed disease than in plaque stage disease (Zoi-Toli et al.,
2000). Staining of serial samples from patients who had progressed from plaque-stage
to tumour-stage MF identified a significant decrease in Fas expression associated with
disease progression (Zoi-Toli et al., 2000). Taken together, these results suggest that
Fas expression level may be linked to disease progression across the whole spectrum
of CTCL in both circulating and skin-restricted disease.
Examination of the cell surface protein expression of Fas using flow cytometry
validated the observed down-regulation of Fas mRNA expression in Sézary cells (Fig-
ure 4.5). Sézary cells are generally derived from CD3+CD4+CD45RO+ memory T-
cells and show variable loss of expression of CD7 and CD26 (Steinhoff et al., 2009).
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At present there are no tumour-specific cell surface biomarkers available to isolate
Sézary cells. In this study it was demonstrated that loss of CD26 does not clearly
distinguish between Sézary and reactive cell populations (Figure 4.7a). In healthy
individuals a large proportion of the CD4+CD45RO+ T-cell population show cell sur-
face Fas expression (Miyawaki et al., 1992, Muench et al., 2003), consistent with
the findings reported here demonstrating Fas expression in at least 95% of the CD3+-
CD4+CD45RO+ T-cells. In contrast, loss of Fas expression was observed in 7/10 SS
patients affecting between 32% and 94% of the CD4+CD45RO+ population and was
associated with down-regulation at the mRNA level. The detection of tumour cells
within both the Fas- and Fas+ subsets and the CD26- and CD26+ subsets highlights
the marked heterogeneity present within the tumour cell population which has previ-
ously been reported by our lab in relation to CD25 expression (Tiemessen et al., 2006)
and will be investigated further in Chapter 5.
Loss of cell surface Fas expression has been reported in several studies of SS lym-
phocytes and cell lines (Contassot et al., 2008, Dereure et al., 2000, Osella-Abate
et al., 2001, Wu et al., 2009) and is associated with the failure of extracorporeal
photochemotherapy to generate haematological remission (Osella-Abate et al., 2001).
Contassot et al. (2008) demonstrated that SS lymphocytes displaying both over- and
under-expression of Fas show resistance to apoptosis and further established that over-
expression of of the inhibitory protein c-FLIP was responsible for the observed resis-
tance to apoptosis in the patient group showing over-expression of Fas. The mechanism
mediating down-regulation of Fas has not yet been determined and down-regulation of
Fas was the dominant mode of Fas dysregulation in the patient cohort investigated here.
Therefore this study focussed on further investigation of the patient group exhibiting
down-regulation of Fas. To address putative molecular mechanisms that may medi-
ate the observed down-regulation of Fas in Sézary cells, a comprehensive mutational
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scan of the Fas gene was performed and the CGI around the Fas promoter region was
analysed for methylation events.
Two mutational studies of Fas have been performed in MF, reporting mutations
in 14% and 18% of cases respectively (Dereure et al., 2002, Nagasawa et al., 2004).
As mentioned in Section 4.1, SSCP studies by Dr. Mary Wain have identified a poly-
morphism of exon 3 in 1/20 SS patients and 1/20 healthy controls (Jones et al., 2010).
Promoter polymorphisms were also found in 3/20 SS patients and 2/20 healthy con-
trols suggesting that, while the functional relevance of these polymorphisms are un-
known, they are unlikely to contribute to the down-regulation of Fas in SS. In the
current study, SSCP was used to further investigate the Sézary cell line SeAx, which
has no cell surface Fas expression, and two SS patients in which less than 10% of
CD3+CD4+CD45RO+ T-cells displayed cell surface Fas expression. The SeAx cell
line was found to have a deletion of all exons of the Fas gene resulting in the complete
absence of Fas protein and mRNA. This observation is supported by a FISH study that
found the Fas gene to be completely absent in SeAx (Wu et al., 2011). No disruption
of the neighbouring PTEN gene was observed, suggesting that the region of deletion
is relatively small . Wu et al. (2011) also found an increased prevalence of the germ-
line -671 GG SNP within their CTCL cohort than was recorded in the control cohort.
Functional analysis demonstrated no effect on basal Fas expression but this SNP did
affect interferon induced up-regulation of Fas, suggesting that this SNP, which was not
covered by the SSCP primers used for mutational screening of Fas, may contribute
towards a dynamic imbalance in Fas expression during immune responses. In the two
SS patient samples examined by SSCP no band shifts were observed, suggesting that
no mutations were present. However, in exons 1, 2 and 3 there was a notable reduction
in the band intensity of some bands suggesting that allelic loss may have occurred in
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these exons (Figure 4.9). These results lead to the conclusion that specific Fas muta-
tions are uncommon in SS however, given that loss of heterozygosity in the region of
10q23.31 spanning the Fas gene has been detected in 50% of SS patients (Vermeer
et al., 2008, Wain et al., 2005) it is likely that chromosomal deletion/loss may also
contribute to loss of Fas protein expression in SS.
Epigenetic events are known to be a critical mechanism of gene dysregulation in
malignancy and aberrant Fas promoter methylation with associated loss of Fas expres-
sion has been previously described in colon, prostatic and small cell lung carcinoma
(Hopkins-Donaldson et al., 2003, Petak et al., 2003, Santourlidis et al., 2001). Re-
cent studies of disease-specific methylation events have demonstrated that complex
methylation patterns exist within CGIs (Brakensiek et al., 2007). As discussed in
Section 1.2.3 a wide variety of methods exist for determining the methylation status
of DNA. This study required a technique that specifically examined the Fas promoter
region in detail and could detect methylation in a mixed population of cells. MSP,
using primers specific to the bisulphite converted sequence to detect methylated DNA,
has previously been used to detect methylation of the Fas CGI (Hopkins-Donaldson
et al., 2003, Petak et al., 2003, Santourlidis et al., 2001) however it only allows ex-
amination of a limited number of CpG dinucleotides in positions suitable for primer
design. Petak et al. (2003) and Santourlidis et al. (2001) investigated some sam-
ples in further detail using direct sequencing of bisulphite converted DNA however
this is only useful in cell lines or pure populations of tumour cells. Pyrosequenc-
ing of bisulphite converted DNA was therefore chosen as the most suitable method
as it facilitates the examination of each individual CpG dinucleotide within a CGI to
allow a thorough evaluation of the methylation status across the whole island (Brak-
ensiek et al., 2007, Oprea et al., 2008, Tost et al., 2003). In addition, this technique
allows quantitative detection of changes in methylation in a mixed cell population and
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therefore is ideally applicable to the study of SS cells, overcoming the problems of
analysis of a heterogeneous population of tumour cells admixed with non-malignant
cells. Five hypermethylated CpG dinucleotides within the Fas CGI were found to be
significantly associated with reduced Fas expression in SS patients. It is recognised
that the methylation status of even a single CpG within a CGI can be responsible for
the control of tissue-specific gene expression (Arányi et al., 2005, Kitazawa & Ki-
tazawa, 2007) and for aberrant gene silencing in cancer (Zou et al., 2006). Three
of the hypermethylated CpG dinucleotides in the Fas promoter are clustered around
the transcriptional start site and therefore could be directly responsible for preventing
the binding of the transcriptional machinery. Furthermore, other studies of the Fas
CGI have identified hypermethylation of CpG dinucleotides located at or near tran-
scription factor binding sites, namely the p53 binding site in colon carcinoma (Petak
et al., 2003) and the NF-κB binding site in prostatic carcinoma (Santourlidis et al.,
2001). Other mechanisms by which DNA methylation affects gene expression include
recruitment of methyl-binding domain proteins that impair binding of transcriptional
machinery and recruitment of histone modifying factors inducing condensation of the
local chromatin structure (Newell-Price et al., 2000).
At present there is no direct functional evidence to provide a link between hyper-
methylation, Fas expression and resistance to apoptosis in primary SS lymphocytes.
Such studies are currently impossible since the demethylating effect of 5aza requires
cellular proliferation in order to become incorporated into DNA and prevent mainte-
nance of methylation. As discussed in Section 1.1.4, primary cultures of Sézary cells
do not proliferate to any significant degree and therefore cannot be used for such stud-
ies. The commonest SS cell lines SeAx and HuT78 respectively exhibit homozygous
deletion of the Fas gene and absence of methylation of the Fas CGI. However, stud-
ies of human colon carcinoma cell lines demonstrating hypermethylation of Fas and
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reduced Fas expression, show that Fas expression and Fas-mediated apoptosis can be
restored by treatment with demethylating agents (Petak et al., 2003). Since this study
was completed, Wu & Wood (2011) have published data investigating Fas methylation
in some additional CTCL cell lines. In line with the data presented here, they found
no methylation within the Fas CGI of HuT78 and also found no methylation in the MF
cell line MyLa. They did however find positional methylation in the SS cell line Sez-4,
which correlated with low Fas expression at both the mRNA and protein levels. They
further demonstrated that the magnitude of methylation could be reduced by treatment
with 5aza and that this led to increased Fas expression and corresponding increased
sensitivity to FasL. Interestingly, they also showed that increased DNA methylation
correlated with decreased NF-κB binding to the Fas promoter and that demethylation
with 5aza led to increased NF-κB binding, supporting the proposal that hypermethyla-
tion of CpG dinucleotides is directly preventing the binding of transcription factors to
the Fas promoter.
It is now apparent that in addition to loss of heterozygosity in the Fas gene locus,
multiple molecular mechanisms can mediate Fas dysregulation and resistance to apop-
tosis in SS. A recent study (Wu et al., 2009) reported similar findings to those reported
here by identifying reduced Fas expression in SS and in CTCL cells from lesional skin
of MF patients. Reduced Fas expression was shown to correlate with loss of sensi-
tivity to Fas-mediated apoptosis. Contassot et al. (2008) have demonstrated that in SS
patients with over-expression of Fas, resistance to Fas-mediated apoptosis is still ob-
served and can be attributed to a concomitant increase in expression of the apoptosis
inhibitory protein c-FLIP. Another study, Klemke et al. (2009), suggests that attenu-
ated TCR signalling leading to loss of FasL up-regulation also contributes to apoptosis
resistance in patients with normal expression of Fas. Fas-mediated apoptosis repre-
sents a key mechanism underlying AICD. These findings all combine to suggest that
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dysregulation of Fas signalling plays a pivotal role in the pathogenesis of SS and occurs
via a myriad of mechanisms.
In summary, this study of a large cohort of SS patients demonstrates that down-
regulation of Fas gene expression is a common feature of Sézary cells. Mutational
events were found to be uncommon and are not linked to the observed loss of Fas
expression in the majority of patients. Significantly, aberrant promoter hypermethy-





T-plastin, encoded by the PLS3 gene on chromosome Xq23, is an actin bundling pro-
tein composed of four calponin homology actin-binding domains and one EF-hand
motif containing two calcium binding sites. Three transcript variants are listed in the
RefSeq database, each comprising 16 exons. Transcripts 1 and 2 differ only in the 5’-
UTR and are predicted to generate a 630 amino acid protein whilst transcript 3 uses an
alternative splice site in exon 2 to generate a 603 amino acid protein. However, tran-
scripts 2 and 3 are based upon bioinformatic analysis of the genomic sequence and a
literature search revealed no experimental evidence to support their existence whereas
transcript 1 is well characterised (Lin et al., 1988, 1990, 1993b). Therefore for the
purposes of this study, only transcript 1 was considered.
PLS3 is one of a family of closely related plastin isoforms, displaying 80% iden-
tity with L-plastin and 75% identity with I-plastin. All three isoforms have the same
domain structure (Figure 5.1), binding actin in a calcium dependent manner. The three
plastin isoforms are expressed in a highly tissue-specific manner, in healthy tissue
L-plastin is restricted to haematopoietic cells (Lin et al., 1993b) whilst I-plastin is ex-
pressed in the small intestine, colon and kidneys (Lin et al., 1994). PLS3 is more
widely expressed in all cells of solid tissues with replicative potential but crucially is
not expressed in any haematopoietic compartment (Lin et al., 1993b). Overproduction
of T- or L- plastin in epithelial cell lines leads to isoform-specific shape changes (Arpin






































































































































































































































































































































































































































































each function differently. L-plastin is the most thoroughly characterised of the plas-
tin isoforms, becoming rapidly phosphorylated in response to IL-2 stimulation in T-
cells (Zu et al., 1990) and enabling T-cell signalling through the formation of the im-
munological synapse (Wang et al., 2010). As discussed in Section 1.1.4, the aberrant
expression of L-plastin in solid tissue malignancies leads to enhanced tumour inva-
siveness (Foran et al., 2006, Klemke et al., 2007), presumably through its ability to
influence cytoskeletal rearrangement. PLS3 is believed to be involved in responding
to DNA damage (Ikeda et al., 2005, Sasaki et al., 2002), a theory that is supported
by its over-expression in cells resistant to agents that cause DNA damage such as cis-
platin (Hisano et al., 1996) or UV light (Higuchi et al., 1998). PLS3 has also been sug-
gested to play a role in regulating actin dynamics (Giganti et al., 2005) and thus may be
involved in cell motility. I-plastin appears to have a less dynamic function maintaining
the structure of the intestinal brush border microvilli (Grimm-Günter et al., 2009).
In SS, PLS3 expression has been identified at the mRNA level in peripheral blood
lymphocytes by a representational difference analysis study searching for potential bio-
markers (Su et al., 2003). The aberrant expression of PLS3 in SS was subsequently
confirmed by several microarray studies (Booken et al., 2008, Kari et al., 2003, van
Doorn et al., 2004) and proposed as part of a five gene qPCR expression signature for
SS (Nebozhyn et al., 2006). Interestingly, aberrant expression of L-plastin has been
described as a marker for many human cancer cells of non-haematopoietic origin (Lin
et al., 1993b) and aberrant L-plastin expression has been shown to enhance the in-
vasiveness of colon cancer cells (Foran et al., 2006). Given the stringency of tissue
restricted plastin isoform expression and its potential role in cytoskeletal rearrange-
ments, which are vital to T-cell migration and activation, aberrant expression of PLS3
could be crucial to the development of SS however, it is unclear how widespread this
alteration is within the SS patient population.
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The mechanism by which aberrant expression of PLS3 occurs in SS has not yet
been addressed and could provide valuable insight into the pathogenesis of the dis-
ease. One study has defined the basal promoter region of the PLS3 gene and identified
a putative enhancer (Lin et al., 1999) that could be affected by somatic mutations. The
PLS3 gene also harbours a 1585bp CGI that has been shown to display partial or com-
plete methylation in K562, Jurkat, CEM and Molt-4 cell lines, which do not express
PLS3, and no methylation in HT-1080, HuT-12 and MCF-7 cell lines, which do express
PLS3 (Lin et al., 1999). However, this study also identified no methylation within the
PLS3 CGI in primary lymphocytes, suggesting that the cell lines may not accurately
reflect the situation in primary tissues. The choice of method, methylation sensitive
restriction enzyme digest followed by Southern blotting, also restricts this study to ex-
amination of a few CpG dinucleotides rather than the whole CGI so it is possible that
methylation of another region of the CGI could play a part in the regulation of PLS3
expression.
Diagnosis of SS and MF is made using a combination of clinical, histological and
molecular features since there are no characterised biomarkers unique to CTCL. In SS,
a measure of circulating tumour burden can be obtained by visual inspection of a blood
smear to quantify those cells with abnormal cerebriform nuclei. Whilst large Sézary
cells can be easily identified, the majority of patients have small Sézary cells that can
be difficult to distinguish from normal activated T-cells on morphology alone (van der
Loo et al., 1981). Since PLS3 is not normally expressed by any cell of haematopoietic
origin it has the potential to be used as a biomarker for the tumour cells if it is found
to be present on the whole population of Sézary cells.
Previous studies have suggested a characteristic phenotype typical of SS including
loss of CD7 (Haynes et al., 1981), loss of CD26 (Jones et al., 2001), and presence of
CD158k (Bagot et al., 2001). Increasingly, these phenotypic features are being used in
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research studies to enrich for the malignant cells (Contassot et al., 2008, Yoon et al.,
2008). However, a study comparing the utility of the different phenotypic markers as
diagnostic tools concluded that no individual marker is present in all cases and a com-
bination of markers is required for flow cytometric diagnosis (Klemke et al., 2008).
In addition, genetically defined tumour cells have been identified in FACS sorted CD7
and CD26 positive subsets from SS patient samples (Steinhoff et al., 2009), suggesting
that these markers may not be appropriate for enrichment of the malignant cell pop-
ulation. PLS3 expression could also be used as a tool to evaluate the utility of these
proposed markers for the identification of SS tumour cells.
5.2 Aim
The aim of this study was to assess the extent of aberrant PLS3 expression in a cohort
of CTCL patients and to examine PLS3 mutations and promoter hypomethylation as
potential regulatory mechanisms leading to the aberrant expression of PLS3 in SS. A
further goal was to test the utility of PLS3 as a marker for malignant cells and use this
tool to investigate immunophenotypic heterogeneity in SS.
5.3 Results
5.3.1 Assessing aberrant expression of PLS3 mRNA
RT-PCR primers specific to PLS3 were first optimised in order to confirm the expres-
sion of PLS3 in SS patient lymphocytes but not in healthy control lymphocytes. The
primer sequences, reaction conditions and expected product size are listed in Table 2.1.
RNA and cDNA were prepared as described in Section 2.3 and Section 2.4 and RT-
PCR was performed as described in Section 2.5. The primers were carefully designed
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in order to prevent cross-reaction with either L- or I- plastin. RT-PCR primers were
tested on cell line cDNA, demonstrating the presence of abundant PLS3 mRNA in
HEK293 cells and primary keratinocytes, presence of PLS3 mRNA in HuT78 and
SeAx cells and no expression in MyLa or Jurkat cells. Examination of a group of SS
patient lymphocyte samples demonstrated PLS3 expression in approximately 70% of
patients whilst no PLS3 mRNA was detected in healthy control lymphocyte samples
(representative data shown in Figure 5.2).
A large variability in RT-PCR band intensity was observed, suggesting a substantial
range of expression levels of PLS3 mRNA may be present within the patient cohort. To
quantify the aberrant expression of PLS3 more accurately, qPCR with primers specific
to PLS3 was performed and expressed relative to Cyclophilin mRNA as described in
Section 2.6. qPCR was able to detect a negligible amount of PLS3 mRNA in 11 healthy
controls representing only 0.001 times the amount of Cyclophilin mRNA present. A
threshold for positive detection of PLS3 mRNA was set at 0.01 times the amount of
Cyclophilin mRNA and using this definition 60% (21/35) of SS patients express PLS3.
A group of 18 MF patients, eight of whom had advanced stage disease (Stage IV)
with demonstrated clonal blood involvement (Stage B0b) and 10 of whom had skin-
restricted disease (Stage IB-III B0a) were also examined. Three of eight MF patients
with blood involvement expressed PLS3 (38%) whilst all those with skin-restricted
disease were PLS3 negative. Comparison of average PLS3 mRNA expression between
the three groups by ANOVA demonstrated a significant increase in PLS3 expression in
SS patients compared to healthy controls (Figure 5.3). Comparison of the expression
of PLS3 with measures of tumour burden such as CD4+ count and CD4:CD8 ratio
revealed only a weak correlation (Pearson’s product-moment correlation coefficient =
0.33 p<0.05) with percentage CD4+ cells (Figure 5.4).
In order to further assess the potential correlation between PLS3 mRNA expression
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Figure 5.2: PLS3 mRNA expression in SS and healthy lymphocyte samples
RT-PCR with primers specific to PLS3 was performed on 12 SS patient lymphocyte
samples (R13-27 and RP9), three healthy lymphocyte samples (H1-3), the cell lines
SeAx and HuT78, and a healthy keratinocyte sample. cDNAs were also amplified
with primers specific to the housekeeping gene Cyclophilin to ensure sample
integrity. A negative control using water as a template for the RT-PCR reaction was
included in each experiment.
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Healthy MF patient SS patient
Figure 5.3: Quantification of the aberrant expression of PLS3
qPCR was used to assess the expression of PLS3 mRNA in CD4+ lymphocytes from
11 healthy controls, 18 MF patients and 35 SS patients. Measurements were
performed in triplicate and expressed relative to the quantity of the housekeeping
gene Cyclophilin. A significant difference between healthy and SS expression was
demonstrated by one way ANOVA.
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Figure 5.4: Relationship between PLS3 mRNA quantity and measures of tumour
burden
Plots showing the relationship between quantity of PLS3 mRNA, expressed relative
to Cyclophilin, and measures of tumour burden: (a) Total lymphocyte count (b)
Percentage CD4+ cells (c) CD4:CD8 ratio (d) Percentage Sézary cells.
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and markers of tumour burden, PLS3 mRNA expression was plotted relative to the
date of sampling in five patients from whom multiple samples were available over a 15
month period. Lymphocyte count, percentage CD4+ and CD4:CD8 were also plotted
over this period. Percentage Sézary cells was not included as this is not routinely mea-
sured with each sample. There were insufficient data points to examine correlation on
a per patient basis but the general trends can be seen in Figure 5.5. None of the patients
showed a large change in the quantity of PLS3 mRNA over the time period examined.
P7 and P9 demonstrated a small reduction over time that was mirrored by CD4:CD8
in P7 but not P9 whereas P13 showed an increase in PLS3 mRNA expression however,
lymphocyte count and CD4+ count were notably reduced over the same period. Per-
centage CD4+, which showed a weak correlation with PLS3 RQ in the overall patient
cohort, remained constant over time in all patients, despite the variation in PLS3 RQ.
5.3.2 Assessing PLS3 expression at the protein level
In order to investigate PLS3 expression at the protein level, an antibody was required
that was specific to PLS3 but did not cross react with L-plastin. This is challenging
since the two proteins share 80% identity. Two commercially available antibodies were
first tested by Western blotting as described in Section 2.15. ab45769 (Abcam) was
tested first and observed to produce very high background staining. Further optimisa-
tion of blocking and washing conditions reduced this background however, no specific
bands of the expected size were apparent (Figure 5.6a). sc-16655-R (Santa Cruz) gen-
erated bands of the expected size however these were also observed in samples from
healthy lymphocytes (Figure 5.6b), suggesting that this antibody is pan-plastin reactive
rather than specific to the PLS3 isoform.
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Figure 5.6: Commercially available antibodies are not specific for PLS3
Example Western blots using commercially available PLS3 antibodies (a) ab45769
demonstrates a large number of non-specific bands with none around the expected
size of 70kDa (b) sc-16655-R demonstrates a band between 50kDa and 75kDa that
may correspond to PLS3 however this band is present in a healthy sample (H6) in
addition to the patient and keratinocyte samples, suggesting the antibody may be
detecting all plastin isoforms. This blot also demonstrates a band just above 37kDa,
which corresponds to re-probing with a β-actin loading control.
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Therefore, a polyclonal antibody was raised against PLS3 as described in Sec-
tion 2.16. Western blotting using the serum from rabbit 3852 generated a lot of back-
ground staining but serum from rabbit 3851 generated a relatively clean blot with a
band just below 75kDa in a fibroblast whole cell lysate (Figure 5.7a), consistent with
the detection of PLS3. Incubation of the serum with a 5 times excess of the immuno-
genic antigen prior to blotting leads to complete absence of this band (Figure 5.7b)
confirming that this band does indeed correspond to detection of PLS3. Glycine and
TEA eluates from the affinity purification of 3851 serum were then tested by Western
blotting and the glycine eluate was found to generate bands in healthy keratinocytes
but not in healthy lymphocytes when used at a dilution of 1 in 1000 following mem-
brane blocking using 5% Marvel in PBS with 0.1% Tween. This antibody, termed
PLS3-3851G was then used to assess the expression of PLS3 protein in SS patient
samples that had already had their PLS3 mRNA status determined. Each blot, an
example of which is shown in Figure 5.8, included a healthy PBMC sample and a
healthy keratinocyte sample as negative and positive controls and was re-probed with
β-actin following PLS3 detection to control for protein loading. Expression status of
PLS3 protein in SS PBMCs was broadly consistent with the expression status of PLS3
mRNA. 8/11 SS samples previously shown to contain PLS3 by qPCR were found
to demonstrate expression of PLS3 protein by Western blotting whilst 2/3 SS samples
with PLS3 mRNA levels below the threshold showed no PLS3 protein expression. The
one sample where PLS3 was detected on the protein but not the mRNA level was only
just below the mRNA detection threshold and had a high protein loading level on the
Western blot as revealed by β-actin staining, which may account for this inconsistency.
PLS3-3851G was then optimised for use in immunostaining. In order to compare
multiple combinations of staining conditions, staining was performed in a 96-well flat-
bottomed tissue culture plate as described in Section 2.21. For each experiment half
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Figure 5.7: Western blot to show specificity of serum from rabbit 3851 for PLS3
Western blot analysis using (a) serum from rabbit 3851 demonstrates a band specific
to fibroblasts, which do express PLS3 mRNA and that is close to the expected size of
70kDa (b) serum from rabbit 3851 pre-incubated with a 5×excess of immunogenic
peptide has no band between 50 and 75kDa, suggesting that the PLS3 antigen has
successfully blocked the antibody binding site. Both blots were re-probed for β-actin
to demonstrate protein loading.
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Figure 5.8: Western blot to detect PLS3 protein expression by SS patient lymphocytes
Seven SS patient lymphocyte samples (R55-85), one healthy control lymphocyte
sample (H6) and a keratinocyte sample were probed using the PLS3-3851G antibody,
demonstrating expression of PLS3 protein in four SS samples and the keratinocyte
sample, but not in healthy lymphocytes. The blot was subsequently re-probed for
β-actin, revealing rather uneven protein loading.
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the wells contained healthy CD4+ lymphocytes as a negative control whilst half con-
tained an SS patient CD4+ lymphocyte sample that had been demonstrated to contain
PLS3 protein by Western blotting. Firstly a range of fixation and permeabilisation
conditions were examined by bright-field imaging and compared to untreated cells in
order to exclude any conditions that disrupted the morphology of the cells. The DAPI
nuclear stain was also examined, leading to exclusion of some conditions where nu-
clear integrity had been compromised. Four conditions were then tested with a primary
antibody concentration of 25µg/ml and secondary antibody concentration of 10µg/ml
to determine which condition generated the clearest difference in staining intensity
between isotype control and PLS3 specific antibody and between PLS3 specific stain-
ing in the positive and negative control cells. Both antibody concentrations were then
titrated across a range in order to pinpoint the combination that gave minimal back-
ground staining with optimal PLS3 specific staining.
Using the optimised PLS3 immunostaining protocol as described in Section 2.21,
PLS3 protein expression was observed in a proportion of the PBMCs from one PLS3
positive SS patient (Figure 5.9). The staining observed suggested that the PLS3 protein
is localised in the cytoplasm. It was hoped that the relationship of PLS3 protein with
the actin cytoskeleton could be determined however the only permeabilisation strategy
that generated strong PLS3 staining was to use ice cold methanol, which disrupts the
phalloidin binding site of actin, preventing the use of phalloidin for a dual stain.
5.3.3 PLS3 correlation with other markers
To quantify PLS3 expression on a single cell level the conditions used for immunos-
taining were tested and successfully applied to suspension cells, allowing their analysis
by flow cytometry. In order to allow dual staining with other antibodies, PLS3-3851G
was directly conjugated to DyLight 488 as described in Section 2.17. The antibody
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Healthy Isotype
Healthy Specic R61 Specic
R61 Isotype
Figure 5.9: Immunostaining using PLS3 antibody
CD4+ lymphocytes from a healthy volunteer and a SS patient (R61) were spun onto
slides, fixed in 1% paraformaldehyde, permeabilised with ice cold methanol and then
immunostained using the PLS3 specific antibody. Goat anti-rabbit Alexa Fluor 488
(green) was used to visualise the staining and nuclei were counterstained with DAPI
(blue).
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dilution was then titrated to generate the optimal signal to background ratio. Multi-
parameter flow cytometry was then performed as described in Section 2.18 and used
to examine the correlation of PLS3 expression with other immunophenotypic markers
including CD3, CD4, CD45RO, CD7, CD26, CD25 and CD158k. Individually stained
controls were included in each experiment in order to check the compensation set
up, which was initially performed using BD compbeads incubated with the relevant
antibodies. Additionally, the distribution of each marker when individually stained
was compared to the distribution in multi-parameter staining to check for any inter-
action between the antibodies. Five healthy control and 16 SS PBMC samples were
stained over several experiments and analysed as described in Section 2.19. None of
the healthy control PBMC samples contained PLS3+ cells. 11 of 16 SS samples con-
tained PLS3+ cells and in all cases the PLS3+ population also expressed CD3 and CD4
(Figure 5.10). In those samples expressing PLS3 the PLS3+ cells comprised between
3% and 76% of the CD4+ peripheral blood lymphocytes.
Next, the distribution of various phenotypic markers within the PLS3+ and PLS3-
populations of each sample was examined (Figure 5.11). Notably, in all 11 samples
the CD4+PLS3+ population showed almost complete loss of CD26 whereas the cor-
responding CD4+PLS3- subsets expressed a significantly greater proportion of CD26
(p=0.0006) suggesting that loss of CD26 is associated with gain of PLS3. However, no
other significant association was found between any of the other phenotypes and PLS3
expression. Notably, Figure 5.11 shows a wide range of CD45RO expression with four
patients demonstrating significantly lower proportions of CD45RO+ in the CD4+ sub-
set than the healthy average of 47% and three patients showing significantly greater
(p<0.05). The distribution of expression between PLS3- and PLS3+ subsets was vari-
able however, in three patients showing significant loss of CD45RO PLS3 expression
was confined to the CD45RO- population.
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Figure 5.10: PLS3+ cells are all CD3+CD4+
Example histogram showing PLS3 expression within the R164 sample gated to show
only viable cells. The dot plot inserts show the CD3/CD4 expression of PLS3- and
PLS3+ subsets.
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Figure 5.11: Heterogeneity in expression of T-cell differentiation markers between
PLS3+ and PLS3- subsets
Viable cells were gated into CD4+PLS3- and CD4+PLS3+ populations then the
percentage of positive cells was assessed for each other differentiation marker
(CD45RO, CD7, CD26, CD25 and CD158k) in each subset.
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5.3.4 Quantification of malignant cells in PLS3 subsets
To assess whether PLS3 expression is heterogeneous in tumour cells from an individ-
ual patient, FACS was used to isolate PLS3+ and PLS3- cell populations from one
well-characterised SS sample (R164) as described in Section 2.20. A genetic assay
was developed, taking advantage of the presence of a unique clonal TCRβ gene re-
arrangement in the malignant cells as described in Section 2.22. An overview of the
assay design procedure can be found in Figure 5.12. Briefly, the sequence of this
rearrangement was first determined by sequencing the clonal SSCP bands generated
after amplification with the BIOMED-2 primer set. The rearrangement was found to
involve Vβ4.2, Dβ1 and Jβ2.2 with the hyper-variable joining sequence shown in Fig-
ure 5.12. A TaqMan qPCR assay was then designed to specifically detect this sequence
and assays for two diploid genomic regions (SDC4 and BCMA) were also obtained to
normalise the input DNA quantity, primer sequences can be found in Table 2.7. The
patient-specific forward and reverse primer pair were firstly analysed by standard PCR
followed by agarose gel electrophoresis to ensure that a band was observed in the pa-
tient sample but not in a healthy control. BCMA and SDC4 primer pairs were similarly
tested and observed to generate strong bands in a range of patient samples and healthy.
In order to test the sensitivity and specificity of the assays and generate standard
curves, the rearranged TCRβ, BCMA and SDC4 sequences were cloned into the pGL3
plasmid using overlap extension PCR (Bryksin & Matsumura, 2010) as described in
Section 2.23, a summary of the steps along with example agarose gel pictures for each
step is provided in Figure 5.13. Given the known size of each construct (pGL3-R164
4885bp, pGL3-BCMA 4896bp and pGL3-SDC4 4924bp) the plasmids were then di-
luted such that 108 copies were present per 5µl. The qPCR assays were then performed
on a dilution series of each construct covering a range from 100,000 copies per well
down to 1 copy per well. The Ct values for each concentration were plotted and the
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TCRβ gene rearranged during development – 
sequence is unique to one T-cell	

Bands are eluted and sequenced using multiplexed F or R BIOMED-2 
primers to determine the rearranged sequence of the clonal 
malignant cells	

Rearranged sequence cloned into a vector and used to test the sensitivity and specificity 
of the assay, copy number can be calculated from the length of the plasmid and the 
concentration of DNA allowing generation of a standard curve.	

PCR with BIOMED-2 multiplex primers amplifies all 
rearranged TCRβ sequences, clonal malignant cells 
generate bands on an SSCP gel	

Patient specific F primer designed for qPCR with Jβ 
region specific R primer and TaqMan probe	

Figure 5.12: Schematic overview of the steps used to generate a qPCR assay for the
quantification of malignant cells from R164
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PCR of the region to be 
cloned with chimeric primers













































































































Figure 5.13: Schematic overview of overlap extension PCR
Blue lines represent genomic DNA sequence and complementary primers, red lines
represent plasmid pGL3 DNA sequence and complementary primers, yellow lines
represent the section of the plasmid sequence that is removed upon successful
insertion of the required genomic DNA region. This region contained a unique XhoI
site which was used to eliminate empty vector by linearisation prior to exonuclease
digestion.
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gradient of the resultant graphs used to calculate the PCR efficiencies, which were
98.6% for the R164 assay (Figure 5.14a), 100.4% for the BCMA assay (Figure 5.14b)
and 101.4% for the SDC4 assay (Figure 5.14c). These graphs also demonstrate that
10 copies per well is the detection limit of these assays as the Ct values for 1 copy per
well were inconsistent between replicates and often undetected. In order to test the
specificity of the R164 assay, seven healthy controls were mixed in order to ensure a
full range of TCR rearrangements was represented and diluted such that 10,000 copies
could be dispensed in 5µl. qPCR was then performed on the R164 construct diluted
in this healthy sample instead of water to determine the sensitivity of the R164 as-
say (Figure 5.14d). The efficiency of the R164 assay when conducted in the presence
of other TCR rearrangements was 99.2%, very similar to the efficiency when diluted
in water, suggesting that the specificity of the the assay is very good. Additionally,
10 copies per well could be accurately detected against a background of 10,000 other
TCR rearrangements, giving a sensitivity of 1 in 1000 cells. The healthy control alone
was also assessed (0 copies per well) and although some signal was observed in two of
the three wells measured, the Ct values were inconsistent, highlighting the importance
of checking replicates for generating valid data.
Once the assays were completely optimised, DNA from the PLS3+ and PLS3-
populations of R164 was subject to qPCR with R164, BCMA and SDC4 assays. The
previously generated standard curves (Figure 5.14) were used to convert the obtained
Ct values into a copy number and the R164 copy number was normalised against the
average of BCMA and SDC4 to calculate the percentage of cells within the population
that contained the R164 rearrangement. Using this method the PLS3+ population was
found to contain 84% (confidence interval 69%-99% p<0.05) cells with the patient-
specific clonal TCRβ gene rearrangement, whilst the PLS3- population contained 28%
(confidence interval 14%-43% p<0.05) cells with the patient-specific clonal TCRβ
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Figure 5.14: Standard curves for qPCR assays
qPCR was performed on a known input copy number of the relevant sequence for the
(a) R164 assay (b) BCMA assay (c) SDC4 assay (d) R164 assay diluted in a mixed
healthy control. All samples were assessed in triplicate, inconsistencies can be seen in
the wells containing only 1 or 0 copies per well due to the sensitivity limit being
reached. Wells where the signal did not reach the threshold fluorescence and therefore
no Ct was defined are plotted just above 40, and the 40 cycle limit is shown with a red
line. The linear part of each plot was used used as a standard curve and to calculate
the PCR efficiency, some outliers were excluded on the basis that they were probably
due to pipetting errors. The wells that were used for the generation of the standard
curve are marked in blue.
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gene rearrangement.
5.3.5 Mutational screen of PLS3
The aberrantly expressed PLS3 mRNA was directly sequenced in six SS patient lym-
phocyte samples to check whether the transcript being expressed was equivalent to that
being expressed in other tissues. Eight overlapping PCR amplicons were designed to
cover the entire coding sequence and 953bp of the 1111bp 3’-UTR (Figure 5.15a).
Each PCR was sequenced in both the forward and reverse directions and the overlap-
ping amplicons allowed confirmation of the sequence present at primer binding sites.
Sequencing was performed as described in Section 2.12 using the primers and con-
ditions detailed in Table 2.5. In all patients each PCR generated only one band of
the expected size suggesting that no exon skipping had occurred (Figure 5.15b). All
sequences were aligned to the PLS3 mRNA reference sequence NM_005032, ambigu-
ous bases were identified and the sequences were inspected for mismatches with the
reference. No mutations were detected within the coding sequence of the six patients
examined however, a G/C polymorphism was observed in exon 1, 390bp up-stream of
the translational start site, in two patients. Further investigation revealed this site to
be a known C/G SNP, rs757124, which in the HapMap european population displays
genotype frequencies of 37% C/C, 27% C/G and 37% G/G.
The promoter region of 12 patients and six healthy controls was also directly se-
quenced to look for polymorphisms that might be causing the aberrant expression.
The patient cohort included three SS patients who had not been seen to express PLS3
mRNA, eight SS patients expressing PLS3, and one MF patient with detectable PLS3
expression. Since the CD4+ T-cell population used for sequencing would not contain
a pure population of tumour cells, patients were selected on the basis of a high tumour
burden, as judged by increased CD4+ count, proportion CD4+ or CD4:CD8 ratio at
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Figure 5.15: PLS3 mRNA sequencing
(a) Diagram showing the binding sites of the PLS3 mRNA sequencing primers. The
purple arrow highlights the coding sequence, grey arrows represent the exons, dark
green arrows the forward primers and light green arrows the reverse primers. Also
marked is the C/G SNP rs757124. (b) PCR gel showing amplification of each of the
PLS3 mRNA sequencing primer pairs from a selection of patient cDNA samples.
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the time of sampling, in order to maximise the chance of detecting any polymorphisms.
Two PCR amplicons were designed to cover from 1845bp upstream of the transcrip-
tional start site to 99bp downstream of the transcriptional start site however, it was
not possible to design amplicons with sufficient overlap to sequence over the primers
leading to a gap of approximately 80bp in the sequencing coverage. Sequencing was
performed as described in Section 2.12 using the primers and conditions detailed in
Table 2.5
The promoter sequencing amplicons also covered the rs757124 SNP and two of
the samples used for mRNA sequencing had matched DNA available, allowing com-
parison of results. One sample, sequenced as C in the transcript was sequenced as
homozygous C at the DNA level, whilst the other sequenced as G in the transcript was
sequenced as homozygous G at the DNA level. Within the healthy group, two sam-
ples were sequenced as homozygous C and three as homozygous G. Across the whole
population of 12 patients, seven were homozygous for G, three were homozygous for
C and two were heterozygous. The genotype at this SNP did not appear to show any
association with PLS3 expression status in these patients.
Promoter sequencing reads were aligned with the reference sequence in Geneious
(Drummond et al., 2011) then the find heterozygotes tool was used with a peak sim-
ilarity setting of 25%. This should allow the sensitive detection of polymorphisms
however, it also leads to false positive detection of heterozygotes, particularly towards
the ends of sequencing reads where the peaks overlap more. All annotated alignments
were therefore examined by hand to exclude heterozygote calls that did not occur in
both forward and reverse sequencing reads. The only polymorphisms detected within
the 1845bp upstream of the transcriptional start site corresponded to known SNPs in
the region (Table 5.1). Whilst a much larger cohort is required to conclusively test for
an association between genotype and PLS3 expression, no clear pattern emerged from
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Sample PLS3 expression rs3813931 rs1557770 rs757124
R67 + C/C T/T G/G
R73 - C/C T/G G/C
R82 + nd G/G C/C
R83 + C/C T/T G/G
R84 + C/C T/T G/G
R85 + C/C T/T G/G
R89 + C/C T/T G/G
R118 (MF) + C/C T/T G/G
R122 - T/T T /T C/C
R125 + C/C T/G G/C
R126 - C/C T/T C/C
R133 + C/C T/T G/G
Table 5.1: Genotypes of the three SNPs within the PLS3 upstream region
the 12 patients studied.
The presence of SNPs proved a useful tool for assessing the sensitivity of direct
sequencing for the detection of polymorphisms within a mixed population of cells. One
sample homozygous for G was spiked into a sample homozygous for T at varying ratios
and then sequenced. Data were analysed using Geneous as described above to detect
heterozygotes with a 25% peak similarity (Figure 5.16). Interestingly, this revealed that
G was detected much more sensitively than T but even T was detected when present
in 50% of the cells. Given the lymphocyte subset counts, all samples examined for
mutations are expected to contain >50% tumour cells and hence mutations should
have been detectable if they were present.
5.3.6 Assessing DNA methylation in the PLS3 CGI
Although Lin et al. (1999) suggested that the PLS3 CGI was unmethylated in primary
lymphocytes, their study used digestion with the methylation sensitive XmaI enzyme
followed by Southern blotting to detect methylation. This assay quantifies only a few
CpG dinucleotides within the XmaI restriction site and does not provide an overview
of the methylation level across the whole island. Since methylation can vary across the
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Figure 5.16: Assessing the sensitivity of direct sequencing for detection of polymor-
phisms
Comparison of the sequencing chromatograms from mixtures of samples containing
G and T in different proportions. The potential polymorphism (K) is highlighted in
grey in the consensus sequence and those mixtures where a polymorphism was
detected.
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CGI, and as previously demonstrated in the Fas gene, positional methylation may play
a role in gene regulation, it was decided to examine the methylation of the entire PLS3
CGI.
Whilst previously, Pyrosequencing of bisulphite converted DNA had been used to
examine methylation of the Fas and SHP-1 CGIs, in PLS3 the assays proved techni-
cally difficult to design. CpG dinucleotides were so densely packed within the PLS3
CGI, as shown in Figure 5.17a that there were very few spaces of sufficient length (15-
20nt) to place the Pyrosequencing primers such that they did not overlap any CpG dinu-
cleotides. Furthermore, where there was space to place them the bisulphite conversion
had frequently reduced the sequence complexity such that there were homopolymeric
tracts unsuitable for primer placement. In addition, Pyrosequencing amplicons have a
maximum length of around 400nt so many amplicons would be required to cover the
1585bp CGI.
To circumvent this issue it was decided to use direct sequencing of bisulphite con-
verted DNA from healthy lymphocytes to screen for any methylation of the PLS3 CGI
that could be subject to dysregulation in SS patients. Although the reduced sequence
complexity made primer design challenging, primers were placed as shown in Fig-
ure 5.17a and detailed in Table 2.5 covering most of the PLS3 CGI. However, upon
testing these primers, only two amplicons, PLS3CGIT2 and PLS3CGIT9 could be
optimised to produce the strong PCR band required for sequencing (Figure 5.17b) al-
lowing investigation of approximately half of the PLS3 CGI. In addition to the healthy
lymphocyte samples, one healthy keratinocyte sample was also sequenced as this was
expected to have no methylation within the PLS3 CGI since keratinocytes strongly
express PLS3. In healthy lymphocytes the majority of the region investigated was
observed to be completely unmethylated, however, one small region containing CpG
dinucleotides 95-99 was found to be partially methylated in four healthy lymphocyte
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samples but not in the keratinocyte sample (Figure 5.18).
Several SS lymphocyte samples from patients with strong PLS3 expression were
also directly sequenced however, it was difficult to quantify the proportion of C and
T at the mixed base positions. Therefore, to investigate this region in further detail
a Pyrosequencing assay was designed to cover CpG dinucleotides 95-99 and used to
quantify methylation in four cell lines and lymphocyte samples taken from 24 healthy
controls and 36 SS patients as described in Section 2.11. Healthy lymphocytes were
found to contain an average of 32% methylation of CpG dinucleotides 95-99 compared
to the SS patient average of 30%. Dividing the SS patients into groups based on PLS3
expression level revealed that those who expressed PLS3 had a significantly reduced
methylation level of 21% (p<0.05) whilst those who did not express PLS3 had an av-
erage methylation level of 46%, which was not found to be different to the healthy
control lymphocytes (Figure 5.19). HEK293 was unmethylated, reflecting the expres-
sion of PLS3 and lack of methylation in healthy keratinocytes, whilst 86% methylation
was present in Jurkat cells that did not express PLS3. In the two SS cell lines, SeAx
and HuT78 that did express PLS3, methylation levels were 39% and 49% respectively
indicating a reduction in comparison with Jurkat.
DNA from the previously sorted PLS3- and PLS3+ populations from sample R164
was also analysed for methylation status of the PLS3 CGI at sites 95-99. In the pre-sort
sample DNA methylation across these sites was 16% whilst after sorting the PLS3+
subset, representing 79% of the pre-sort sample, was found to be 10% methylated and
the PLS3- subset 43% methylated showing that hypomethylation of CpG dinucleotides
95-99 is restricted to the PLS3+ cells.
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Figure 5.17: Optimisation of bisulphite sequencing primers for the PLS3 CGI
(a) Sequence of the PLS3 CGI showing the densely packed CpG dinucleotides
(highlighted by grey boxes) and the frequently homopolymeric tracts in between. The
designed sequencing primers pairs are highlighted with forward primers as dark green
arrows and reverse primers as light green arrows. (b) PCR gel showing amplification
of each of the PCR products from a selection of healthy and patient bisulphite
converted DNAs. PLS3CGIT1 and PLS3CGIT12 do not generate strong enough
bands for successful sequencing despite extensive optimisation of the PCR conditions.
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Figure 5.18: Hypomethylation of CpGs 95 - 99 in keratinocytes
Bisulphite converted DNA from four healthy lymphocyte samples and one healthy
keratinocyte sample were sequenced to assess DNA methylation across the PLS3
CGI. The section shown covers CpG dinucleotides 95-99. The bisulphite converted
reference sequence shows potentially methylated cytosine residues (N) and the
resultant C+T mixed base (Y) highlighted in grey.
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Figure 5.19: Quantification of methylation in the PLS3 CGI
Pyrosequencing was used to assess the methylation in CpG dinucleotides 95-99 of the
PLS3 CGI. Average methylation across the island is plotted for 24 healthy controls,




This study has demonstrated that aberrant expression of PLS3 in circulating lympho-
cytes is a feature of 60% of SS patients (Figure 5.3). In accordance with other studies
(Capriotti et al., 2008, Kari et al., 2003, Nebozhyn et al., 2006, Tang et al., 2010)
a negligible quantity of PLS3 mRNA was detected in healthy PBMCs using qPCR.
A threshold of over ten times this amount was then used to define statistically sig-
nificant PLS3 mRNA expression in patient samples. PLS3 mRNA expression status
determined using this threshold was found to be consistent with PLS3 protein expres-
sion status in 10/14 patients. The inconsistency observed in 4/14 patients are likely to
be due to differences in the sensitivity threshold of the detection methods and could
potentially indicate regulation on the translational level.
This is the first study to quantify the proportion of patients expressing statistically
significant levels of PLS3 mRNA in a large cohort. Su et al. (2003) demonstrated
SS mRNA over-expression by RT-PCR in 8/9 patients whilst the microarray studies
showed only a fold increase in the patient group compared to healthy controls. Capri-
otti et al. (2008) found expression in all 31 of their samples however their figures show
that some patient samples are within the range of normal healthy samples so it is un-
clear how many had significant over-expression. Tang et al. (2010) found significant
expression in a group of 8 SS patients as compared to MF patients with no blood in-
volvement, psoriasis/PRP patients and healthy controls but their results showed only
the mean and variance for each group so it is unclear what proportion of the 8 SS pa-
tients were PLS3+. Defining each sample as PLS3+ or PLS3- will be crucial to further
investigation of how PLS3 status affects prognosis, a cutaneous lymphoma prognos-
tic index has recently been validated (E. Benton et. al., manuscript submitted) and it
would be interesting to determine whether the addition of further molecular markers to
this model could provide any further refinement.
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Three MF patients demonstrating a T-cell clone in blood that was identical to the T-
cell clone in their skin lesions, were also show to express significant amounts of PLS3
(Figure 5.3). Of these, one demonstrated 41% Sézary cells by morphological analysis
suggesting that this patient had in fact developed SS. The presence of PLS3 in the other
two raises the question of whether the expression of PLS3 is an early sign that these
patients have developed SS or whether PLS3 expression is also a feature of circulating
cells in MF. It has been demonstrated by Campbell et al. (2010) that the clonal T-cells
from SS patients, as identified by expansion of one TCRVβ subfamily to greater than
50% of the total T-cell population, express CCR7/L-selectin/CD27 characteristic of
central memory T-cells whilst clonal T-cells from MF express CCR4/CLA character-
istic of effector memory T-cells. Skin resident T-cells in SS were shown to retain their
effector memory phenotype with the additional expression of the skin-homing addresin
CLA. It would be interesting to further investigate the expression of T effector mem-
ory and T central memory markers on PLS3 expressing circulating T-cells from MF
patients with blood involvement and such a study may provide evidence to add to the
debate over whether MF and SS are separate clinical entities or different stages of one
disease.
PLS3 mRNA expression level was compared with various lymphocyte subset cou-
nts in order to determine if there was any correlation with tumour burden (Figure 5.4).
A weak correlation was observed with percentage CD4+ cells however, close exami-
nation of the graph would suggest this is due to the majority of PLS3+ samples having
greater than 80% CD4+ cells with a wide range of PLS3 expression levels. In con-
trast to Capriotti et al. (2008), this study found no correlation between Sézary count
and PLS3 mRNA level however, Capriotti et al. (2008) used absolute Sézary count
whereas this study used percentage Sézary cells which may account for the difference.
Given that the percentage of PLS3+ cells within the CD4+ population varied between
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3% and 76% it appears that PLS3+ cells comprise only a subset of the tumour cells
so it is not expected that any measure of tumour burden would correlate with PLS3
mRNA level in a cohort of patients. It may however be possible to follow changes
in tumour burden in individual patients by monitoring PLS3 expression. Five patients
had multiple samples available over the course of 15 months and these were plotted
alongside lymphocyte counts however no clear patterns emerged (Figure 5.5). Tang
et al. (2010) followed one patient who progressed from MF to SS then received a bone
marrow transplant. Large changes in PLS3 expression were observed, following the
pattern of Sézary cell percentage closely, suggesting that PLS3 expression may be of
use in monitoring patients but further data is necessary to confirm this.
PLS3 and L-plastin are closely related actin-bundling proteins that normally demon-
strate tissue-specific expression (Lin et al., 1993b). However, aberrant L-plastin ex-
pression has been demonstrated in a wide range of epithelial malignancies (Lin et al.,
1993b) and shown to induce proliferation and invasion in colon cancer cells (Foran
et al., 2006) and melanoma cells (Klemke et al., 2007). Aberrant PLS3 expression
has been identified in SS but the functional role it plays has yet to be identified. As
discussed in Section 5.1 L-plastin plays a vital role in healthy T-cells, leukocytes de-
ficient for L-plastin are incapable of killing pathogens despite showing normal migra-
tion, adhesion, spreading and phagocytosis (Chen et al., 2003). Given the importance
of actin cytoskeletal dynamics in formation of the immunological synapse (reviewed
by Gomez & Billadeau (2008)) and the deficiencies in T-cell signalling observed in
CTCL, aberrantly expressed PLS3 may interfere with assembly of the immunologi-
cal synapse and has the potential to play a functional role in the pathogenesis of SS.
Further investigation is necessary to determine the extent of any functional role and
whether it represents a therapeutic target. Here, an antibody specific to PLS3 has
been developed and demonstrated not to cross-react with L-plastin. The antibody has
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been optimised for use in Western blotting (Figure 5.8), intracellular staining for flow
cytometry (Figure 5.10) and immunofluorescent staining (Figure 5.9). It is anticipated
that this antibody will enable future studies to examine the functional role of aberrantly
expressed PLS3 in SS.
The mechanism leading to aberrant expression of PLS3 in CTCL has not yet been
defined. No mutations were found in the coding or regulatory regions of the PLS3
gene to account for aberrant PLS3 expression in CTCL. Consistent with other stud-
ies (Lin et al., 1999, Oprea et al., 2008) no methylation was observed across the bulk
of the CGI in healthy PBMCs, however, in a region not previously investigated, cov-
ering CpG dinucleotides 95-99, methylation was observed in healthy lymphocytes but
not in keratinocytes (Figure 5.18). Further, hypomethylation of this region was found
only in SS patients displaying expression of PLS3 (Figure 5.19) and upon sorting the
PLS3+ and PLS3- populations from one patient, hypomethylation was found to be
restricted to the PLS3+ population. These observations strongly suggest that methyla-
tion of this region may contribute to the regulation of PLS3 expression, both in terms
of the healthy tissue-specific context, and in aberrant disease-specific expression. Ide-
ally, this hypothesis would have been tested by transfecting cell lines with a reporter
construct containing the PLS3 promoter and CGI with or without methylation of CpG
dinucleotides 95-99 and measuring the resultant expression of the reporter gene. Un-
fortunately this turned out to be a particularly complex proposal as no method exists
for the selective methylation of specific CpG dinucleotides, currently the only agent
that can be used to methylate cytosines in the CpG context is M.SssI methyltrans-
ferase, which will methylate all CpG dinucleotides present. One option would have
been to isolate the DNA segment containing CpG dinucleotides 95-99 and methylate
this prior to ligation back into the plasmid however, an elaborate cloning strategy was
required to do this which was not possible within the time available. New methods are
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emerging that endeavour to use the sequence specificity of zinc finger binding domains
linked covalently to a methyltransferase domain to target methylation to a particular se-
quence (Meister et al., 2010) however, these technologies require further development
before they can be used for the application proposed above.
It has previously been demonstrated by members of our group that malignant cells
in SS are present within CD4+CD26+, CD4+CD26-, CD4+CD25+ and CD4+CD25-
populations by quantifying PLS3 mRNA within sorted cell subsets (Jones et al., 2010,
Tiemessen et al., 2006). In this study the correlation between T-cell differentiation
marker expression and PLS3 expression was further explored, finding loss of CD26 to
be significantly associated with the PLS3+ subpopulation, whereas loss of CD7 and
gain of CD158k were not (Figure 5.11). Interestingly, Capriotti et al. (2008) observed
a weak correlation between PLS3 mRNA quantity and absolute CD26- count but not
absolute CD7 count in their cohort of patients suggesting that there may be a mecha-
nistic link between loss of CD26 expression and gain of PLS3 expression. It was also
observed that malignant cells were not necessarily confined to the CD45RO+ popu-
lation as widely assumed. Indeed, in three samples with significant loss of CD45RO
it was confirmed that the PLS3 expression was confined to the CD45RO- population
suggesting that the neoplastic cells have in these cases lost expression of CD45RO.
Similar results have been reported recently by Campbell et al. (2010) who saw het-
erogeneity in both CD45RO and CD45RA expression which in some cases included
co-expression, suggesting dysregulation of the mechanisms that normally lead to the
switch between CD45RA and CD45RO upon development from naïve to memory T-
cell (Dutton et al., 1998).
In all samples examined, PLS3 expression was observed to be restricted to CD3+
CD4+ T-cells (Figure 5.10), suggesting that PLS3 expression is a feature of the ma-
lignant cells rather than being induced in other haematopoietic compartments by the
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malignant microenvironment. The wide range of proportions of PLS3+ cells observed
suggests that PLS3 expression is confined to a subset of malignant cells rather than the
whole population. This hypothesis is further supported by the detection of genetically
defined tumour cells within the PLS3 negative population in one patient. Whilst loss
of CD7 and CD26 and gain of CD158k have been tested as diagnostic tools it is not
established if any of these markers can be used to quantify tumour burden accurately.
The current observations of phenotypic heterogeneity within the malignant cells with
respect to PLS3 co-expression are supported by a previous study which determined
that genetically defined tumour cells are not restricted to CD7- or CD26- subpopula-
tions (Steinhoff et al., 2009). The results presented here preclude the use of PLS3
sorting to isolate malignant cells in SS patients expressing PLS3 as doing so may lead
to the exclusion of a proportion of the malignant cells. In addition, cell sorting based
upon CD45RO, CD7, CD26 or CD158k is found to be likely to identify only a subset
of malignant cells, whilst still potentially including reactive cells. Therefore isolation
of the CD4+ subset still provides the most reliable approach for the enrichment of the
malignant cell population in SS.
In order to quantify genetically defined tumour cells within sorted cell subsets a
patient tumour cell-specific real-time TCR copy number assay was developed based
upon those used in acute lymphoblastic leukaemia (Brüggemann et al., 2004, van der
Velden & van Dongen, 2009). Quantification using a genetic assay was chosen in pref-
erence to the use of TCRVβ antibodies in order to enhance the specificity of detection
and to avoid excluding cells where cell surface TCRβ chain was not being produced
from the rearranged TCR gene. It was demonstrated that it is possible to determine
the exact sequence of the clonal TCRβ gene rearrangement by multiplex sequencing
of SSCP bands and thus identify the V, D and J regions along with the hyper-variable
joining segments (Figure 5.12). Identical sequences were obtained from diagnostic
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skin and blood samples from the patients investigated, confirming that the clonal T-
cells in the two sites are in fact identical. Assays were designed for four patients and
although only one had sufficient sorted cells for use in investigating the PLS3+ and
PLS3- populations, the testing process highlighted necessary steps in the development
of such assays and also demonstrated a sensitivity of 1 in 1000 cells was consistently
achievable. Patient tumour cell-specific real-time TCR copy number assays have po-
tential for future use in quantifying tumour burden allowing detailed monitoring of
response to therapy and with such a high sensitivity and specificity they could also be
used to monitor minimal residual disease following bone marrow transplantation.
In summary, the prevalence of aberrant PLS3 expression has been determined in a
large cohort of SS patients and demonstrated to be associated with hypomethylation of
CpG dinucleotides 95-99 in the PLS3 CGI. The expression of both PLS3 and pan-T-
cell differentiation markers in SS patient CD4+ T-cells is shown to be heterogeneous
and hence unsuitable for further enrichment of the malignant cells. In the course of
these investigations an antibody specific to PLS3 has been developed, which should
provide a valuable tool for further studies into the functional role of PLS3. In addition
a method for designing and optimising patient tumour cell-specific real-time TCR copy
number assays was developed, which could be used for future monitoring of tumour
burden in SS patients.
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In this thesis, three genes potentially key to the pathogenesis of SS were investigated
to determine whether DNA methylation could act as a regulatory feature. In all three
genes, DNA hypermethylation was observed to correlate with decreased gene expres-
sion suggesting a regulatory role. SHP-1 hypermethylation and correspondent down-
regulation of isoform-specific expression was however only observed in cell lines and
keratinocytes, no aberrant hypermethylation was observed in SS patient PBMCs. Hy-
permethylation of certain CpG dinucleotides in Fas was observed in PBMCs from SS
patients showing down-regulation of gene expression. Positional hypermethylation of
PLS3 was observed in healthy lymphocytes but not healthy keratinocytes, with sub-
stantial hypomethylation in PBMCs from SS patients showing aberrant gene expres-
sion. Thus, these candidate genes effectively demonstrate the role of gene silencing by
positional hypermethylation in both tissue-specific gene regulation and disease-specific
dysregulation of gene expression. Notably, this is the first report of gene-specific hy-
pomethylation in CTCL. Below, several interesting features observed during this study
are discussed in terms of their consequences for the study of epigenetic dysregulation
in SS.
6.1 Magnitude of methylation changes
Using the bioinformatic definitions of a CGI discussed in Section 1.2, SHP-1 contains
the weaker CGI of the three genes, only just covering the minimum length of 200bp
defined by Gardiner-Garden & Frommer (1987) and not having sufficient ‘strength’
according to the functional analysis of Bock et al. (2007). Fas and PLS-3 by con-
trast, contain much longer CGIs of over 1000bp, which are predicted by Bock et al.
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(2007) to play a strong functional role. Interestingly, the hypermethylation observed
in SHP-1 tissue-specific isoform II regulation was of a much greater magnitude than
that observed in Fas and PLS3, affecting all 11 CpG dinucleotides and averaging 90%
methylation in healthy keratinocytes compared to 12% methylation in healthy lym-
phocytes. The hypomethylation of the PLS3 CGI by comparison, affected only 5 CpG
dinucleotides and corresponded to an average methylation difference of only 12% be-
tween healthy control CD4+ T-cells and SS patient CD4+ T-cells with dysregulated
gene expression.
One possible explanation for this difference is that only a subset of T-cells have
their PLS3 gene expression silenced by CGI methylation whereas the entire popula-
tion of keratinocytes have their SHP-1 isoform II expression silenced by CGI methy-
lation. Another possibility is that ‘stronger’ CGIs are in a more sensitive equilibrium
where methylation of a single CpG site can perturb gene expression whereas ‘weaker’
CGIs require more extensive methylation to bring about silencing of gene expression.
Since the CGI strength algorithm proposed by Bock et al. (2007) was based upon hi-
stone modifications and chromatin accessibility, the ‘strong’ CGIs may be in a state
that is poised ready for methylation induced silencing whilst ‘weaker’ CGIs require
more modification to reach the same state. This is of particular relevance given the
number of studies looking to define a DNA methylation pattern characteristic to spe-
cific healthy tissue types and disease states. Smaller changes in methylation may not
be detected by the high throughput methods used in these studies although they may
have strong functional relevance to the disease under study. Similarly, a more sensitive
assay may be limited in terms of how many samples it is feasible to study or how many
CpG dinucleotides within each CGI can be examined. Further study of these factors
may enable better design of high throughput assays to enable the accurate detection of
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functionally relevant changes in DNA methylation.
6.2 Methylation in cell lines
Whilst the level of methylation in the cell lines examined broadly reflected the situation
in primary tissue, several notable exceptions were observed. The SHP-1 promoter II
CGI was heavily methylated in the keratinocyte cell line HEK293T and unmethylated
in the leukaemic cell line Jurkat, consistent with the methylation observed in primary
keratinocytes but not in primary lymphocytes. However, within the CTCL cell lines
methylation was observed in SeAx and HuT78, which is inconsistent with the lack
of methylation observed in SS patient lymphocytes suggesting that SHP-1 promoter
II methylation is a consequence of the immortalisation of these cell lines. No Fas
methylation was observed in the cell lines examined as the absence of Fas expression
in SeAx was attributed to gene deletion. Wu & Wood (2011) examined further cell
lines and demonstrated positional methylation of the Fas CGI in the SS cell line Sez-4.
The demonstration of positional Fas methylation in 1/3 SS cell lines appears consis-
tent with the situation in primary cells where a proportion of SS patients demonstrate
down-regulation of Fas gene expression and consequent positional methylation of the
Fas CGI. In sites 95-99 of the PLS3 CGI, methylation in cell lines broadly reflected the
situation in primary cells with no methylation in HEK293, consistent with the absence
of methylation and presence of expression in primary keratinocytes whilst substantial
methylation was present in Jurkat cells that did not express PLS3. SeAx and HuT78,
which did express PLS3 demonstrated reduced methylation levels compared to Jurkat
however, all three lymphocyte cell lines demonstrated a greater proportion of methy-
lation than healthy CD4+ lymphocytes, which do not express PLS3. This may be due
to the cell lines being a purer population of cells than CD4+ lymphocytes and may
187
6.2 METHYLATION IN CELL LINES
support the suggestion that PLS3 is only silenced by methylation in a subset of CD4+
lymphocytes. Alternatively, it may suggest that methylation level alone does not de-
termine the expression status of PLS3 and additional regulatory mechanisms are in
use.
The inconsistencies observed between cell lines and primary tissue, particularly in
SHP-1, highlight the issues with extrapolating from studies examining only cell lines
in the case of DNA methylation. Generally it is assumed that since DNA methylation
is preserved between generations, it will be preserved across multiple passages in a cell
line. Several studies have been performed to assess the consistency between cell lines
and the primary tissues they were derived from. Paz et al. (2003) compared the methy-
lation frequency of 15 genes between cell line and primary tissues of colon, breast
and lung carcinoma and leukaemia and observed significant differences in frequency
of methylation in up to three genes dependent upon the tissue type. Interestingly, only
one gene showed an excess of methylation in cell lines from several tissues, all the
other genes identified as differentially methylated between cell line and primary tissue
were unique to that tissue suggesting that the subset of genes that become differen-
tially methylated due to immortalisation may be tissue-specific. Another investigation
demonstrated that 42/50 genes that had been identified as differentially methylated in
colon cancer cell lines were differentially methylated in clinical tissue samples (Ehrich
et al., 2008). Together these results suggest that a small but measurable proportion of
differentially methylated regions are a consequence of immortalisation rather than than
reflecting the situation in primary tissue. This study also identified a greater magnitude
of differential methylation between normal and cancer cell lines than observed between
normal and malignant clinical tissue, similar to the results observed for PLS3 methyla-
tion discussed above. Ehrich et al. (2008) conclude that this effect is likely to be due to
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the heterogeneity of clinical samples. The relative impact of differential methylation
between cell lines and primary tissue may differ dependent upon the disease model
and mode of immortalisation. For example, clustering analysis of the methylation
profile of lung tumour cell lines, which proliferate spontaneously in the appropriate
serum-free growth factor supplemented medium (Oie et al., 1996), showed grouping
by disease subtype with cell lines and primary tissue clustered together suggesting
these cell lines represent an accurate model (Toyooka et al., 2001). In contrast, EBV-
transformed lymphoblastoid cell lines cluster separately to their originating PBL sam-
ples, indicating that ‘methylation differences between peripheral blood lymphocyte-
and lymphoblastoid cell line-derived DNA samples from a single individual are ac-
tually greater than the methylation profile differences between individuals’ (Brennan
et al., 2009). Given this complex picture and the inconsistencies observed, particularly
in SHP-1 CGI methylation, it is concluded that assessment of the DNA methylation
profile of genes in SS is best carried out on primary tissue. Cell lines remain a valu-
able tool for functional studies, for example assessing the effect of demethylation using
5aza, however, DNA methylation in the gene of interest should first be characterised in
cohort of SS patients before determining if any of the available cell lines act as a good
model for the observed pattern.
6.3 Measuring tumour burden
For each of the three genes studied, the correlation of mRNA expression level with
lymphocyte count, CD4+ count, percentage CD4+ and percentage Sézary cells was
examined as a proxy for tumour burden. The most useful measure was observed to
be percentage CD4+ cells, which correlated negatively with SHP-1 and Fas mRNA
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expression and positively with PLS3 mRNA expression. Additionally, CD4:CD8 ra-
tio correlated negatively with SHP-1 and Fas mRNA expression and lymphocyte and
CD4+ counts correlated negatively with SHP-1 mRNA expression. It is possible that
the absence of strong correlations between lymphocyte or CD4+ count and gene ex-
pression is due to the skewed nature of these data in the patient data set, with some
patients recording values that are orders of magnitude greater than the normal range.
Pearson’s product-moment correlation does not require a normal distribution in the
source data (Kowalski, 1972) but it is strongly susceptible to outliers (Devlin et al.,
1975) hence the skewing could suggest the use of rank based measures of correlation
may be more appropriate. Re-analysis of the correlation data using Spearman’s rank
correlation revealed no differences for Fas and SHP-1 expression but did reveal signifi-
cant correlation between PLS3 mRNA expression and lymphocyte count, CD4+ count
and CD4:CD8 ratio and validated the previously observed strong correlation with per-
centage CD4+. Since this effect was limited to one gene it is likely this is due to the
skewing observed in the PLS3 mRNA expression dataset and does not suggest any
benefit to using Spearman’s rank when examining correlation of expression data with
lymphocyte or CD4+ counts.
Interestingly, whilst percentage Sézary cells showed a weak correlation in the ap-
propriate direction in each gene, this did not reach significance in any of the genes
examined, whether by Pearson’s or Spearman’s tests. This may be due in part to the
difficulty in accurately quantifying Sezary cells based upon morphology alone (Lutzner
et al., 1973). Additionally, a subset of patients display a clear TCRVβ clone in blood
but have no morphologically defined Sézary cells, suggesting that morphological anal-
ysis may not identify all the malignant cells present. Ideally, a marker would be iden-
tified that clearly enumerates the population of malignant cells, however, as shown in
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Section 5.3.3 and discussed in Section 5.4, none of the markers proposed to date are
expressed on all malignant cells in all patients. The method described in Section 5.3.4
for determining the TCRVβ gene rearrangement in an individual patient and hence
designing a qPCR assay to specifically detect the clonal malignant cells has potential
for the accurate enumeration of malignant cells. Due to the patient-specific nature of
this method it is probably not viable for routine analysis in all patients however, for
longitudinal studies examining response to treatment in a small cohort of patients it
could provide a very accurate means of monitoring tumour burden, particularly given
the high sensitivity.
6.4 Heterogeneity within the tumour cell population
In Section 5.3.3 a detailed investigation of the expression of PLS3 on a single cell level
and the correlation with other immunophenotypic markers demonstrated the high level
of heterogeneity in marker expression both within and between patients. Heterogeneity
was also observed in the Fas studies, with Fas expression both up- and down-regulated
and no correlation observed between Fas, CD26 and PLS3 expression. Based upon
these results it was concluded that enrichment of CD3+CD4+ T-cells remains the op-
timal means of isolating the entire malignant cell population. This observation of ex-
treme heterogeneity is interesting because it suggests no individual gene or set of genes
are serving as a driver for the malignancy, which would lead to much more consistent
dysregulation over the tumour population. This suggestion is supported by the ab-
sence of chromosomal rearrangements unique to CTCL as discussed in Section 1.1.2.
Heterogeneity is observed in many different cancers and two theories of cancer devel-
opment can explain the observation of heterogeneity in cancer cells (Shackleton et al.,
191
6.5 DYSREGULATION OF T-CELL SIGNALLING
2009). The cancer stem cell model suggests that a cancer is driven by a small subpop-
ulation of cancer stem cells that generate progeny with the potential to differentiate,
creating heterogeneity within the tumour cell population (Jordan et al., 2006). Addi-
tionally these progeny will have an increased likelihood of picking up further genetic
and epigenetic mutations, adding to the heterogeneity of gene expression observed.
If this is the case then a subset of genetic, epigenetic and phenotypic features may
be identified that define the cancer stem cells. The clonal evolution model proposes
that as the malignant cell population develops further genetic and epigenetic mutations
some will confer a selective advantage, allowing outgrowth of a particular clone until
further mutations occur (Nowell, 1976). However, clones are not necessarily mutu-
ally exclusive and heterogeneity may arise if several sub-clones have developed which
show differing phenotypic features.
6.5 Dysregulation of T-cell signalling
The pathways affected by dysregulation of the investigated genes are discussed in
greater detail in the individual results chapters however, a common feature of the
selected candidate genes is their potential contribution to dysregulation of the T-cell
signalling pathways and hence to the persistence of the malignant cells highlighted
in Section 1.1.4. Aberrant expression of PLS3 was confirmed in Chapter 5 and it is
hypothesised that this aberrant expression may disrupt T-cell interactions due to the
similarity between PLS3 and L-plastin, which is critical to the formation of the im-
munological synapse (Wang et al., 2010). The signals encountered during these T-cell
interactions are critical to the establishment of cell type subsets and may initiate an
anergic state whereby it is difficult to promote proliferation or the subsequent apop-
totic clearance of these cells. In addition to this, loss of Fas receptor as demonstrated
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in Chapter 4 and gain of the downstream pathway inhibitor c-FLIP (Contassot et al.,
2008) combine to increase the threshold for initiation of apoptosis, allowing these cells
to persist further. Although SHP-1 was not found to be dysregulated in primary SS tis-
sues, constitutive phosphorylation of STAT3 was underlined as a common feature of
SS (McKenzie et al., 2011). STAT3 is a crucial integrator of cytokine signalling path-
ways and it’s constitutive activation contributes to immune evasion by tumour cells
through the promotion of T-cell tolerance (Yu et al., 2007). As discussed in Section 3.4,
it has recently been discovered that methylation of the STAT3 protein on an arginine
residue may directly influence the phosphorylation state opening up the possibility that
imbalances of methylation may impact directly upon the STAT3 pathway.
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From the data presented in this thesis the following major conclusions are proposed:
• SHP-1 is not silenced by DNA methylation in primary lymphocytes from
SS patients.
• Fas is frequently down-regulated by aberrant positional hypermethylation
of the Fas CGI in SS patient lymphocytes.
• PLS3 mRNA is aberrantly expressed in 60% of SS patient lymphocytes,
this may be due to aberrant positional hypomethylation of the PLS3 CGI.
• Cell lines should be used with caution in studies examining DNA methy-
lation in SS as their methylation status may have arisen during immortali-
sation.
• Sézary cells display distinct heterogeneity in expression of CD45RO, CD7,
CD26, CD25, CD158k, Fas and PLS3 between patients and importantly
within tumour cell populations from individual patients. Therefore enrich-
ment of CD4+ T-cells by negative selection is the best method for enrich-
ing the tumour cell population.
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This thesis successfully met its aims of determining the contribution of DNA methy-
lation to the dysregulation of three candidate genes in SS and further allowed the ex-
ploration of the pathogenic roles of these genes. Several research tools have been
developed during the course of these studies which are expected to be of value to
other scientists looking to further these studies. As with any substantial body of sci-
entific endeavour however, more questions were raised than were resolved, ranging
from the molecular mechanistic dissection of how aberrant positional hypo- or hyper-
methylation occurs to the clinical relevance of each gene’s dysregulated methylation.
The most pertinent of these are discussed below along with the feasibility of instigating
future studies with currently available technology and methods.
Having comprehensively ruled out loss of SHP-1 as a mechanism leading to con-
stitutive activation of STAT3 the question remains of what causes this activation. This
is a fairly major question and has been the subject of extensive study over the years.
Avenues currently being pursued by others in our lab include the role of upstream cy-
tokine receptor dysregulation and direct STAT3 methylation on arginine residues as a
regulatory mechanism for STAT3 phosphorylation.
The mechanistic link between positional hypermethylation in the Fas CGI and re-
duced Fas mRNA expression has been conclusively demonstrated thanks to the pres-
ence of positional methylation in Sez-4 that could be reduced by 5aza treatment, with
consequent re-expression of Fas mRNA (Wu & Wood, 2011). However, this has not
yet been demonstrated for the positional hypomethylation observed in the PLS3 CGI
of SS patients. The most straightforwards approach that could be taken would be to
treat healthy CD4+ lymphocytes with 5aza to determine whether this led to a reduction
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of PLS3 CGI methylation and consequent re-expression of PLS3 mRNA. 5aza treat-
ment requires the active proliferation of cells in order to become incorporated in the
DNA (Stresemann & Lyko, 2008) so it would be necessary to stimulate the healthy
CD4+ lymphocytes with anti-CD3/CD28 to promote proliferation.
The loss of Fas and gain of PLS3 may have a prognostic impact, determining if
this is the case will take time as patients whose Fas and PLS3 status were determined
at diagnosis need to be followed through the course of treatment. If additional samples
can be obtained it would also be interesting to conduct a more thorough investigation of
changes in expression over time as the preliminary data presented here suggested Fas
may become progressively down-regulated. Alterations in PLS3 mRNA expression
has previously been followed over time in only one SS patient where it appeared to be
consistent with alterations in tumour burden (Tang et al., 2010). The preliminary data
on the change in PLS3 mRNA expression over time in five SS patients presented in
Chapter 5 was more mixed with no clear relationship to the changes in tumour burden.
Following the changes in a cohort of patients over time may allow a clearer picture
to be determined, particularly with respect to response to treatment and alterations in
tumour burden.
So far it has only been possible to speculate on the functional role played by PLS3
when aberrantly expressed in SS lymphocytes. The optimisation of a specific and
sensitive antibody for the detection of PLS3 described here should hopefully open up
many avenues for analysis of the localisation and interactions of PLS3 in SS lym-
phocytes. Another potential approach would be to introduce PLS3 to healthy CD4+
lymphocytes by transfection of a vector containing the PLS3 gene under the control of
a constitutive promoter and examine the effect upon T-cell signalling pathways. Pre-
viously it has been challenging to introduce extra DNA into primary lymphocytes as
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most commercial transfection agents are ineffective or induce apoptosis (Ebert et al.,
1997). However, devices such as the nucleofector have reported high success rates
with difficult-to-transfect cells such as primary lymphocytes so this may now be a vi-
able option (Magg et al., 2009).
Finally, since altered DNA methylation events have been shown to be so crucial
to the dysregulated T-cell signalling observed in SS the question of how to therapeuti-
cally modify these effects is relevant. The most obvious way to reduce methylation is
to treat with 5aza however, since hypomethylation of PLS3 has been observed this kind
of broad brush approach may be inappropriate. As mentioned previously, HDIs have
proven efficacious in CTCL patients and induce increased apoptosis of ex vivo tumour
cells (Duvic et al., 2007, Whittaker et al., 2010). Since histone modifications and DNA
methylation have been shown to exert their effects in a synergistic fashion (Cameron
et al., 1999) it may be that HDI induced changes in the chromatin structure lead to
alterations in DNA methylation in relevant genes. Further characterisation of ex vivo
tumour cells treated with HDIs and of lymphocytes from patients treated with HDIs
should allow the elucidation of which genes and T-cell signalling pathways are influ-
enced by HDI treatment.
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Downregulation of Fas Gene Expression in Se´zary
Syndrome Is Associated with Promoter
Hypermethylation
Christine L. Jones1, E. Mary Wain1, Chung-Ching Chu2, Isabella Tosi3, Rosalind Foster4,
Robert C.T. McKenzie1, Sean J. Whittaker1 and Tracey J. Mitchell1
Se´zary Syndrome (SS) is an aggressive leukemic variant of primary cutaneous T-cell lymphoma characterized by
the presence of tumor or Se´zary cells that generally display a mature memory T-cell immunophenotype. Se´zary
cells proliferate poorly and therefore their accumulation may be due to defective T-cell homeostasis involving
resistance to apoptosis. In this study, we analyzed Fas expression in CD4þ lymphocytes at the mRNA and
protein levels in a large cohort of SS patients as compared with healthy controls. Fas mRNA expression was
dysregulated in 34/47 patients, with significant under- and overexpression of Fas mRNA detected in 21 and 13
patients respectively (Po0.01). Examination of cell-surface Fas expression showed correlation with the observed
downregulation of mRNA in CD4þ T cells. Mutational analysis demonstrated that functional FAS gene
mutations are rare. Moreover, 16 SS patients who showed significant under-expression of Fas mRNA also
showed significant positional hypermethylation within the FAS CpG island, which was not present in healthy
controls or SS patients determined to have normal or overexpression of Fas mRNA. These data demonstrate that
dysregulation of Fas expression is a common feature of SS, and provide a rationale for targeted therapies to
restore the extrinsic Fas-dependent apoptotic pathway in this malignancy.
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INTRODUCTION
Se´zary Syndrome (SS) is an aggressive, leukemic variant of
primary cutaneous T-cell lymphoma (CTCL). Clinically SS is
characterized by erythroderma, lymphadenopathy, pruritus,
and presence in the peripheral blood of a clonal population
of malignant T cells with hyper-convoluted, cerebriform
nuclei, known as Se´zary cells (Willemze et al., 2005). The
immunophenotype of Se´zary cells is typically that of a mature
memory T-cell (CD4þ /CD45ROþ ) expressing the skin-
homing marker cutaneous lymphocyte antigen and the
chemokine receptor CCR4, but frequently lacking expression
of other T-cell surface markers such as CD7 and CD26
(Burg et al., 2005).
Unlike other T-cell lymphomas/leukemias such as adult
and childhood T-cell acute lymphoblastic leukemia, which
are commonly associated with balanced chromosomal
translocations, no specific karyotype is associated with SS,
although genetic instability with recurrent ‘‘hotspots’’ of
chromosomal abnormalities are a common feature of the
disease. Of note are frequent deletions within the long arm of
chromosome 10, which harbors the FAS gene. Loss of
heterozygosity at microsatellite markers in 10q23.31 has
been reported by two independent studies in up to 50% of SS
patients (Wain et al., 2005; Vermeer et al., 2008). Loss of 10q
has also been described in several other malignancies and is
associated with tumor progression in prostatic and bladder
carcinomas (Cappellen et al., 1997; Komiya et al., 1996).
The FAS gene, which encodes the death receptor
Fas (CD95/APO-1), is activated by its natural ligand
(FasL/CD95 L) and plays a key role in regulating T-cell
homeostasis, primarily through induction of apoptosis via
activation-induced cell death (AICD). Fas signaling leads to
the formation of a multi-molecular complex called the death-
inducing signaling complex, which in turn triggers a cascade
of caspase activation that constitutes the activation phase of
apoptosis. Induction of an immune response following
antigen challenge leads to rapid clonal expansion and
differentiation of naı¨ve T cells resulting in a large pool of
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effector T cells. During the termination phase of the
immune response, the vast majority of effector T cells are
eliminated by AICD, with only a small proportion surviving
AICD and entering the memory T-cell pool (reviewed by
Krammer et al., 2007). Several studies have revealed
that the Fas system is highly regulated during the phases of
a T-cell immune response. Resting T cells express marginal
amounts of Fas and are resistant to apoptosis (Klas et al.,
1993). During the activation phase, Fas is upregulated
(Ju et al., 1995) although short-term activated effector
T cells remain resistant to AICD (Klas et al., 1993), which is
thought to be due to incomplete death-inducing
signaling complex formation and the presence of high levels
of the apoptosis inhibitor c-FLIP (Kirchhoff et al., 2000;
Schmitz et al., 2004). Long-term activated T cells express
comparable levels of Fas to short-term activated T cells, but
have complete death-inducing signaling complex formation
with concomitant downregulation of c-FLIP expression, and
are therefore sensitive to Fas-mediated AICD (Dhein et al.,
1995).
Given the high frequency of deletion within the FAS gene
locus in SS and the fundamental role of the Fas system in
T-cell homeostasis, Fas is an attractive candidate for a pivotal
role in the pathogenesis of this disease. Studies determining
the molecular basis of Canale–Smith syndrome have shown
that heterozygous FAS mutations are sufficient to compromise
Fas function (Drappa et al., 1996). Somatic FAS gene
mutations have been described in several malignancies,
including multiple myeloma and non-Hodgkin’s lymphoma
(Lee et al., 1999; Park et al., 2001; Takakuwa et al., 2002;
Wohlfart et al., 2004). Somatic FAS gene mutations have
been described rarely in tumor cells isolated from skin lesions
of mycosis fungoides (Dereure et al., 2002; Nagasawa et al.,
2004), which is an indolent form of CTCL. However, it
remains to be determined if these mutations result in loss of
function. To date there are no reports of mutational analysis
of the FAS gene in SS. A recent report has demonstrated
frequent resistance (9/16 cases) to Fas-mediated apoptosis in
freshly isolated primary Se´zary cells (Contassot et al., 2008).
Heterogeneity of Fas expression levels was observed with five
cases showing normal or increased Fas expression, and four
cases showing reduced Fas expression. In cases with normal
or enhanced Fas expression, resistance to apoptosis was
attributed to increased expression of the apoptosis inhibitor
c-FLIP. However, the mechanism mediating reduced Fas
expression was not addressed.
Epigenetic gene silencing through promoter hypermethy-
lation of CpG islands is recognized as an important
mechanism regulating transcriptional silencing of genes,
expression of imprinted genes, and in tumorigenesis (Jones
and Baylin, 2002; Schaefer et al., 2007). Tumor suppressor
genes involved in DNA repair, cell cycling, proliferation, and
apoptotic pathways are commonly inactivated through
hypermethylation in malignancy. The FAS gene contains a
1,072 bp CpG island, which spans the transcriptional start
site and exon 1. Hypermethylation of the FAS gene promoter
has been described in colon, prostatic, and small-cell lung
carcinoma (Santourlidis et al., 2001; Hopkins-Donaldson
et al., 2003; Petak et al., 2003), and associated with
decreased Fas gene expression in these malignancies.
In this study we investigated Fas expression status in tumor
cell populations from patients with SS. We demonstrate that
reduced Fas mRNA and protein expression is common in SS
and can be attributed to a specific pattern of methylation
within the FAS CpG island.
RESULTS
Heterogeneity in tumor cell surface markers
We enriched for tumor cells using negative selection to
remove all non-CD4þ cells from the PBL population. This
was justified by experiments we performed on a subset of
patients to identify the cell subset which included the whole
tumor cell population while excluding as many reactive cells
as possible. We examined CD26 as a potential marker to
further isolate the tumor cell population (Jones et al., 2001).
Fluorescence-activated cell sorting was used to isolate
the CD3þCD4þ /CD45ROþ /CD26 and CD3þCD4þ
/CD45ROþ /CD26þ cell populations from five patients,
and T-plastin mRNA expression levels were used to identify
those populations that contained Se´zary cells (Su et al.,
2003). We detected T-plastin mRNA in both CD26 and
CD26þ subsets, with no significant difference in expression
between the two groups (Figure 1).
Decreased Fas mRNA expression in CD4þ cells from SS
patients
Quantitative reverse transcription PCR (qPCR) was used to
determine Fas mRNA expression levels in CD4þ T cells
isolated from peripheral blood. The expression of Fas mRNA
was measured in 47 SS patients and compared to average
expression levels from 16 healthy controls (Figure 2a). Fas
mRNA expression in the healthy control samples showed
little variation, whereas expression in SS patients was highly
heterogeneous, ranging from a three-fold increase to a
30-fold reduction as compared with healthy controls. Over-
all, 21 samples showed significant underexpression (P¼0.01)
























Figure 1. Expression of T-plastin mRNA in sorted patient-cell subsets. PBL’s
from five SS patients were sorted into CD3þCD4þ /CD45ROþ /CD26 and
CD3þCD4þ /CD45ROþ /CD26þ subsets then expression of T-plastin
mRNA was quantitated in each subset using qPCR and expressed relative to
the housekeeping gene cyclophilin.
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mRNA. Total lymphocyte count, CD4þ count, and
CD4:CD8 ratio were used to assess tumor burden in all
patients. No correlation between the expression of Fas and
tumor burden or survival was found.
Sequential samples taken at least six months apart were
available from 12 patients, which allowed us to investigate
any changes in Fas mRNA expression over time. Figure 2b
shows the change in expression for each patient between
their first and second samples. The general trend is toward a
decrease in Fas expression over time, which was shown to be
significant using a pairwise t-test (P¼0.021); however, there
is a notable subset of patients who maintained a consistent
level of Fas expression. Total lymphocyte count, CD4þ
count, and CD4:CD8 ratio were recorded at the time of
sampling and are presented in Table 1. There was no
association between the observed decrease in Fas expression
and changes in CD4þ lymphocytes, suggesting that this
decrease is not simply due to an increase in tumor burden.
Loss of cell surface Fas protein in memory T cells from SS
patients
To validate the Fas mRNA expression data, we determined
the level of cell surface protein expression of Fas on the
CD3þCD4þ /CD45ROþ T-cell population by flow cyto-
metry using peripheral blood lymphocytes (PBLs) from 10 SS
patients and six healthy controls. We also examined the cell
surface Fas expression on the Se´zary cell lines SeAx and
HuT78, and the mycosis fungoides cell line MyLa. Figure 3a
shows representative Fas histogram plots for one healthy
individual (H6), two SS patients (P2, P7), and the cell lines.
Whereas HuT78 and MyLa expressed Fas, SeAx displayed
complete absence of cell surface Fas protein.
The proportion of Fas-positive cells within the
CD3þCD4þ /CD45ROþ population was calculated for each
sample (Figure 3b). As expected, nearly all of the memory T
cells in healthy control samples expressed Fas protein on their
cell surface (range: 95.2–99.4% Fasþ ). Patient samples,
however, showed loss of cell surface Fas expression in a
proportion of their memory T cells (range: 1.5–96% Fasþ ).
Patient samples were considered significantly different to
healthy if the proportion of Fas-positive cells within the
CD3þCD4þ /CD45ROþ cell population was less than
80.7% (mean healthy proportion10 standard deviations).
Overall, 7/10 SS patients showed significant loss of Fas cell
surface expression on the memory T-cell population.
To determine whether loss of Fas expression could be used
to identify the tumor cells, we isolated the CD3þCD4þ
/CD45ROþ /Fas- and CD3þCD4þ /CD45ROþ /Fasþ sub-








Sample 1 Sample 2
Figure 2. Expression of Fas mRNA in SS patient samples. Quantitative
reverse transcription-PCR analysis of Fas mRNA expression in SS samples
expressed as a fold difference in amount of mRNA relative to the mean of 16
healthy controls (RQ). Measurements were performed in triplicate and
normalized against cyclophilin A. (a) Means±99% confidence interval for 47
patient samples. (b) Sequential samples taken from 12 patients between six
months and two years apart to assess the change in Fas mRNA expression over
time.
Table 1. Lymphocyte counts for the 12 SS patients








SS5a NA 1.12 8.00
SS5b 8.57 6.74 38.58
SS14a NA 2.27 22.00
SS14b 2.02 1.51 124.33
SS16a NA 0.32 11.00
SS16b 6.65 6.28 108.39
SS18a NA 1.22 11.00
SS18b 3.04 2.34 19.65
SS20a 4.07 3.62 40.41
SS20b 3.21 2.78 24.53
SS21a 6.57 5.89 16.02
SS21b 9.26 8.77 342.00
SS23a 0.61 0.43 9.86
SS23b 1.59 1.33 26.57
SS28a 4.19 3.70 55.25
SS28b 7.79 7.12 53.76
SS31a 6.44 6.08 42.91
SS31b 31.67 31.41 119.48
SS33a 5.04 4.77 80.85
SS33b 5.22 4.92 84.20
SS34a 25.06 24.71 164.33
SS34b 24.85 24.63 198.20
SS46a 1.33 0.67 1.56
SS46b 1.65 0.79 1.61
NA, not available; SS, Se´zary Syndrome.
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used to detect the expression of T-plastin in each subset. Both
subsets had detectable T-plastin expression and there was no
significant difference between the two subsets (data not
shown). We also used RNA from the sorted cell populations
in Figure 1 to determine Fas mRNA expression by qPCR. This
was used to demonstrate the correlation between Fas mRNA
expression and cell surface protein (r¼ 0.816 and
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Figure 3. Flow cytometry analysis of Fas on Se´zary patient cells and cell lines. (a) Histogram plots showing the expression of Fas by one healthy control
(H6), two patients (P2 and P7), and the SeAx, HuT78, and MyLa cell lines. The isotype control is shown with the curve filled in grey. (b) PBLs from six healthy
controls (H1–H6) and 10 patients (P1–P10) were gated on CD3þ , CD4þ , and CD45ROþ and the proportion of Fas-positive cells measured within this
population. The gray line represents the average healthy proportion10 standard deviations. (c) Scatter plot to show the relationship between Fas mean
fluorescent intensity (MFI) and Fas mRNA expression level relative to cyclophilin, the line of best fit is also shown.
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Absence of functional mutations within the FAS coding region
in SS
To establish whether the observed decrease in Fas expression
was due to a genomic mutation, we performed single-strand
conformational polymorphism (SSCP) spanning nine exons
and the 30 end of the promoter of the FAS gene. Abnormal
banding patterns with SSCP as seen in Figure 4a were
identified in 4/20 SS samples. Sequencing of these bands
revealed that one corresponded to a previously reported silent
polymorphism of exon 3 (250A-G), while the other three
anomalies were found to be single-base substitutions within
the promoter region (one 274C-A and two 34A-G).
Single-strand conformational polymorphism analysis of
the promoter and exon 3 was then performed on DNA
extracted from the PBLs of 20 healthy controls to investigate if
the observed substitutions were unique to SS patients. This
revealed a similar rate of detection of the exon 3 polymorph-
ism (1/20) and of promoter region band shifts (2/20).
Sequencing established that the healthy promoter region
band shifts also represented single-base substitutions consist-
ing of one 373C-T and one 295G-A.
Single-strand conformational polymorphism was also
performed on DNA from the SeAx cell line since this had
demonstrated a lack of Fas protein (Figure 3a). Failure to
amplify any of the exons using PCR revealed that the FAS
gene has been deleted in this cell line and further
investigation revealed a complete absence of Fas mRNA
(data not shown). In the two patients who showed minimal
cell surface Fas expression, SSCP analysis revealed loss of
some bands using primer pairs 1.1 (P2a, P2b, and P9), 2 (P2a,
P2b and P9), and 3 (P9). This suggests that allelic loss of some
exons may have occurred in the malignant cells of these
patients (Figure 4b).
Downregulation of Fas mRNA expression in Se´zary patients is
associated with promoter hypermethylation
The FAS gene contains a 1,072 bp CpG island, which spans
the transcriptional start site and first exon of the gene.
Pyrosequencing of bisulfite-converted DNA was used to
assess the methylation status of each of the 74 CpG
dinucleotides in the FAS CpG island. Pyrosequencing is a
quantitative sequencing by synthesis technique (Tost et al.,
2003) and facilitates the analysis of mixed cell populations,
circumventing the need for a specific tumor-cell marker.
We first demonstrated the highly quantitative nature of the
pyrosequencing assays using artificially methylated DNA
mixed in varying proportions with unmethylated DNA.
Average methylation across the CpG island was plotted for
each of these mixtures (Figure 5a); this shows a linear
relationship across the entire range of measurements
(r2¼ 0.99). However, the graph achieved a maximum
methylation measurement of only 80%. We believe this is
due to the CpG methyltransferase reaction not proceeding to
completion rather than any deficiency in the actual measure-
ment. This data suggested that a minimum of 5% tumor cells
displaying methylation could be detected within the reactive
T-cell background.
Methylation of each CpG dinucleotide was then measured
in DNA from 10 healthy control samples and 35 patient
samples comprising 16 who showed downregulation of Fas
mRNA expression, nine who showed normal Fas mRNA
expression, and 10 who showed upregulation of Fas mRNA
expression. Wilcoxon unpaired U-test was used to compare
the methylation in each group of patients with that in healthy
controls at each CpG dinucleotide. In the 16 patients
showing downregulation of Fas mRNA expression, five CpG
dinucleotides (1, 2, 3, 31, and 51 numbered from the start of
the CpG island) were found to have significantly greater
methylation than in healthy controls (Figure 5b). No
significant differences were seen between patients with
normal Fas mRNA expression and healthy controls, or
between patients with upregulation of Fas mRNA expression
and healthy controls in these CpG dinucleotides (data not
shown).
The CpG dinucleotides which showed hypermethylation
in patients with downregulated Fas mRNA expression have
been highlighted on the schematic diagram of the FAS CpG
island shown in Figure 5c. Also highlighted are the NF-kB-
and p53 transcription factor binding sites, which have been
experimentally validated, and the transcriptional start site and
first exon of the gene.
DISCUSSION
This study of a large cohort of SS patients demonstrates that
downregulation of Fas gene expression, associated with
positional methylation of the FAS CpG island, is a common
feature of Se´zary cells.
Our results show a distinct heterogeneity in Fas mRNA
levels with significant underexpression in 21/47 (B45%) and
overexpression in 13/47 (B28%) of patient-derived CD4þ
T cells as compared with healthy controls. These data are
similar to those of a recently published study that reported
Control with mutant primer
Healthy control
Abnormal SSCP pattern
Healthy P2a P2b P9
Figure 4. SSCP analysis of the FAS gene in SS patients. (a) Patient samples
analyzed using primer pair 1.1 for the promoter region demonstrating an
abnormal band shift in one SS patient sample. (b) Sequential samples from
Patient 2 and one sample from Patient 9 who showed minimal cell surface
protein expression of Fas by fluorescence-activated cell sorting; arrows indicate
the decreased intensity of bands in exon two consistent with allelic loss.
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disparity in the levels of Fas expression in a cohort of 16 SS
patients (Contassot et al., 2008). The study by Contassot et al.
focused on the group of patients in whom overexpression of
Fas was demonstrated and showed that resistance to
apoptosis in this group was due to overexpression of c-FLIP.
In addition, those patients with downregulation of Fas
expression also showed resistance to apoptosis, but
the mechanism was not addressed. We sought to investigate
the patient group exhibiting downregulation of Fas as this
was the dominant mode of Fas dysregulation in our
patient cohort.
Follow-up analysis of samples taken at least six months
apart demonstrated a trend for decreased Fas mRNA
expression over time, with the most significant reduction
observed in patients showing increase in disease severity over
time. These findings are consistent with a study demonstrat-
ing an association between loss of Fas protein expression and
aggressive types of CTCL (Zoi-Toli et al., 2000).
Examining cell surface expression of Fas validated the
observed downregulation of Fas mRNA expression in Se´zary
cells. Se´zary cells are generally derived from CD3þCD4þ
/CD45ROþ memory T cells and show variable loss of
expression of CD7 and CD26 (Steinhoff et al., 2008).
At present there are no tumor-specific cell surface biomarkers
available. We found that loss of CD26 does not clearly
distinguish between Se´zary and reactive cell populations
since both CD26 and CD26þ populations contain
detectable T-plastin, a Se´zary-cell-specific mRNA. In healthy
individuals, a large proportion of the CD4þ /CD45ROþ
T-cell population show cell surface Fas expression (Miyawaki
et al., 1992; Muench et al., 2003), which is consistent with
the findings reported here demonstrating Fas expression in at
least 95% of the CD3þCD4þ /CD45ROþ T cells.
In contrast, loss of Fas expression in 7/10 SS patients affected
between 32 and 94% of CD3þCD4þ /CD45ROþ cells
(shown in Figure 3b) and was associated with downregula-
tion at the mRNA level. The detection of tumor cells within
both the Fas and Fasþ subsets (data not shown) and the
CD26 and CD26þ subsets (Figure 1) highlights the marked
heterogeneity present within the tumor cell population,
which we have previously observed in relation to CD25
expression (Tiemessen et al., 2006). Fas expression was
also examined in three CTCL cell lines HuT78, MyLa, and
SeAx. Whereas HuT78 and MyLa cells displayed cell surface
Fas expression, SeAx cells were found to have loss of
expression, which is consistent with the absence of Fas
mRNA expression in this cell line. Loss of cell surface Fas
expression has been reported in several previous studies of
SS, although the underlying mechanism has not established
(Dereure et al., 2000; Osella-Abate et al., 2001; Wu et al.,
2009).
To address putative molecular mechanisms that may
mediate the observed downregulation of Fas in Se´zary cells,
we performed comprehensive mutational scan of the FAS
gene and analyzed the CpG island around the FAS promoter
region for methylation events. Promoter polymorphisms were
identified in 3/20 SS patients and also in some healthy
controls, suggesting that, while the functional relevance of
these polymorphisms are unknown, they are unlikely to
contribute to the downregulation of Fas in SS. The Se´zary cell
line SeAx was found to have a deletion of all exons of the FAS
gene, resulting in complete absence of Fas protein and
mRNA. Loss of multiple exons was also observed in two
SS patients, in whom we found less than 10% of CD4þ
/CD45ROþ T cells displaying surface Fas expression.
However, the commonest finding was the demonstration of
hypermethylation of five specific CpG dinucleotide repeats in
the FAS promoter, which was associated with downregula-
tion of Fas expression.
As a mediator of apoptosis, Fas plays a critical role in
regulating T-cell homeostasis. Heterozygous germ-line muta-
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Figure 5. Quantification of methylation in the FAS CpG island. (a) Mixtures
of artificially methylated and unmethylated DNA were quantified at
each CpG dinucleotide. Data represent the mean methylation across all
CpG dinucleotides±SEM. (b) Methylation in each sample at five CpG
dinucleotides showing significantly increased methylation in the patients
with downregulation of Fas mRNA (D) when compared to the healthy
samples (H). The mean value for each group is shown as a horizontal bar;
*Po0.05 and **Po0.01. (c) Diagram of the region around the FAS promoter
numbered relative to the transcriptional start site (TSS). CpG dinucleotides are
marked by a vertical dash, the five hypermethylated CpG dinucleotides are
highlighted by *, and important gene regulatory elements within the CpG
island are marked.
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Canale–Smith Syndrome (Drappa et al., 1996), which is
characterized by marked lymphoproliferation and autoim-
munity. FAS is located on chromosome 10q23.31 and 10q is
a frequent region of genomic loss in many malignancies
(Cappellen et al., 1997; Komiya et al., 1996) including CTCL
(Wain et al., 2005; Vermeer et al., 2008). Somatic loss of
function FAS mutations have been described in both
lymphoid (Takakuwa et al., 2002) and non-lymphoid
(Takayama et al., 2002) malignancies, and in some cases
have been found to inhibit Fas ligand induced apoptosis in a
dominant-negative mode (Wohlfart et al., 2004). Two
mutational studies have been performed in mycosis fun-
goides, reporting mutations in 14 and 18% of cases
respectively (Dereure et al., 2002; Nagasawa et al., 2004).
Our study suggests that specific FAS mutations are uncom-
mon in SS, but given that loss of heterozygosity in the region
of 10q23.31 spanning the FAS gene has been detected in
50% of SS patients (Wain et al., 2005; Vermeer et al., 2008),
it is likely that chromosomal deletion/loss may also con-
tribute to loss of Fas protein expression in SS.
Epigenetic events are known to be a critical mechanism of
gene dysregulation in malignancy, and aberrant FAS promo-
ter methylation with associated loss of Fas expression has
previously been described in colon, prostatic, and small-cell
lung carcinoma (Santourlidis et al., 2001; Hopkins-
Donaldson et al., 2003; Petak et al., 2003). Recent studies
of disease-specific methylation events have demonstrated
that complex methylation patterns exist within CpG islands
(Brakensiek et al., 2007). Pyrosequencing of bisulfite-
converted DNA facilitates examination of individual CpG
dinucleotides within a CpG island to allow thorough
evaluation of the methylation status across the whole island
(Tost et al., 2003; Brakensiek et al., 2007; Oprea et al., 2008).
In addition, this technique allows quantitative detection of
changes in methylation in a mixed cell population, and,
therefore, is ideally applicable to the study of SS cells,
overcoming the problems of analysis of a heterogeneous
population of tumor cells admixed with non-malignant cells.
Five hypermethylated CpG dinucleotides within the FAS CpG
island were significantly associated with reduced Fas expres-
sion in SS patients. It is well recognized that the methylation
status of even a single CpG within a CpG island can be
responsible for the control of tissue-specific gene expression
(Aranyi et al., 2005; Kitazawa and Kitazawa, 2007) and for
aberrant gene silencing in cancer (Zou et al., 2006). Three of
the hypermethylated CpG dinucleotides in the FAS promoter
are clustered around the transcriptional start site and,
therefore, could be directly responsible for preventing the
binding of the transcriptional machinery. Furthermore, other
studies of the FAS CpG island have identified hypermethyla-
tion of CpG dinucleotides located at or near transcription
factor binding sites, namely the p53-binding site in colon
carcinoma (Petak et al., 2003) and the NF-kB-binding site in
prostatic carcinoma (Santourlidis et al., 2001). Other
mechanisms by which DNA methylation affects gene
expression include recruitment of methylation binding
domain proteins, which impairs binding of transcriptional
machinery, and recruitment of histone-modifying factors
inducing condensation of the local chromatin structure
(Newell-Price et al., 2000).
At present there is no direct functional evidence to provide
a link between hypermethylation, Fas expression, and
resistance to apoptosis in SS. Such studies require the
availability of suitable cell lines since the demethylating
effect of 50-azacytidine requires cellular proliferation in order
to become incorporated into DNA and prevent maintenance
of methylation. Primary cultures of Se´zary cells do not
proliferate to any significant degree (Berger et al., 2002;
Tiemessen et al., 2006) and, therefore, cannot be used for
such studies. We show that the commonest SS cell lines SeAx
and Hut78, respectively, exhibit homozygous deletion of the
FAS gene and absence of methylation of the FAS CpG island.
However, studies of human colon carcinoma cell lines in
which hypermethylation of Fas and reduced expression has
been found, demonstrate that Fas expression and Fas-
mediated apoptosis can be restored by treatment with
demethylating agents (Petak et al., 2003).
It is now apparent that in addition to loss of heterozygosity
in the FAS gene locus, multiple molecular mechanisms can
mediate Fas dysregulation and resistance to apoptosis in SS.
A recent study (Wu et al., 2009) reported some findings
similar to those reported here, identifying reduced Fas
expression in SS and in CTCL cells from lesional skin of
mycosis fungoides patients. Reduced Fas expression was
shown to correlate with loss of sensitivity to Fas-mediated
apoptosis. Contassot et al. have demonstrated that in SS
patients with overexpression of Fas, resistance to Fas-
mediated apoptosis is still observed and can be attributed
to a concomitant increase in expression of the apoptosis
inhibitory protein c-FLIP. Another study (Klemke et al., 2009)
suggests that attenuated T-cell receptor signaling leading to
loss of FasL upregulation also contributes to apoptosis
resistance in patients with normal expression of Fas.
Fas-mediated apoptosis represents a key mechanism under-
lying activation induced T-cell death. Therefore, these
findings suggest that dysregulation of T-cell homeostasis
may play a pivotal role in the pathogenesis of SS.
In summary, we have identified that loss of Fas receptor on
the surface of malignant T cells is a common feature of SS.
Our data suggest that mutational events are uncommon and
are not linked to the observed loss of Fas expression in the
majority of patients. Significantly, aberrant promoter hyper-
methylation appears to be the most frequent mechanism that
is associated with loss of Fas expression in SS.
MATERIALS AND METHODS
Patient material and cell lines
DNA and cDNA samples derived from Se´zary Syndrome patients
were obtained from a nationally approved research tissue bank (07/
H10712/106), while flow cytometry studies were performed on
freshly isolated PBLs with the approval of the Guy’s and St. Thomas’
Hospital Research Ethics Committee (EC01/301). SS patient blood
samples were obtained during the course of standard clinical
procedures, whereas those from 20 healthy volunteers were
obtained by venepuncture. For all samples, informed consent was
obtained in accordance with the Declaration of Helsinki Principles,
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1975, as revised in 2005. Lymphoprep (Axis-Shield, Kimbolton, UK)
gradient centrifugation was used either directly to isolate PBLs or
following incubation with RosetteSep CD4þ T-cell enrichment
cocktail (Stem Cell Technologies, London, UK) to isolate CD4þ T
cells. We chose to use negative selection in order to avoid activating
the cells and causing any changes in gene expression due to
processing.
All patients had a T-cell clone detected in the peripheral blood as
demonstrated by T-cell receptor V beta and gamma gene rearrange-
ment studies using BIOMED-2 primer sets and fulfilled the
WHO–EORTC diagnostic criteria for SS (Willemze et al., 2005).
Se´zary cell counts were determined at the time of diagnosis and all
patients included in the study had a Se´zary count of greater than
1000 cells/mm3. However, we did not routinely determine Se´zary
counts at the time of patient sampling for our research study, but
relied on measuring total lymphocyte and lymphocyte subset counts,
and using total CD4þ T-cell count and CD4:CD8 ratio as an
indicator of tumor burden.
The cell lines HuT78 and HEK293 were kind gifts from Dr S. John
(King’s College London); SeAx was a kind gift from Dr M. Vermeer
(Leiden University Medical Centre); and MyLa was obtained from
the ECACC (Salisbury, UK). All cultures were maintained in
Roswell’s Park Memorial Institute medium containing 10% fetal calf
serum and 1% penicillin/streptomycin (Invitrogen, Paisley, UK);
SeAx cells were supplemented with 25 U ml1 interleukin-2.
Quantitative RT-PCR
Total RNA was extracted from CD4þ T cells (RNeasy minikit;
Qiagen Ltd, Crawley, UK) and the high-capacity cDNA
archive kit (Applied Biosystems, Warrington, UK) was used to
generate randomly primed cDNA. Quantitative RT-PCR was
performed on the ABI Prism 7000 sequence detection system
(Applied Biosystems) with the following optimized TaqMan probe/
primer sets: Hs00236330 m1–Fas and Hs99999904 m1–cyclophilin
A. Each sample was analyzed in triplicate for both the target gene
(Fas) and an endogenous control (cyclophilin A). The DDCt method
was used to compare the Ct of each patient sample to the mean Ct of
16 healthy control samples after ascertaining that the PCR reactions
for Fas and cyclophilin A proceeded with equal amplification
efficiency.
Flow cytometry
Peripheral blood lymphocytes were incubated with monoclonal
antibodies APC-aCD3 (eBioscience, San Diego, CA), PerCp-aCD4
(BD Biosciences, Erembodegem, Belgium), FITC-aCD45RO (DAKO,
Ely, UK), and PE-aFas (BD Biosciences) or the appropriate isotype
controls (BD Biosciences). Flow cytometry analysis was performed
on a FACSAria II (BD Biosciences) and data were analyzed using
FlowJo software (Tree Star Inc., Ashland, OR). Fluorescence-
activated cell sorting was performed on a FACSAria II (BD
Biosciences) and used the additional antibodies APC-aCD26
(Miltenyi Biotech, Bisley, UK) and PE-Cy7-aCD3 (eBioscience).
SSCP
DNA was isolated from PBLs using standard procedures. PCR was
performed with primer pairs (as described by Beltinger et al. (1998))
designed to amplify all nine exons and the 30 end of the promoter.
PCR products were labeled using a-33PdCTP as previously described
(Scarisbrick et al., 2000). Denatured PCR products were separated
by electrophoresis through polyacrylamide gels containing both 5%
glycerol and no glycerol. A negative control (deionized water) was
performed for each primer pair. DNA from healthy individuals was
used as a positive control.
Sequencing
Abnormal bands were excised from the SSCP polyacrylamide gels.
DNA was eluted, re-amplified, and sequenced using the fmol DNA
Cycle Sequencing System (Promega, Southampton, UK). DNA from
a healthy control was subjected to the same technique and run
simultaneously to ensure reproduction of the published sequence.
Preparation of methylated and unmethylated DNA standards
DNA from the HEK293 cell line was used as completely
unmethylated DNA. An aliquot was subjected to in vitro methylation
using the M. SssI CpG methyltransferase enzyme (NEB, Hitchin, UK)
followed by purification using the MinElute reaction cleanup kit
(Qiagen) to generate completely methylated DNA. Mixtures of
methylated and unmethylated DNA were then prepared prior to
bisulfite treatment.
Bisulfite conversion of DNA
Methylated and unmethylated DNA standards and PBL-derived
genomic DNA from SS patients and healthy controls were bisulfite
treated in 20 ml aliquots containing 1 mg DNA using the EZ DNA
methylation kit (Zymo Research, Orange, CA) according to the
manufacturer’s instructions.
Pyrosequencing
A set of PCR primers specific to bisulfite-treated DNA were designed to
cover the FAS CpG island (available on request). After PCR with one
biotinylated primer, 20ml of PCR product were immobilized onto 4ml
of streptavidin Sepharose HP beads (GE Healthcare, Chalfont St Giles,
UK) and a vacuum prep workstation (Biotage AB, Uppsala, Sweden)
was used to isolate and wash the beads with bound single-stranded
PCR product. These were deposited into a pyrosequencing plate
(Biotage) and the sequencing primer annealed. The pyrosequencing
reaction was carried out using a PSQ HS 96 machine (Biotage)
following the manufacturer’s instructions for methylation analysis. The
PSQ HS 96 software was used to analyze the success of each reaction
and to calculate the corresponding percentage methylation. Data were
exported into an Excel spreadsheet and summarized using a pivot table.
For each of the standards with known methylation, an average was
taken across all the positions measured.
Statistics
All statistical tests were performed using the R statistical software
package (http://www.r-project.org/).
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ORIGINAL ARTICLE
Constitutive activation of STAT3 in Se´zary syndrome is independent of SHP-1
RCT McKenzie, CL Jones, I Tosi, JA Caesar, SJ Whittaker and TJ Mitchell
Skin Tumour Unit, St John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, King’s College London,
London, UK
Constitutive and persistent activation of STAT3 has been
implicated in the pathogenesis of many malignancies. Studies
of CTCL cell lines have previously suggested that aberrant
activation of STAT3 is mediated via silencing of the negative
regulator SHP-1 by promoter methylation. In this study of ex
vivo tumour cell populations from 18 Se´zary syndrome (SS)
patients, constitutive phosphorylation of STAT3, JAK1 and
JAK2 was present in all patients, but was absent in comparative
CD4þ T-cells from healthy controls. Furthermore, no loss or
significant difference in SHP-1 expression was observed
between patients and healthy control samples. Methylation-
specific PCR analysis of the SHP-1 CpG island in 47 SS patients
and 11 healthy controls did not detect any evidence of
methylation. Moreover, small interfering RNA knockdown of
SHP-1 had no effect on phosphorylation of STAT3. In contrast,
treatment of SS tumour cells with the pan-JAK inhibitor
pyridone 6 led to downregulation of phosphorylated STAT3
(pSTAT3), its target genes and induction of apoptosis. No
evidence for common JAK1/JAK2-activating mutations was
found. These data demonstrate that constitutive activation of
STAT3 in SS is not due to the loss of SHP-1, but is mediated by
constitutive aberrant activation of JAK family members.
Leukemia advance online publication, 5 August 2011;
doi:10.1038/leu.2011.198
Keywords: Se´zary syndrome; cutaneous T-cell lymphoma; STAT3;
SHP-1; JAK
Introduction
Se´zary syndrome (SS) is the leukaemic variant of primary
cutaneous T-cell lymphoma (CTCL) with an aggressive clinical
course, poor prognosis and median survival of 3.13 years.1 The
aetiology of SS is not well understood, but in common with
other types of CTCL, it is characterised by a clonal proliferation
of malignant mature T-cells (Se´zary cells) that display skin-
homing properties mediated via expression of the receptors CLA
and CCR4. A recent immunophenotypic study suggests that the
origin of Se´zary cells is the central memory T-cell pool, while
skin-restricted mycosis fungoides (MF) is derived from skin-
resident effector memory T-cells.2 Se´zary cells can also
be further differentiated from MF cells, based on high level
co-expression of the lymph node homing markers CCR7 and
L-selectin.
Se´zary cells have a low proliferative potential and their
accumulation appears to be due to defective T-cell homeostatic
mechanisms mediated by dysregulation of key signalling path-
ways controlling apoptosis and survival.3 The signal transducers
and activators of transcription (STATs) are a pleiotropic family of
transcription factors that have a pivotal role regulating many
gene networks, including those involved in cell survival and
proliferation.4 There are seven STAT family gene members that
show a high degree of sequence identity at the amino-acid level.
Phosphorylation of STATs is normally a rapid and transient
process mediated via protein ligand binding of cell-surface
cytokine and growth factor receptors that trigger a cascade of
phosphorylation events involving the JAK kinases and culminat-
ing in the phosphorylation of STATs on a single tyrosine
residue.5 Phosphorylated STATs (pSTATs) dimerise and are
transported to the nucleus where they activate transcription of
target genes. Until recently it was thought that only pSTATs
could function as transcription factors, but it is now clear that
unphosphorylated monomeric STATs have a distinct set of target
genes to their phosphorylated counterparts and can shuttle
between the cytoplasm and nucleus in the absence of cytokine
activation.6,7
The most strongly implicated STAT in oncogenesis is STAT3,
which is considered an oncogene through its ability to transform
cultured cells.8 Persistent or constitutive JAK–STAT3 activation is
common in many solid and haematological malignancies, and is
recognised as a significant driver of pathways mediating tumour
initiation, development and progression.9 Constitutive activation
of STAT3 has been demonstrated in studies of cell lines derived
from MF and SS patients and anaplastic large cell lymphoma.10–19
In lesional patient-derived material, strong expression of pSTAT3
has been identified by immunohistochemistry in tumour biopsy
samples from advanced stage MF patients, but only weak
expression was detected in early patch/plaque lesions.11 In SS
patients, the activation status of STAT3 is less clear, with one study
demonstrating the strong expression of pSTAT3 in peripheral blood
mononuclear cells (PBMCs) from only 2 of 14 patients.10 Another
study of six SS patients suggested that activation of STAT3 is not
constitutive, but is cytokine dependent.17 However, a recent
report demonstrated persistent and constitutive activation of
STAT3 in PBMCs from 4/4 SS/MF patients.18
STAT3 activation may be a key abnormality in CTCL because
abrogation of constitutive STAT3 activity by dominant-negative
STAT3 mutant proteins or STAT3 knockdown by small interfer-
ing RNA (siRNA) induces apoptosis in CTCL cell lines.11,12 The
downstream effects of STAT3 knockdown are downregulation of
expression of key pSTAT3 target genes including the prosurvival
genes Bcl-XL, Mcl-1 and Survivin and the regulators of cell
growth cyclin D1, cyclin D2 and cMyc.20
No activating mutations of STAT3 have been reported, and
persistent or constitutive STAT3 activation has been attributed to
a variety of upstream events in different malignancies based
on both studies, in vitro using cell lines and ex vivo using
primary cancer cells. In the chronic myeloproliferative dis-
orders, essential thrombocythemia, primary myelofibrosis and
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polycythemia vera, the activating JAK2 mutation, JAK2 V617F
has been detected at a very high frequency.21 In contrast,
activating JAK mutations appear to be much less frequent in
lymphoid malignancies, and alternative mechanisms of STAT3
activation includes the anaplastic lymphoma kinase (ALK) gene
fusion with nucleophosmin found in a subset of anaplastic large
cell lymphoma patients,22 and the nuclear pore protein
NUP214–ABL1 kinase fusion protein in a small proportion of
T-cell acute lymphoblastic leukaemia cases.23 Gain-of-function
mutations in JAK1 and JAK3 are notably absent in adult T-cell
leukaemia/lymphoma.24 To date, only JAK3 mutations have
been investigated in CTCL, and a study of 30 patients found the
JAK3 A572V mutation in only one patient with MF and large cell
transformation.25
In normal cells, the JAK–STAT3 pathway is tightly regulated,
primarily by negative feedback mechanisms involving the
protein inhibitors of activated STATs, the suppressors of cytokine
signalling (SOCS) and the SH2-containing phosphatases (SHPs).
Loss of SHP-1 expression has been linked to aberrant JAK–
STAT3 activation in several malignancies, including multiple
myeloma,26 adult T-cell leukaemia/lymphoma27 and in a
subset of MF patients with large cell transformation28,29 or
advanced tumour stage disease.30 The mechanism of SHP-1
inactivation has been attributed to epigenetic silencing by
aberrant promoter hypermethylation, demonstrated by methyla-
tion-specific PCR (MSP) in CTCL-derived cell lines,28 and in
diagnostic samples from myeloma26 and adult T-cell leukaemia/
lymphoma27 rather than due to inactivating mutations. To date,
the role of SHP-1 in the persistent activation of the JAK–STAT3
pathway in SS patients has not been investigated.
The aim of this study was to examine the frequency of
JAK–STAT3 activation in ex vivo-enriched primary tumour cell
populations derived from the peripheral blood of SS patients and
to determine whether this is mediated by inactivation of SHP-1.
Patients and methods
Patients and cell lines
All patients fulfilled the WHO–EORTC diagnostic criteria for
SS,1 and the presence of an identical T-cell clone was
demonstrated in peripheral blood and lesional skin biopsy by
TCR gene rearrangement studies using BIOMED-2 primer sets.31
Se´zary cell counts were determined at the time of diagnosis and
all patients included in the study had a Se´zary count 41000
cells/ml3. Total lymphocyte, CD4 counts and CD4/CD8 ratios
were noted at sampling as an indicator of tumour burden. All
patient samples were obtained from the nationally approved
Cutaneous Lymphoma Research Tissue Bank (07/H10712/106).
Healthy control samples were obtained with the approval of the
Guy’s and St Thomas’ Hospital Research Ethics Committee
(EC01/301).
A total of 59 patients were involved in this study. For
experiments involving freshly isolated enriched tumour cell
populations, 18 patients were studied. Multiple samples were
available from 10 of the 18 patients, and were used for the
functional studies. In addition, genomic DNA from enriched
tumour samples from 47 SS patients were analysed for the SHP-1
methylation study.
Primary keratinocytes from healthy skin biopsy samples were
available in the department. The CTCL cell lines, HuT78 and
SeAx, were gifts from Dr S John (King’s College London) and
Dr M Vermeer (Leiden University Medical Centre), respectively.
MyLa and HEK293 cells were obtained from the ECACC
(Salisbury, UK). All cultures were maintained in RPMI containing
10% fetal calf serum and 1% penicillin/streptomycin (Invitro-
gen, Paisley, UK). SeAx cells were supplemented with inter-
leukin (IL)-2 (25 U/ml).
Enrichment of SS tumour cell populations
At present, there are no tumour-specific cell surface biomarkers
available to isolate Se´zary cells. We have previously shown
that because of the marked heterogeneity of tumour cell
populations, isolation of CD4þ T-cells is the most appropriate
method to enrich for tumour cells without loss of tumour cell
sub-populations.32,33 Lymphoprep (Axis-shield, Kimbolton, UK)
gradient centrifugation was used either directly to isolate
peripheral blood lymphocytes or following incubation with
RosetteSep CD4þ T-cell enrichment cocktail (Stem Cell
Technologies, Grenoble, France) to isolate CD4þ T-cells.
Immunoblotting
Cell lysates were prepared and immunoblotting was performed
using standard procedures. Each blot was incubated overnight at
4 1C with anti-STAT3, anti-phospho-STAT3, anti-JAK1, anti-
phospho-JAK1, anti-JAK2, anti-phospho-JAK2 (New England
Biolabs, Hitchin, UK) or polyclonal anti-SHP-1 (Atlas antibodies
AB, Stockholm, Sweden) according to the manufacturer’s instruc-
tions. Immunoreactivity was detected using peroxide-conjugated
anti-mouse or anti-rabbit secondary antibody (Abcam, Cambridge,
UK), and was visualised using enhanced chemiluminescence
(ECL, GE Healthcare, Chalfont St Giles, UK).
Intracellular flow cytometry
All experiments analysed with multiple antibodies were per-
formed sequentially on the same day. A total volume of
1 106 cells/ml were fixed in 1% formaldehyde and then
permeabilised in 90% methanol. Following permeabilisation,
cells were treated for 1 h with the following primary antibodies;
anti-STAT3 (1/100), anti-phospho-STAT3 (1/50), anti-JAK-1
(1/100), anti-phospho-JAK1 (1/50), anti-JAK2 (1/100), anti-phos-
pho-JAK2 (1/50) and anti-SHP-1 (1/150). Cells were then
incubated with a fluorescent secondary antibody (Alexa Fluro
488 goat anti-rabbit IgG or Alexa Fluro 588 goat anti-mouse IgG,
Invitrogen). To detect background fluorescence, samples were
incubated with a rabbit or mouse isotype control (Invitrogen).
Flow cytometry analysis was performed on a FACSAriaII (BD
Biosciences, Oxford, UK); machine settings were standardized
and retained throughout the study; 10000 events were acquired
per sample and delta mean fluorescent intensity was calculated by
subtracting the mean fluorescent intensity of the isotype control
from the mean fluorescent intensity of the specific antibody using
Flowjo software (Tree Star Inc., Ashland, OR, USA).
Methylation-specific PCR
DNA was bisulphite converted using the EZ DNA Methylation-
Gold Kit (Zymo Research Corporation, Orange, CA, USA), then
amplified using the previously published SHP-1 primers.34
Methylation and unmethylation-specific PCRs were performed
concurrently for each set of samples and each PCR included the
following samples: DNA from the Jurkat cell line as a positive
control for unmethylated DNA; Jurkat DNA, which had been
methylated in vitro using the M.SssI CpG methyltransferase
enzyme (New England Biolabs) to generate completely
methylated DNA.
Activation of STAT3 in Se´zary syndrome
RCT McKenzie et al
2
Leukemia
APPENDIX B: PUBLISHED PAPER CONTAINING SHP-1 DATA
251
Pyrosequencing




CTTCA. An aliquot was taken to check for amplification of the
correct size product then 20 ml of PCR amplicon was immobi-
lised onto 4 ml of streptavidin sepharose HP beads (GE
Healthcare) and a vacuum prep workstation (Biotage AB,
Uppsala, Sweden) was used to isolate and wash the beads with
bound single-stranded PCR product. These were deposited onto
a pyrosequencing plate (Biotage) and sequencing primer S1S–
CCTCCACCAACTACTTTT or S2S–GGAGGAGGGAGAGATG
annealed. The pyrosequencing reaction was carried out using
a PSQ HS 96 machine (Biotage) following the manufacturer’s
instructions for methylation analysis.
siRNA knockdown
MyLa cells were washed and resuspended to a cell density of
1 106 cells/ml. Electroporation was performed using the
electroporator Bio-Rad, Gene Pulser II and 4 mm electropora-
tion cuvettes (Flowgen, East Yorkshire, UK). The samples were
electroporated at 240 V and 975 mF with 100 nM of either SHP-1-
specific or scrambled siRNA (Abgene, Surrey, UK) and cultured
for up to 48 h. A total volume of 1 106 cells were examined by
intracellular flow cytometry (as described above), and the
remanants were extracted for total RNA using the RNeasy
minikit (Qiagen Ltd, Crawley, UK) and converted into cDNA
using the high-capacity cDNA archive kit (Applied Biosystems,
Warrington, UK). cDNA was analysed by RT-PCR with SHP1-
specific primers35 and cyclophilin-specific primers (forward:
50-AAAGCATACGGGTCCTGGCATC-03; reverse 50-CGAGTTGT
CCACAGTCAGCAATG -30) to confirm SHP-1 knockdown.
Pan-JAK inhibitor treatment
Cell lines and CD4þ tumour cell populations isolated from SS
patients were re-suspended at 1 106 cells/ml in complete
medium and treated with 0.5mM of the pan-JAK inhibitor,
pyridone 6 (P6) (Merck, Laufelfingen, Switzerland) or a vehicle
control (dimethyl sulfoxide) for 120 min.
Detection of apoptosis
Commitment to apoptosis was measured using the Annexin
V–PE apoptosis detection kit I (BD Biosciences) and intracellular
staining with an antibody against caspase-3 (1/100, Santa Cruz
Biotechnology, Heidelberg, Germany). Both assays were
quantified using flow cytometry with 10 000 events acquired
on a FACSAriaII (BD Biosciences).
Real-time quantitative PCR
cDNA was generated from CD4þ tumour cell populations
isolated from SS patients as described above. Real-time PCR was
performed on the ABI prism 7000 sequence detection system
(Applied Biosystems) using the following optimised TaqMan
probe/primer sets: Hs00236329_m1–Bcl-XL, Hs00172036_m1–Mcl-1,
Hs00153353_m1–Survivin, Hs00355782_m1–p21, Hs01047580_
m1–STAT3, Hs00197982_m1–Bim and Hs99999904_m1–
cyclophilin A as an endogenous control. Each sample was
analysed in triplicate for both target gene and endogenous
control. The DDCt method was used to determine the fold-
change by comparison with the relevant untreated sample.
Mutational studies
DNA from 19 SS patients and 8 healthy controls were amplified.
For the regions containing V658 (JAK1) or V617 (JAK2), the
following JAK1- and JAK2-specific primer pairs were used (JAK1
forward: 50-CTGGCCTGAGACATTCCTATG-30; JAK1 reverse:
50-CCCCTTTGAAAGAGAACACACT-30) and (JAK2 forward:
50-CAAGCATTTGGTTTTAAATTATGGAGTATGT-30; JAK2 reverse:
50-TAAATTATAGTTTACACTGACACCTAG-30). PCR products
were labelled using a-33PdCTP as previously described.36
Denatured PCR products were analysed by single-stranded
conformational polymorphism analysis using 6% polyacryla-
mide gels with and without 5% glycerol. A negative control
(deionised water) was performed for each primer pair.
Statistics
Analysis of flow cytometry data comparing JAK–STAT3, SHP-1
expression levels between SS patients and healthy control samples
and the apoptosis data was performed using two-tailed t-test.
Paired t-tests with Po0.05, indicating statistical significance, were
used to analyse SHP-1 siRNA-treated cells and the P6-treated cells.
Results
Constitutive activation of the JAK–STAT3 pathway in
primary Se´zary cells
The activation status of the JAK–STAT3 pathway was assessed by
immunoblotting using whole-cell lysates from enriched tumour
cell populations from six SS patients, CD4þ T-cells from two
healthy controls and the CTCL cell line MyLa (Figure 1a). All
samples expressed STAT3, JAK1 and JAK2, but in contrast to
healthy control CD4þ T-cells, all six SS patients and the CTCL
cell line showed strong expression of phosphorylated (pSTAT3,
pJAK1 and pJAK2) components, consistent with constitutive
JAK–STAT3 activation. Furthermore, the observed constitutive
STAT3 activation was found to be persistent, as pSTAT3
expression was retained in enriched CD4þ tumour cell
populations maintained in vitro for a 5-day period in the
absence of exogenous cytokine stimulation (Supplementary
Figure 1).
Previous studies in CTCL cell lines have suggested that loss or
reduced expression of the protein tyrosine phosphatase SHP-1
mediates aberrant activation of the JAK–STAT3 pathway.28,30
This led us to examine the SHP-1 status in Se´zary tumour cell
populations. No difference in SHP-1 expression between
patients and healthy controls relative to the b-actin loading
control (Figure 1a) was apparent.
To validate these data, we extended the study to include 18 SS
patients and 6 healthy controls, and quantified expression
accurately using intracellular immunofluorescent staining and
flow cytometry. JAK–STAT3 activation was confirmed in all 18
patients (Figures 1b–d), which was significantly increased
(pSTAT3 Po0.001, pJAK1 Po0.001 and pJAK2 Po0.0001)
compared with healthy control samples. In contrast, no
significant difference in total unphosphorylated STAT3, JAK1
or JAK2 expression between patients and healthy controls was
observed (data not shown). Furthermore, consistent with the
immunoblotting data, no loss or significant difference in SHP-1
expression was observed in patients compared with healthy
controls (Figure 1e).
STAT3 activation is independent of SHP-1 in primary
Se´zary cells
Methylation of the SHP-1 promoter has previously been
reported in CTCL cell lines,28,30 therefore, we compared the
Activation of STAT3 in Se´zary syndrome
RCT McKenzie et al
3
Leukemia
APPENDIX B: PUBLISHED PAPER CONTAINING SHP-1 DATA
252
methylation status of the SHP-1 promoter in ex vivo-enriched
Se´zary tumour cells, cell lines and CD4þ lymphocytes from 11
healthy donors. Previously published34 MSP and unmethylation
specific (USP) PCR primers were used to amplify bisulphite-
converted DNA. Methylation was detected in the CTCL cell
lines, Hut78 and SeAx, which correlates with lack of SHP-1
mRNA and protein expression (data not shown) and is consistent
with the published findings. In contrast, a weak methylation
amplicon was detected in only 1/47 SS patients and 1/11 healthy
control samples. Representative MSP/USP data from eight SS
patients, eight healthy controls and the CTCL cell lines are
shown in Figure 2a.
MSP/USP does not assess the methylation status of all CpG
dinucleotides in the CpG island. Therefore, pyrosequencing was
used to quantify the methylation status of each CpG dinucleo-
tide in the SHP-1 CpG island in a subset of nine Se´zary patient
samples, seven healthy control samples and six cell lines.
Consistent with SHP-1 expression status (data not shown), MyLa
and Jurkat were found to have very low levels of methylation
across the SHP-1 CpG island, whereas high levels of methyla-
tion were detected in HuT78, SeAx, primary keratinocytes and
HEK293 cells. Pyrosequencing analysis also demonstrated very
low levels of methylation in both patient tumour cell popula-
tions and CD4þ T-cells from healthy controls (Figure 2b),
confirming the expression and the MSP data.
These data suggest that activation of JAK–STAT3 pathway in
Se´zary cells is independent of SHP-1. This was confirmed using
siRNA-mediated SHP-1 knockdown in MyLa cells and was
validated using SHP-1-specific RT-PCR, intracellular staining
and flow cytometry (Figures 2c and d). A significant reduction
(P¼ 0.0001) in SHP-1 expression was demonstrated in siRNA-
transfected cells and importantly no effect on STAT3 phosphor-
ylation was observed (Figure 2e). These data support our ex vivo
finding that in Se´zary cells, activation of STAT3 is not mediated
by loss of SHP-1 expression.
JAK inhibition downregulates STAT3 activation and
induces apoptosis in primary Se´zary cells
Enriched tumour cell populations from 10 of the 18 previously
assessed patients were treated with the pan-JAK inhibitor P6 for
120 min. P6 was selected, as previous reports suggest it is a more
specific and effective inhibitor of JAK–STAT3 activity compared
with AG490 in cell lines.37,38 Intracellular staining and flow
cytometry showed a significant decrease in activation of pJAK1
(Figure 3a, P¼ 0.005), pJAK2 (Figure 3b, P¼ 0.002) and
consequent decrease in activation of pSTAT3 (Figure 3c,
P¼ 0.001) in all samples treated with the pan-JAK inhibitor.
The effect of JAK inhibition on the commitment to apoptosis was
assessed in five of these patients and two healthy controls using
quantitative flow cytometry to detect cleaved caspase-3 and
Annexin V (Figures 4a and b). Apoptosis was strongly induced in
tumour cell from all five patients, whereas no induction of
apoptosis following P6 treatment was observed in healthy
control samples. A concomitant decrease in mRNA expression
of the pSTAT3 target and anti-apoptotic genes Bcl-XL, Mcl-1 and
Survivin was also evident in the tumour cell populations. In
contrast, expression of p21 and the proapoptotic gene BIM were
both induced in response to P6 treatment as was STAT3 itself
(Figure 4c).
JAK1 V658F and JAK2 V617F mutations are not present
in primary Se´zary cells
To establish whether activating mutations of JAK1 or JAK2
are responsible for constitutive activation of the JAK–STAT3
Figure 1 Constitutive activation of the JAK–STAT3 pathway in primary Se´zary cells. (a) Immunoblot analysis of whole-cell lysates derived from
enriched tumour cell populations from six SS patients (P1–P6), CD4þ T-cell from two healthy control samples and the MyLa cell line. Blots are
probed with the indicated antibodies against components of the JAK–STAT3 pathway and re-probed with b-actin as loading control. Quantitative
flow cytometric analysis of CD4þ -enriched tumour samples from 18 SS patients and CD4þ T-cells from 6 healthy control samples of (b) pSTAT3
(c) pJAK1 (d) pJAK2 (e) SHP-1. Data are shown as delta mean fluorescent intensity calculated as described in Patients and methods.
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Figure 3 JAK inhibition downregulates STAT3 activation in primary Se´zary cells. Quantitative flow cytometric analysis was performed on
P6-treated enriched tumour samples from 10 SS patients to determine the effect of P6 on the expression of (a) pJAK1 (b) pJAK2 (c) pSTAT3. Data are
expressed as delta mean fluorescent intensity, calculated as described in Patients and methods in untreated (0 min) and P6-treated (120 min) cells.
Figure 2 STAT3 activation is independent of SHP-1 in CTCL cells. (a) Representative agarose gel of SHP-1 MSP on eight Se´zary tumour cell samples,
eight healthy controls and four cell lines (b) Pyrosequencing across the 11 CpG dinucleotides in the SHP-1 CpG island in nine Se´zary samples (SS),
seven healthy controls (H) and six cell lines (CL). Convert is the conversion control, which indicates successful bisulphite conversion ifo5% (c) RT-
PCR using specific primer pairs for SHP-1 and cyclophilin using cDNA from MyLa cells, which were untreated, electroporated alone, treated with
scrambled or with SHP-1 specific siRNA for 24 or 48 h. (d, e) Quantitative flow cytometric analysis of electroporated MyLa cells expressed as delta
mean fluorescent intensity, calculated as described in Patients and methods after 24 or 48 h in culture for (d) SHP-1 and (e) pSTAT3.
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pathway in Se´zary cells, we performed single-stranded con-
formational polymorphism analysis of the region containing the
common V658 (JAK1) and V617 (JAK2) mutations, which
are frequently mutated in other malignancies with constitutive
activation of the JAK–STAT3 pathway.39 No band shifts were
observed in DNA samples extracted from the enriched tumour
cell populations of 19 Se´zary patients (data not shown). The
CTCL cell lines HuT78, SeAx and MyLa, and the leukaemic cell
line Jurkat also did not harbour either mutation.
Discussion
Aberrant activation of STAT3 has been widely reported in a variety
of malignancies (reviewed in Al Zaid Siddiquee and Turkson9 and
Yu et al.40). This study of ex vivo-enriched tumour cell populations
from a series of SS patients demonstrate that JAK–STAT3 activation is
a consistent feature of SS, providing compelling evidence that
aberrant STAT3 expression is a significant pathogenetic abnormality
in this malignancy. Furthermore, we have shown that in contrast to
that reported in vitro studies using CTCL-derived cell lines, persistent
JAK–STAT3 activation in primary Se´zary cell populations is
independent of SHP-1. Moreover, treatment of ex vivo tumour cells
from SS patients with the JAK inhibitor P6 demonstrates that JAK
phosphorylation is essential for constitutive activation of STAT3 in SS.
Our data supports previous studies demonstrating constitutive
expression of STAT3 in CTCL cell lines,10–19 and confirm
findings in a recent report that showed constitutive and
sustained ex vivo expression of pSTAT3 over 24 h in PBMCs
from a group of four SS/MF patients.18 In contrast, an earlier
study documented strong expression of pSTAT3 in only 2 out of
14 SS patients.10 However, this study examined total PBMCs
rather than enriched tumour cell populations and some patients
had low proportions of Se´zary cells (1–91%). Therefore, the
apparent contrasts to our data may be explained by a low
tumour burden in the PBMCs analysed. It has also been
suggested that STAT3 activation in SS is not constitutive, but is
dependent on exogenous cytokine stimulation, as expression of
pSTAT3 was significantly reduced after overnight culture of
Se´zary cells from three patients.17 However, another report18
clearly demonstrated persistent expression of pSTAT3 in vitro in
the absence of cytokine stimulation, which is consistent with our
own observations and supports the conclusion that STAT3 is
constitutively activated in SS patients and is independent of
exogenous cytokine stimulation.
The underlying mechanism responsible for aberrant STAT3
activation in CTCL has proved elusive, although studies have
been mostly restricted to cell lines. The protein tyrosine
phosphatase SHP-1 has been proposed as a candidate for
aberrant STAT3 activation in CTCL due to its role as a negative
regulator of JAK1 and JAK2.41,42 Previous studies have shown
that SHP-1 protein expression is absent in some CTCL cell
lines,28 and immunohistochemical analysis has demonstrated
reduced SHP-1 expression in lesional tumour biopsy samples
from MF patients with advanced stage disease.30 Furthermore,
studies of anaplastic large cell lymphoma cell lines revealed
STAT3 and DNA methyltransferase-mediated epigenetic silen-
cing of SHP-1.29 However, we found no evidence of SHP-1
downregulation or promoter methylation in primary SS samples
when compared with healthy PBMCs, despite using pyrose-
quencing, which has sufficient sensitivity to detect hypermethy-
lation against a background of normal cells.33 It has been
previously recognised that the immortalisation of cell lines can
itself cause aberrant DNA methylation as a result of selective
pressures present during the growth of these cells in culture.43
Given the lack of changes in DNA methylation or protein
expression of SHP-1 in primary cells and the absence of an
effect of SHP-1 knockdown in MyLa cells, our results suggest
that SHP-1 does not contribute to persistent activation of the
JAK–STAT3 pathway in SS. Our data, therefore, suggests that in
SS and MF, alternative mechanisms may be responsible for
aberrant STAT3 activation. This is consistent with studies of
other malignancies40 that have demonstrated multiple mechan-
isms can lead to aberrant STAT3 activation and also supports
recent findings,2 suggesting that SS and MF may have distinct
clinicopathogenetic origins.
Figure 4 Downregulation of STAT3 activation by pan-JAK inhibition
induces apoptosis. Apoptosis analysis was performed on 5 from the 10
P6-treated enriched tumour samples (Figure 3) to determine the
downstream effects of P6 on primary (P) tumour and healthy (H)
samples (a) Caspase-3 apoptosis assay (b) Annexin V apoptosis assay
(c) qPCR of pSTAT3 target genes Bcl-XL, Mcl-1 and Survivin, in
addition to p21, STAT3 and BIM. The graph denotes the fold change of
mRNA expression of P6-treated Se´zary samples compared with the
untreated Se´zary samples.
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The SOCS family of negative STAT regulators is also unlikely
to mediate aberrant STAT3 activation in SS, as it has been
reported that SOCS3 is expressed at high levels in CTCL cell
lines and SS patients.19 Moreover, the use of a dominant-
negative STAT3 in CTCL cell lines was shown to downregulate
constitutive expression of SOCS3, demonstrating that SOCS3
expression is a consequence rather than a mediator of aberrant
STAT3 activation. Furthermore, no SOCS3-associated mutations
have been identified in CTCL.44
We also detected consistent expression of activated JAK1 and
JAK2 in primary SS samples and demonstrate that down-
regulation of JAK1 and JAK2 expression using the P6 pan-JAK
inhibitor results in significant downregulation of STAT3 expres-
sion in primary SS cells. Previous studies of a SS cell line and an
MF patient sample ex vivo treated with a pan-JAK inhibitor
AG490 also showed downregulation of activated STAT3.13
Although activation of JAK3 in CTCL is well documented, no
previous studies of JAK1 and JAK2 have been published.25,45
Although further experiments are required to elucidate the
specific contribution and role of individual JAKs, our findings
indicate that aberrant activation of STAT3 is mediated via JAK
signalling in SS.
In the last decade, several JAK mutations have been identified
in acute lymphoblastic leukaemia and myeloproliferative
diseases.46,47 A recent report identified a JAK3 A572V mutation
in 1 of 30 MF patients48 studied. We have found no evidence for
the most common activating mutations, JAK1 V658F and JAK2
V617, in primary SS samples. This is perhaps not surprising as
the literature suggests that JAK mutations, including JAK2 V617,
are uncommon in non-Hodgkin’s lymphoma.49 However, other
rare activating JAK mutations have been described in various
malignancies,47,50 and therefore, a comprehensive analysis for
JAK mutations in SS patients is required to fully exclude other
activating mutations.
Although an unidentified activating mutation of JAK1 and/or
JAK2 might explain the aberrant activation of STAT3 in primary
SS, aberrant signalling further upstream of JAK1 and JAK2 should
also be considered. JAKs are activated by a plethora of cytokines
and growth factors, as well as by signalling through the T-cell
receptor. Studies of CTCL cell lines have shown dysregulation of
T-cell activation including constitutive IL-2Ra expression,13
spontaneous IL-5 production,14 enhanced secretion of IL-10(ref. 51)
and aberrant expression of IL-17.52 In classical Hodgkin’s
lymphoma, HSP90 is essential for JAK/STAT signalling, as it
activates JAK1 and JAK2.53 The Ephrin family of tyrosine kinase
receptors have also been shown to activate the JAK–STAT3
pathway.54 Overexpression of one Ephrin family member,
EphA4, has been reported in several human cancers, including
SS,55 and therefore it represents a potential mechanism for
aberrant JAK–STAT3 activation.
Persistent STAT3 signalling is a major feature of many
malignancies and it is well recognised that downstream targets
of pSTAT3 include a large number of genes that contribute to
apoptotic resistance, differentiation and proliferation.40 Our
ex vivo findings of the induction of apoptosis following
inhibition of STAT3 activation in Se´zary cells, supports the
hypothesis that pSTAT3 has a pivotal role in mediating the
known resistance to apoptosis. These data confirm several in
vitro studies using CTCL cell lines, which have induced
apoptosis via STAT3 knockdown,11,12 or STAT3 inhibition with
different agents including Curcumin,18 Cucurbitacin,17 Panobi-
nostat15 and Avicin D.16 Our data suggests that downregulation
of the pSTAT3 anti-apoptotic genes BCL-2, Survivin and Bcl-XL
contribute to the observed commitment to apoptosis. Further-
more, it is now recognised that unphosphorylated monomeric
STATs, including STAT3, regulate gene transcription and have
distinct target genes to their phosphorylated isoforms.6,7
Our findings support these observations as P6 inhibition of
JAK–STAT3 phosphorylation induced STAT3 mRNA expression
and upregulated expression of BIM, a known target of unpho-
sphorylated monomeric STAT3(refs 6,7) and a pro-apoptotic
member of the BCL-2 protein family (reviewed in ref. 56).
In conclusion, by studying ex vivo-enriched tumour cell
populations from a large cohort of SS patients, we have
established that aberrant expression of pSTAT3 is a consistent
feature of this malignancy and is likely to be a key pathogenetic
abnormality and thus a potential therapeutic target. We have
also shown that aberrant STAT3 expression in SS patients is
primarily mediated via activation of JAKs. Specifically, we have
found no evidence that downregulation of SHP-1, SHP-1
promoter methylation or common activating mutations of
JAK1/JAK2 is involved in STAT3 activation. Further studies to
exclude rare activating mutations of JAKs and upstream
signalling abnormalities in SS are now required.
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Regulation of T-Plastin Expression by Promoter
Hypomethylation in Primary Cutaneous T-Cell
Lymphoma
Christine L. Jones1, Silvia Ferreira1, Robert C.T. McKenzie1, Isabella Tosi2, Jacqueline A. Caesar1,
Martine Bagot3, Sean J. Whittaker1 and Tracey J. Mitchell1
T-plastin (PLS3) is an actin-bundling protein normally expressed in epithelial cells but absent in cells of
hematopoietic origin. Aberrant PLS3 expression has been demonstrated in lymphocytes from Se´zary syndrome
(SS) patients and has been proposed as a biomarker for SS; however, the mechanism underlying dysregulation
of PLS3 has not been determined. In this study, PLS3 mRNA expression was demonstrated in 21/35 (60%) SS
patients and in 3/8 (38%) mycosis fungoides patients, all of whom had clonal blood involvement. No evidence
for PLS3 mutations within coding or promoter regions was found, but significant hypomethylation of CpG
dinucleotides 95–99 within the PLS3 CpG island was observed and this was restricted to the PLS3þ population.
A polyclonal antibody specific to PLS3 was raised to examine coexpression of PLS3 with a panel of T-cell
differentiation markers. All PLS3þ cells were CD3þCD4þ and CD26, suggesting that loss of CD26 is
consistently associated with gain of PLS3, whereas all other markers were distributed heterogeneously.
However, a patient-specific TCR copy number assay also demonstrated heterogeneity in PLS3 expression in
tumor cell populations. Importantly, our findings demonstrate PLS3 expression in the majority of SS patients
and provide insight into the molecular regulation of PLS3 expression in CTCL.
Journal of Investigative Dermatology (2012) 132, 2042–2049; doi:10.1038/jid.2012.106; published online 12 April 2012
INTRODUCTION
Primary cutaneous T-cell lymphoma (CTCL) is the second
most common form of extranodal non-Hodgkin’s lymphoma
with an incidence of 7.7 in 1,000,000 person-years (Bradford
et al., 2009). Mycosis fungoides (MF) is the most prevalent
form of CTCL, accounting for 54% of cases (Bradford et al.,
2009). In MF, the tumor cells are usually restricted to the skin
compartment, and prognosis is generally favorable with a
5-year overall survival of 78% (Agar et al., 2010). Se´zary
syndrome (SS) is a closely related but more aggressive
subtype in which a leukemic clone of T cells is present in
the peripheral blood. SS is associated with a poor prognosis
and a 5-year overall survival of only 26% (Agar et al., 2010).
Diagnosis of the various subtypes of CTCL is made using a
combination of clinical, histological, and immunophenotypic
features, because there is a lack of biomarkers unique to the
disease or its subtypes. In SS, a measure of circulating tumor
burden can be obtained by visual inspection of a blood smear
to quantify those cells with abnormal cerebriform nuclei.
However, Se´zary cells are morphologically heterogeneous
and can be difficult to distinguish from normal activated
T cells based on morphology alone.
Previous studies have suggested a characteristic immuno-
phenotype typical of SS, including loss of CD7 (Haynes et al.,
1981), loss of CD26 (Jones et al., 2001), and the presence of
CD158k (Bagot et al., 2001). Increasingly, these differentia-
tion markers are being used in research studies to enrich for
the tumor cells (Contassot et al., 2008; Yoon et al., 2008).
However, a study comparing the use of the different
phenotypic markers as diagnostic tools concluded that no
individual marker is present in all cases, and that a
combination of markers is required for flow cytometric
diagnosis (Klemke et al., 2008). In addition, tumor cells have
been identified in FACS-sorted CD7- and CD26-positive
subsets from SS patient samples using a clone-specific TCR
PCR (Steinhoff et al., 2009), suggesting that these markers
may not be appropriate for enrichment of the tumor cell
population.
T-plastin (PLS3) is an actin-bundling protein, the expres-
sion of which is restricted to epithelial cells with replicative
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potential (Lin et al., 1993). A closely related isoform, L-
plastin, is normally expressed only in hematopoietic cells, but
ectopic expression of L-plastin has been reported in epithelial
malignancies including colon and breast cancers (Lin et al.,
1993). This appears to be critical in some tumors for
enhancing migration and invasion (Foran et al., 2006).
Aberrant expression of PLS3 mRNA was first identified in a
complementary DNA (cDNA) array–based study of peripheral
blood mononuclear cells from 48 SS patients (Kari et al.,
2003) and was proposed as a potential diagnostic biomarker.
Similar findings were reported by a representational difference
analysis study of mRNA derived from CD4þ /CD7-enriched
tumor cells from nine SS patients, which demonstrated
high levels of PLS3 mRNA expression in Se´zary cells and con-
firmed PLS3 protein expression by western blot analysis in
one patient (Su et al., 2003). Subsequent studies including
our own have identified that high levels of PLS3 mRNA
expression is a common feature of Se´zary cells (van Doorn
et al., 2004; Nebozhyn et al., 2006; Tiemessen et al., 2006;
Booken et al., 2008; Capriotti et al., 2008; Tang et al., 2010).
However, the mechanism by which aberrant expression of
PLS3 occurs in SS has not yet been determined. A key
potential mechanism that may contribute to the dysregulation
of PLS3 expression in SS is promoter methylation, as the PLS3
gene harbors a 1,585 bp CpG island (CGI), which may be
differentially methylated in Se´zary cells compared with
healthy T cells.
As PLS3 is not normally expressed by any cell of hema-
topoietic origin, it has potential as a Se´zary cell biomarker and
as a tool to evaluate the utility of other proposed markers for
the identification of SS tumor cells. Here we assess the extent
of PLS3 expression in CTCL and undertake a detailed
investigation of potential regulatory mechanisms. We further
show that an antibody against PLS3 can be used to identify a
subset of malignant circulating cells in SS and characterize in
detail the immunophenotype of this subset of malignant cells.
RESULTS
PLS3 is expressed in the majority of SS patients
To establish the prevalence of PLS3 in our patient cohort, the
expression of PLS3 mRNA was determined in CD4þ
peripheral blood lymphocytes (PBLs) by quantitative reverse
transcriptase–PCR (qPCR). qPCR detected a minimal amount
of PLS3 mRNA in 11 healthy controls representing one
thousandth of the amount of cyclophilin mRNA present. A
threshold for positive detection of PLS3 mRNA was set at one
hundredth of the amount of cyclophilin mRNA, using this
definition 60% (21/35) of SS patients expressed PLS3. A group
of 18 MF patients, 8 of whom had advanced-stage disease
(Stage IV) with no morphological evidence of Se´zary cells but
with a T-cell clone identical to that observed in the skin
(Stage B0b) and 10 of whom had skin-restricted disease (Stage
IB–III B0a) were also examined. Of the eight MF patients
with peripheral blood involvement, three expressed PLS3
(38%), whereas all those with skin-restricted disease were
PLS3 negative. Comparison of average PLS3 mRNA expres-
sion among the three groups demonstrated a significant
increase in PLS3 expression in SS patients compared with
healthy controls (Po0.05; Figure 1). The expression of PLS3
was also compared with measures of tumor burden such as
total lymphocyte count, CD4þ count, and CD4/CD8 ratio,
and demonstrated only a weak correlation (r¼0.33,
P¼0.008) with the percentage of CD4þ T cells.
The absence of coding or promoter mutations in the PLS3 gene
To address whether mutational events may be responsible for
aberrant PLS3 expression, PBL mRNA from six SS patients
was sequenced using primer sets that covered the entire
coding sequence and 953bp of the 1,111 bp 30-untranslated
region. No mutations were detected within the PLS3 coding
sequence and 30-untranslated region of the six patients
examined. A C/G polymorphism was observed in exon
1,390 bp upstream of the translational start site in two
patients. Further investigation revealed this site to be a
known single-nucleotide polymorphism, rs757124. As PLS3
mRNA was found with the C variant in four patients and
the G variant in two patients, we conclude that this
single-nucleotide polymorphism is not influencing the
expression of PLS3.
The promoter region of 12 SS patients was also sequenced
to establish whether other polymorphisms might be asso-
ciated with aberrant PLS3 expression. This cohort included
three SS patients not expressing PLS3 mRNA, eight SS patients
expressing PLS3, and one MF patient expressing PLS3. The
only polymorphisms detected within the region 1,845 bp
upstream of the transcriptional start site corresponded to
known single-nucleotide polymorphisms in this region
(Table 1). Although a much larger cohort is required to
conclusively test for an association between genotype and
























Healthy MF patient SS patient
Figure 1. T-plastin (PLS3) mRNA is aberrantly expressed in CD4þ
lymphocytes from Se´zary syndrome (SS) patients. Quantitative reverse
transcriptase–PCR (qPCR) was used to assess the expression of PLS3 mRNA
in CD4þ lymphocytes from 11 healthy controls, 18 mycosis fungoides
(MF) patients, and 35 SS patients. The housekeeping gene Cyclophilin was
used as a normalization control. A significant difference between healthy
and SS patient expression was demonstrated by one-way analysis of variance
(ANOVA).
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Site-specific hypomethylation may contribute to aberrant PLS3
expression
Although Lin et al. (1999) found that the PLS3 CGI was
unmethylated in primary lymphocytes, the assay used only
investigated those CpG sites that were within the restriction
site of EagI, NruI, and PvuI. Therefore, we used direct
sequencing of bisulfite-converted DNA to examine the
methylation of the entire PLS3 CGI. The majority of the
CGI was observed to be unmethylated in healthy controls;
however, one small region containing CpG dinucleotides
95–99 was found to contain methylation in four healthy
lymphocyte samples but not in keratinocytes, which express
PLS3 (Figure 2a).
To investigate this region further, a pyrosequencing assay
was designed and used to quantify methylation in PBL samples
taken from 24 healthy controls and 36 SS patients. Healthy
PBLs were found to contain an average of 32% methylation of
CpG dinucleotides 95–99, which was significantly greater than
the 21% methylation observed in PLS3þ patient samples
(Po0.05). An average methylation level of 46% was detected
in PLS3 samples, which was not significantly different from
the healthy PBL samples (Figure 2b).
Development of an antibody against PLS3
We tested the two commercially available PLS3 antibodies by
western blotting and observed a lack of specificity and
sensitivity. Therefore, a polyclonal antibody was raised
against a PLS3 antigen and specificity was demonstrated by
western blotting (Figure 3a). Expression status of PLS3 protein
in SS PBLs was broadly consistent with the expression status
of PLS3 mRNA. Expression of PLS3 protein was demonstrated
in 8/11 SS samples shown to express PLS3 mRNA by qPCR,
whereas 2/3 SS samples with PLS3 mRNA levels below the
threshold showed no PLS3 protein expression. In the one SS
sample where PLS3 was detected at the protein level but not
the mRNA level, the quantity of PLS3 mRNA was just below
the threshold for PLS3 expression. Immunostaining of PBLs
from one PLS3-positive SS patient demonstrated PLS3 protein
expression in a proportion of lymphocytes and suggested that
the PLS3 protein is localized in the cytoplasm (Figure 1b).
PLS3þ cells are CD3þCD4þ and CD26 and heterogeneous
for other markers
Multiparameter flow cytometry was used to examine the
correlation of PLS3 expression with other immunophenotypic
markers including CD3, CD4, CD45RO, CD7, CD26,
CD25, and CD158k. PLS3þ cells were demonstrated in 11
of 16 SS samples by flow cytometry, and in all cases the
PLS3þ population also expressed CD3 and CD4 (Figure 4).
In those samples expressing PLS3, the PLS3þ cells com-
prised between 3 and 76% of the CD4þ PBLs (data not
shown).
Next, we examined the distribution of various phenotypic
markers within the PLS3þ and PLS3 populations (Figure 5).
Notably, in all 11 samples the CD4þ PLS3þ population
showed almost complete loss of CD26, whereas the corre-
sponding CD4þ PLS3 subsets expressed a significantly
greater proportion of CD26 (P¼0.0006), suggesting that loss
of CD26 is associated with gain of PLS3. However, no other
significant association was found between any of the other
differentiation markers and PLS3 status. Notably, a wide range
of CD45RO expression was observed, with four patients
demonstrating a significantly lower proportion (Po0.05) and
three patients showing a significantly greater proportion
(Po0.05) of CD45ROþ in the CD4þ subset than the healthy
control average of 47% (Figure 5). Although the distribution of
expression between PLS3 and PLS3þ subsets is variable, in
three patients showing significant reduction of CD45RO
expression, the PLS3 expression was confined to the
CD45RO population.
PLS3 expression is enriched in cells with the tumor-specific TCR
gene rearrangement
To assess whether PLS3 expression is heterogeneous in tumor
cells from individual patients, we used FACS to isolate
PLS3þ and PLS3 cell populations from one well-char-
acterized SS patient (R164). These cell populations were
analyzed for the presence of the patient-specific clonal TCR-b
gene rearrangement using a qPCR assay. The PLS3þ
population contained 84% (confidence interval 69–99%
Po0.05) cells with the tumor-specific clonal TCR-b gene
rearrangement, whereas the PLS3 population contained
28% (confidence interval 14–43% Po0.05) cells with the
tumor-specific clonal TCR-b gene rearrangement.
PLS3-positive cells show hypomethylation of CpG sites 95–99
DNA from the PLS3 and PLS3þ populations was also
analyzed for the methylation status of the PLS3 CGI at sites
95–99. In the pre-sort sample, DNA methylation across these
sites was 16%, whereas after sorting DNA from the PLS3þ
subset, which represented 79% of the pre-sort sample, was
found to be 10% methylated and DNA from the PLS3 subset
was 43% methylated.
Table 1. Genotypes of the three SNPs within the
T-plastin (PLS3) upstream region
Sample PLS3 expression rs3813931 rs1557770 rs757124
R67 + C/C T/T G/G
R73  C/C T/G G/C
R82 + ND G/G C/C
R83 + C/C T/T G/G
R84 + C/C T/T G/G
R85 + C/C T/T G/G
R89 + C/C T/T G/G
R118 (MF) + C/C T/T G/G
R122  T/T T /T C/C
R125 + C/C T/G G/C
R126  C/C T/T C/C
R133 + C/C T/T G/G
Abbreviations: MF, mycosis fungoides; ND, not determined; SNP, single-
nucleotide polymorphism.
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DISCUSSION
We have shown that aberrant expression of PLS3 is observed
in 60% of SS patients and 38% of MF patients with peripheral
blood involvement (stage B0b). No mutations were found in
the coding or regulatory regions of the PLS3 gene to account
for aberrant PLS3 expression in CTCL. Consistent with other
studies, no evidence of DNA methylation was found across
the bulk of the CGI (Lin et al., 1999; Oprea et al., 2008);
however, in a region that has not previously been investi-
gated, methylation was found in healthy lymphocytes but not
in keratinocytes, which correlates with PLS3 expression. In
contrast, this region was hypomethylated in lymphocytes
from PLS3þ SS patients. Furthermore, sorting of the PLS3þ
and PLS3 populations demonstrated that hypomethylation
was restricted to the PLS3þ population. These observations
strongly suggest that methylation of this region may
contribute to the silencing of PLS3 expression in healthy
lymphocytes and that loss of methylation may lead to
aberrant PLS3 expression in Se`zary cells. Further longitudinal
studies are now required to address whether therapies that
reduce tumor burden are associated with the reversal of the
observed hypomethylation.
We have previously demonstrated that Se´zary cells
are present within CD4þCD26þ , CD4þCD26, CD4þ
CD25, and CD4þCD25þ populations by quantifying
PLS3 mRNA within sorted cell subsets (Jones et al., 2010;
Tiemessen et al., 2006). In this study, we further explored the
correlation between T-cell differentiation marker expression
and PLS3 expression using an antibody specific for PLS3. In
all samples, PLS3 expression was observed to be restricted to
CD3þCD4þ T cells. We found that loss of CD26 was
significantly associated with the PLS3þ subpopulation,
whereas loss of CD7 and gain of CD158k were not. We also
observed that tumor cells were not exclusively confined to
the CD45ROþ population as widely reported (Willemze
et al., 1997). Indeed, in three samples with significant loss of
CD45RO, we were able to confirm that PLS3 expression was
confined to the CD45RO population. Similar results have
been reported recently, showing heterogeneity in CTCL
tumor cells in both CD45RO and CD45RA expression
(Campbell et al., 2010). The study by Campbell et al.
also identified significant differences in the expression
of cell differentiation markers and addressins in SS and MF
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Figure 2. CpG dinucleotides 95–99 are partially methylated in healthy lymphocytes, unmethylated in healthy keratinocytes, and show reduced
methylation in lymphocytes from Se´zary syndrome (SS) patients expressing T-plastin (PLS3). (a) Bisulfite-converted DNA from four healthy lymphocyte
samples and one healthy keratinocyte sample were sequenced to assess DNA methylation across the PLS3 CpG island (CGI). The section shown covers
CpG dinucleotides 95–99. The bisulfite-converted reference sequence shows potentially methylated cytosine residues (N) and the resultant Cþ T mixed
base (Y) highlighted in gray. (b) Pyrosequencing of bisulfite-converted DNA was used to measure methylation of CpG dinucleotides 95–99 in lymphocytes
from 24 healthy controls, and in tumor cells from 12 PLS3-negative (PLS3) and 24 PLS3-positive (PLS3þ ) SS patients. The median of each group is
represented by a horizontal line. A significant difference in methylation was demonstrated between healthy and PLS3þ groups by one-way analysis of
variance (ANOVA).
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compared with MF patients with skin-restricted disease.
Circulating tumor cells from leukemic patients were found
to express high levels of the lymph node–homing receptors
CCR7/L-selection and CD27, a phenotype consistent with
central memory T cells. MF tumor cells derived from lesional
skin lacked expression of the lymph node–homing markers
but expressed high levels of the skin-homing receptors CCR4
and CLA, a phenotype in keeping with skin-resident effector
memory T cells. Thus, it was proposed that SS and MF arise
from distinct functional T-cell subsets. As we did not include
such markers, our data do not address the functional T-cell
subset origin of CTCL tumor cells. However, the PLS3
antibody described may facilitate future validation of the
model proposed by Campbell et al. by using PLS3 expression
to identify CTCL tumor cells in effector versus central
memory T-cell populations, although heterogeneity in PLS3
expression within tumor cell populations may confound data
interpretation.
The wide range of proportions of PLS3þ cells observed
suggests that PLS3 expression is confined to a substantial
subset of tumor cells rather than the whole population. This
hypothesis is further supported by the detection of tumor cells
within the PLS3-negative population in one patient. This
effectively precludes the use of PLS3 sorting to isolate tumor
cells in SS patients expressing PLS3.
Although loss of CD7 and CD26 and gain of CD158k have
been proposed as diagnostic tools, it is not established
whether any of these markers can be used to quantify tumor
burden accurately. Our observations of phenotypic hetero-
geneity within the tumor population are supported by a
previous study, which determined that tumor cells are not
restricted to CD7 or CD26 subpopulations (Steinhoff
et al., 2009). This supports our conclusion that cell sorting
based upon these phenotypic markers is likely to identify only
a subset of tumor cells, although still potentially including
reactive cells. Therefore, isolation of the CD4þ subset still
provides the most reliable approach for the enrichment of the
tumor population in SS.
To quantify tumor cells within sorted cell subsets, we have
developed a patient-specific real-time TCR assay based upon
those used in acute lymphoblastic leukemia (Bruggemann
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Figure 3. A newly generated antibody is specific for the detection of
T-plastin (PLS3) protein. (a) Western blot analysis to determine PLS3
expression in primary keratinocytes, and lymphocyte samples from one
healthy control, 6 Se´zary syndrome (SS) patients shown to express PLS3
mRNA (R83, R63, R55, R58, R72, R85), and one SS patient who did not
express PLS3 mRNA (R73). PLS3-specific bands are at the expected size of
70 kDa. b-Actin (40 kDa) is included as a loading control. (b) Immunostaining
to detect PLS3 expression. Healthy CD4þ lymphocytes and SS patient
lymphocytes (R61) were cytospun onto slides, fixed in 1% paraformaldehyde,
permeabilized with ice-cold methanol, and then immunostained using the
PLS3-specific antibody or a rabbit polyclonal isotype control. Goat anti-rabbit
Alexa Fluor 488 (green) was used to visualize the staining, and nuclei were































Figure 4. T-plastin (PLS3)-positive cells are CD3þCD4þ . Lymphocytes
were stained with fluorescent antibodies against CD3, CD4, CD45RO, CD25,
CD26, CD7, CD158k, and PLS3, and then examined by flow cytometry.
Viable lymphocytes were gated into PLS3 and PLS3þ populations to allow
examination of CD3 and CD4 scatterplots. The example shown is taken from
Se´zary syndrome (SS) patient sample R164.
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chose to utilize a genetic assay rather than Vb antibodies to
enhance the specificity of detection and to avoid excluding
cells where cell surface TCR was not expressed. Patient-
specific real-time TCR copy number assays have the potential
for future use in quantifying tumor burden, allowing detailed
monitoring of response to therapies.
PLS3 and L-plastin are closely related actin-bundling
proteins, which normally demonstrate tissue-specific ex-
pression (Lin et al., 1993). However, aberrant L-plastin
expression has been demonstrated in a wide range of
epithelial malignancies (Lin et al., 1993) and shown to
induce proliferation and invasion in colon cancer cells
(Foran et al., 2006). In healthy tissue, L-plastin becomes
phosphorylated upon leukocyte activation (Wabnitz et al.,
2007) and leukocytes deficient for L-plastin are incapable of
killing pathogens despite showing normal migration, adhe-
sion, spreading, and phagocytosis (Chen et al., 2003). PLS3
has been proposed to have a role in DNA damage repair
(Sasaki et al., 2002; Ikeda et al., 2005) in healthy tissue
and is overexpressed in cisplatin-resistant (Hisano et al.,
1996) and UV-resistant (Higuchi et al., 1998) cells. Given
the importance of actin cytoskeletal dynamics in the
formation of the immunological synapse and the dysregula-
tion of T-cell signaling observed in CTCL, aberrantly
expressed PLS3 may interfere with the assembly of the
immunological synapse. Further investigation is necessary
to determine the functional role of aberrant PLS3 expression
in CTCL.
In conclusion, we have determined the prevalence of PLS3
expression in a large cohort of SS patients and developed an
antibody specific for PLS3, which should provide a valuable
tool for further studies into the functional role of PLS3. We
have demonstrated that hypomethylation of CpG dinucleo-
tides 95–99 in the PLS3 CGI is a likely mechanism
responsible for aberrant expression of PLS3 in Se´zary cells.
Longitudinal studies are now required to assess the prognostic
relevance of aberrant PLS3 expression in CTCL. We
further conclude that the expression of T-cell differentiation
markers in SS patients is heterogeneous and that CD4
expression remains the most reliable approach for enrich-
ment of tumor cells.
MATERIALS AND METHODS
Patient material
Patient lymphocytes were obtained from a nationally approved
research tissue bank (07/H10712/106) in accordance with the
Declaration of Helsinki Principles of 1975, as revised in 1983.
Lymphocytes were isolated using Lymphoprep (Axis-Shield, Kim-
bolton, UK) gradient centrifugation, whereas CD4þ lymphocytes
were obtained by incubating blood with RosetteSep CD4þ T-cell
enrichment cocktail (Stem Cell Technologies, London, UK) before
Lymhoprep gradient centrifugation. Diagnosis was made using the
WHO-EORTC diagnostic criteria for CTCL (Willemze et al., 2005).
All SS patients had an identical T-cell clone detected in lesional skin
and peripheral blood as demonstrated by TCR gene rearrangement
studies using BIOMED-2 primer sets (van Krieken et al., 2007).
Quantitative RT-PCR
RNA was isolated from CD4þ lymphocytes using the RNeasy mini
kit (Qiagen, Crawley, UK), followed by conversion into randomly
primed cDNA using the high-capacity cDNA archive kit (Applied
Biosystems, Warrington, UK). Quantitative RT-PCR was performed
on an ABI Prism 7000 (Applied Biosystems) using optimized TaqMan
probe/primer sets for PLS3 (Hs00192406_m1) and the endogenous
control Cyclophilin A (Hs99999904_m1).
Sequencing
DNA was isolated using standard procedures; cDNA was generated
as described above; bisulfite conversion was performed using the
Epitect bisulfite kit (Qiagen). Primer sequences and cycling condi-
tions are available on request. PCR products were sequenced by
Geneservice (London, UK) using the original PCR primers and
additional sequencing primers. Data were examined using Geneous
(Drummond et al., 2011) with a 25% peak height similarity cutoff to
detect potential mutations.
Pyrosequencing
Pyrosequencing was performed as described in Jones et al. (2010)
using the following primers: PLS39599_F-50-TGGAGTGGGGGT
TAATGGTAT-30, PLS39599_R-50-CCTCCCAATCCCTCTTAACAAA-
30 and sequencing primers PLS39599_SF-50-TTAAGTGGGTTGGA
GAGT-30, PLS39599_SR-50-AATCCCTCTTAACAAACC-30.
Antibody generation
Antibody production was performed by Cambridge Research

















































































Figure 5. T-cell differentiation marker expression is heterogeneous between
PLS3þ and PLS3 subsets. Lymphocytes were stained with fluorescent
antibodies against CD3, CD4, CD45RO, CD25, CD26, CD7, CD158k, and
PLS3, and then examined by flow cytometry. Viable cells were gated into
CD4þ PLS3S3 and CD4þ PLS3þ populations, and then the percentage of
positive cells was quantified for every other differentiation marker (CD45RO,
CD7, CD26, CD25, and CD158k) in each subset.
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Ac-MATTQISKDELDELKC-amide. Antisera were subjected to affinity
purification on thiopropyl sepharose 6B derivatized with the antigen
followed by elution using Glycine.
Western blotting
Western blotting was carried out using standard procedures.
Commercial antibodies against PLS3 used were ab45769 (AbCam,
Cambridge, UK) and sc-16655-R (Santa Cruz Biotechnology, Santa
Cruz, CA). Anti-b-actin (AbCam) was used as a loading control.
Flow cytometry
Lymphocytes were stained with LIVE DEAD Fixable Aqua dye (Life
Technologies, Paisley, UK) before incubation with APC-aCD26
(Miltenyi Biotech, Bisley, UK) and APC-Cy7-aCD158k (gift from
Dr Bagot conjugated using Innova Lightening-Link kit, Innova
Bioscience, Cambridge, UK) or appropriate isotype controls.
Following fixation and permeabilization, cells were incubated with
PE-Cy7-aCD3 (eBioscience, Hatfield, UK), PE-TxR-aCD4 (Caltag-
Medsystems, Little Balmer, UK), PacificBlue-aCD45RO (Biolegend,
Cambridge, UK), PE-Cy5-aCD7 (eBioscience), PE-aCD25 (eBioscience),
and DyLight488-aPLS3 (in-house antibody conjugated using Pierce
amine-reactive DyLight dye kit, Thermo Fisher Scientific, Rockford,
IL), or appropriate isotype controls. Flow cytometry acquisition and
sorting was performed on a FACSAria II (BD Biosciences, Oxford,
UK), and data were analyzed using the FlowJo software (Tree Star,
Ashland, OR).
Patient clone–specific qPCR assay
PCR/SSCP with the BIOMED-2 TCR-b primers was performed as
described in Fraser-Andrews et al. (2001) using the diagnostic
sample from SS patient R164. Clonal bands were sequenced
(Geneservice) using multiplexed forward or reverse BIOMED-2
primers. A rearrangement-specific forward primer was designed to
overlap V, D, and N regions. J region–specific reverse primer and
probe were synthesized according to published sequences. Quanti-
tative PCR was performed on an ABI 7000, and the assay was
validated using the diagnostic sample as a positive control and
pooled healthy lymphocyte DNA as a negative control. Sensitivity
was tested and a standard curve generated by spiking a synthetic
positive control into pooled healthy lymphocyte DNA. Patient-
specific Ct values were normalized against the Ct values from two
diploid genomic control regions (SDC4 and BCMA) to calculate the
proportion of tumor cells present in each cell subset.
Statistics
Comparison between two groups was made using Student’s t-test,
whereas comparisons among three groups were made by analysis of
variance. All statistical tests were performed using the R statistical
software package (http://www.r-project.org/).
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